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Abstract
B ackground: Flavonoids are a class of phytochemicals which have been associated 
with several health benefits, including reduced risk of cancer and cardiovascular disease. 
Quercetin is one of the most ubiquitous dietary flavonoids with estimated intakes of 3-15 
mg/day. The bioactivity of dietary constituents is dependent upon their bioavailability, 
but the absorption and biotransformation of quercetin is poorly understood as reflected 
by estimates of absorption rates from <0.1% to 50%. Further investigations of the 
putative health effects of quercetin require more reliable data on its bioavailability and 
metabolism in the gastrointestinal tract (Gl-tract) and its distribution to body tissues.
Section 1 and II: Using a radiolabelled quercetin glycoside, the oral absorption and 
subsequent body distribution of [2-^"^C]quercetin-4’-glucoside and its metabolites were 
traced in Rowett Hooded Lister rats. Based on the radioactivity content of plasma and 
body tissues, -10% of the oral dose (7.6 mg/kg BW) was absorbed and appeared in 
tissues almost exclusively in the form of >20 different methylated, glucuronated, and/or 1
sulfated quercetin metabolites. The Gl-tract held >85% of the ingested radioactivity at 
0.5, 1, 2 and 5 hours after oral administration; at 2 hours all radiolabelled compounds in f
the GI tract were metabolised forms of the ingested compound. It was hypothesized that 
quercetin-4-glucoside was completely metabolised in the Gl-tract before absorption into 
the circulation. Biological effects of dietary quercetin may be due to its metabolites.
Section III: To investigate the individual contribution of the liver (the primary 
metabolising organ for xenobiotic compounds), G I-tissues or GI-microflora in quercetin 
metabolism, cultured rat liver (CC-1) and small intestinal (IEC-6) cells were used as a 
model for pre-systemic metabolism. Both cell lines produced similar types and numbers 
of quercetin metabolites and 11 of the 16 cell culture metabolites were identical with 
quercetin metabolites formed in the rat. The degree of chemical instability of [2-*'^C] 
quercetin-4'-glucoside in cell culture medium was not anticipated a priori. Less than 
0.2% of the administered [2-*"^C]quercetin-4'-glucoside, its radiolabelled break down 
products or metabolites were associated with the cells. Despite apparent metabolism in 
the cell culture medium, the presence of cells was essential for the formation of quercetin 
metabolites, indicating that metabolites had been formed either on the cell membrane or 
inside the cells with quick subsequent export from cells into the medium. In conclusion, j
cell culture experiments may be a useful tool to investigate potential health effects of 
dietary quercetin and in vivo metabolites, provided 1) chemical break down of quercetin 
can be controlled and 2) the cell line can synthesize similar metabolites as found in vivo.
Section iV: Previous reports indicate quercetin up-regulates glutathione in vitro and in 
vivo, a mechanism by which this flavonoid may increase cellular antioxidant activity. 
However, glutathione is also up-regulated by oxidative stress and some studies suggest 
quercetin may possess pro-oxidant activity. Therefore, it was investigated whether 
dietary glycosylated quercetin up-regulates glutathione in cells that form in vivo 
metabolites of quercetin. We found free and glycosylated quercetin had different effects 
on glutathione regulation, suggesting that the biological activity of these forms of the 
flavonoid may be different. We now hypothesize that pro-oxidant by-products formed U
during quercetin oxidation in cell culture medium may be responsible for many of the 
observed effects of quercetin in vitro.
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Context
"... it's sometimes iiard to se e  w h a t  the  lessons are. (...) 
Not only m ay  w e  h a v e  difficulty understanding w h a t  is 
being taught, w e  m ay  never know which lessons w e 're  
supposed  to master, it would b e  impossible to  master 
them  all perfectly, a n d  there  a re  undoub ted ly  som e 
d ragons w e 're  not supposed  to slay this lifetime. 
Sometimes no t slaying them  is the  lesson. Its easy  to look 
a t  so m eo n e  else a n d  say, "Oh, its so sad, h e  d idn 't  g e t  
the  lesson of forgiveness before  he  died." But m ay b e  he  
still learned  w h a t  he  w as supp osed  to. Or pe rh ap s  h e  was 
p resen ted  with opportunities to learn, but ch ose  not to. 
And who knows? M aybe he w asn 't  sup posed  to g e t  the 
lesson by forgiving. Perhaps you w ere  offered an  
opportunity to g e t  th e  lesson of forgiveness by w atching  
him..,"
Elisabeth KCibler-Ross & David Kessler
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1. Flavonoids and Quercetin
1.1. Flavonoids -  a large family of polyphenolic compounds
Flavonoids are polyphenolic molecules synthesized in plants, consisting of two 
aromatic rings which are linked together with a bridge of one oxygen and three carbon 
atoms (forming an oxygenated heterocycle) (Figure 1). Flavonoids have important 
functions in plant physiology, they are involved in electron transport during 
photosynthesis (Das, 1994), are powerful UV protectors (Jorgensen, 1993), interact with 
plant growth hormones and play an important role in the defence against viral or bacterial 
pathogens (Havsteen, 2002). Flavonoids are synthesised in all vascular plants and are 
found in considerable quantities in fruits, vegetables, nuts, seeds, herbs, spices, stems and 
flowers. Flavonoids are present in cooked vegetables and in plant extracts such as tea, 
coffee and red wine (Beecher, 2003).
Flavonoids are divided into subclasses based on the connection position of the B 
and C rings as well as the degree of saturation, oxidation, and hydroxylation of the C 
ring. The subclasses are most commonly categorized as flavan-3-ols (or catechins), 
flavanones, flavones, isoflavones, flavonols, and anthocyanidins (Figure 2). Examples of 
molecular structures of individual flavonoids are given in Table 1. Flavonoids are 
ubiquitously distributed in the plant kingdom. The content of individual flavonoids and 
entire flavonoid subclasses can vary markedly, even between similar foods (Sellappan et 
al, 2002; Crozier et al, 1997). As a result, diverse dietary patterns can provide 
considerably different intakes of these nutrients. Examples of the principal flavonoids 
present in some common foods ai'c provided in Table 2.
With the exception of some flavan-3-ols, most flavonoids in food are found linked 
to one or more sugar molecules via (3-glycosidic bonds with phenolic hydroxyl groups. 
The binding site of the sugar moiety (e.g. 3 or 4' position) affects the bioactivity of the 
glycosilated flavonoid (Murota et al, 2004, Yamamoto et al, 1999; Williamson et al, 
1996; loku et al, 1995). Sugar conjugation generally increases the water-solubility of the 
flavonoid, hence it is easier to handle by the plant. Glucose is the most commonly found 
sugar adduct, although conjugation with galactose, rhamnose, arabinose or xylose is 
possible, as well as conjugation with glucuronyl and galacturonyl moieties. The diversity 
of these conjugates contributes to the large number of different naturally occurring 
flavonoids, estimated at more than 5000 different compounds (Harborne and Baxter, 
1999).
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Figure 1 : Basic structure and numbering system  of 
flavonoids.
Flavonoids contain two aromatic rings (A and B) that are 
linked via an oxygenated heterocycle (ring C).
O H
Flavonols
O H
Flavan-3-ols
Flavones
Flavanones
Anthocyanidins
Isoflavones
Figure 2: C lasses of Flavonoids.
The core structures of six different flavonoid subclasses are shown above. Individual 
flavonoids are structurally distinct due to different patterns of hydroxylation, méthylation and 
conjugation with various mono and disaccharides. Molecular structures of individual flavonoids 
are exemplified in Table 1.
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Flavonoid Class Individual Flavonoid
Substituents
3 5 7 3' 4' 5*
quercetin OFI OH OH OH OH HFlavonols kaempfero! OH OH OH H OH H
myricetin OH OH OH OH OH OH
apigenin H OH OH H OH Hiricivuiivo luteolin H OH OH OH OH H
catechin OH OH OH OH OH H
Flavan-3-ols epigalloeatechin OH OH OH OH OH OH
epigallocatechin gallate G OH OH OH OH OH
hesperetin H OH OH OH OCH3 H
Flavanones naringenin H OH OH H OH H
eriodictyol H OH OH OH OH H
cyanidin OH OH OH OH OH H
Anthocyanidins malvidin OH OH OH OCH3 OH OCH3
petunidin OH OH OH OCH3 OH OH
Isoflavones genistein H OH OH H OH Hdaidzein H H OH H OH H
Table 1 : Structures of individual flavonoids.
Individual molecular structures of flavonoids are determined by the addition of hydroxyl, methyl and methoxy 
groups, most commonly at positions, 3, 5 ,7 ,3‘, 4' or 5' on the main flavonoid nucleus. Quercetin and catechin have 
hydroxyl groups at positions 3, 5, 7, 3' and 4', their core structures however are different, with quercetin belonging 
to the class of flavonols and catechin to the class of flavan-3-ols (Figure 2). The number and positioning of hydroxyl 
groups together with the degree of saturation of the C ring determines the antioxidant activity of individual 
flavonoids. G = gallate, H * = in the case of isoflavones, H it attached to position 2, due to the connection of C and 
B ring at position 3.
Through plant synthesis and also via some types of food processing, flavonoids can 
be polymerised into larger molecules called tannins. According to their polymerisation 
pattern and monomeric constituents, tannins are classified into three major groups: 
pro anthocyanidins (or condensed tannins), derived tannins, and hydroly sable tannins 
(Table 3).
p age  4
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Flavonoid
Class
Compound
Exam ple Food Sources
C ontent 
(mg /lOO g)
Flavonols quercetinkaempfero!
myricetin
onion, raw 
broccoli, raw 
apples 
black grapes
15.36
9.37
4.42
2.99
Flavones apigeninluteolin
celery, raw 
parsley, raw 
thyme, fresh
5.92
303.24
56.00
Flavan-3-ols
catechin
epigallocatechin
epigallocatechin
gallate
apples 
red wine 
green tea 
black tea
9.09
11.90
132.12
34.26
Flavanones
hesperetin
naringenin
eriodictyol
oranges
lemons
grapefruit
43.88
49.81
54.50
Anthocyanidins
cyanidin
malvidin
petunidin
blueberries 
raspberries 
red wine 
red onion
112.55 
47.60 
9.19 
13.14
Isoflavones genisteindaidzein
soymilk
tofu
9.65
28.15
Table 2: Flavonoid content of selected  foods.
Content of six flavonoid subclasses in the edible portion of selected foods are 
taken from the US DA Database for the Flavonoid Content of Selected Foods 
{http://www.nal.usda.gov/fnic/foodcomp/Data/Flav/flav.html), except for isoflavone 
values, which are derived from the Iowa State University Database on the 
Isoflavone Content of Foods (http://www.nal.usda.gov/fnic/foodcomp/Data/lsoflav 
.html, April, 2004).
.Îa
Tannins C haracteristics Compound nam es Food sources
Condensed tannins 
(pro-anthocyanidins)
convert in part into anthocyanidins pro-cyanidins
after acid catalyzed de-polymerization. pro-delphinidins
apple
blueberries 
dark chocolate
are formed during food processing, 
Derived tannins particularly during production of
oolong and black tea.
thearubigi ns 
theaflavins
green tea 
black tea 
red wine
;
Hydrolyzable tannins esters o f gallic acid or ellagic acid and gallotanninsnon-aromatic polyols (mainly glucose), ellagitannins
pomegranate
raspberries
■15
Table 3: Tannins are di-, oligo-, or polym ers of flavonoids and other polyphenols.
Data is adapted from Beecher, 2003
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1.2. Dietary intake of fiavonoids
Flavonoids have been a component of human plant foods for millions of years 
(Swain, 1975) therefore throughout evolution the human organism must have 
accommodated to the dietary intake of flavonoids. A first step towards exploring the 
impact of flavonoids on human health was the quantification of the daily exposure to 
flavonoids. Flavonoid intake (based on aglycones) in today’s populations has been 
estimated to range between 10 and 100 mg daily and is summarized in Table 4. These 
estimates however are likely to be imprecise for the following reasons.
(1) The flavonoid content in food and beverages varies considerably depending on 
cultivar, growth conditions, ripeness, post-harvest processing, cooking, and storage 
(Price et al, 1997; Price et al, 1998a; Crozier et al, 1997). For example, quercetin content 
of 100 g yellow-skinned onion can vary between 8.57 mg (King-Midas, Georgia, USA) 
and 81.0 mg (Cross Bow, U.K.) and red skinned onions can contain up to 139.0 mg 
quercetin (Red Baron, U.K.) (Sellappan et al, 2002; Price et al, 1997). In addition, 
published estimates of flavonoid content in foods are confounded by methodological 
factors, such as varying analytical procedures and equipment in different laboratories.
(2) Flavonoids are relatively resistant to heat and are stable in lightly fried 
vegetables, but substantial losses (of up to 75%) may occur due to their solubility in 
cooking water (Crozier et al, 1997; Price et al, 1997). Therefore when the daily intake of 
flavonoids is estimated, allowances should be made for losses during food preparation.
(3) Estimates of the daily average flavonoid intake in different countries, were 
based on the quantification of only selected groups of flavonoids, namely flavonols and ) 
flavones, while other important groups of flavonoids, such as catechins and 
anthocyanidins, were not included.
(4) A single main meal together with a small glass of red wine can contain up to 
265 mg of flavonoids (Rechner et al, 2002; Serafini et al, 1998). If this is rounded up by 
a small piece of dark chocolate (20 mg) and a cup of black tea (200 ml) 50 mg of 
catechins can be added (Arts et al, 2001), and the total intake was >300 mg. Therefore 
the calculated daily averages, ranging between 14 and 79 mg (Table 4), appear 
unrealistically low.
Cultural dietary habits influence which foods are most frequently consumed in 
different countries, so it is not surprising that isoflavone intake from soy is high in Japan 
(Arai et al, 2000), while in Scotland and Wales, where consumption of black tea is the 
main source of dietary flavonoids (Kyle et al, 2002; Flertog et al, 1997) and intake of
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catechins is highest (Duthie et al, 2003). In addition, the consumption of selected 
subclasses of flavonoids, rather than the total flavonoid intake, may prove relevant to 
specific health outcomes. In conclusion, the flavonoid content in foods varies 
significantly and the actual flavonoid intake of an individual is difficult to determine. 
Given the above reasons, it is likely that the average flavonoid intake in humans may 
well be higher than 100 mg per day.
Daily flavonoid intake in different countries
1 1 1 i I 1Country Population i 1 1 Î 1 Sum R eference
Scotland 81 subjects 4 day weighed intake 19 0.1 1 59 79.1
Duthie et al, 
2003
U.K.
(Wales)
1,900 men, aged 45-59 y 
FFQ and 
weighed dietary intake
26.3 26.3 Hertog et al, 1997
Finland 10,054 subjects, 39 ±16 y (dietary history) 4 <1 20 24
Knekt et al, 
2002
Holland
Holland
4,807 subjects, 
aged 67.4 ± 7,8 y 
(FFQ)
806 men, 
aged 65-84 y in 1985, 
(dietary history)
26.6
72
26.6
72
Geleijnse 
et al, 2002
Arts et al, 
2001
USA
(Boston)
34,789 men, aged 40-75 y 
in 1986 (FFQ) 19.9 0.2 20.1
Rimm et al, 
1996
USA
(Boston)
38,445 women, > 45 y, 
in 1992, FFQ 23.9 0.7 24.6
Sesso et al, 
2003
USA
(Iowa)
34,492 postmenopausal 
women, 55-69 y in 1986, 
FFQ
13.84 0.06 13.9 Yochum et al, 1999
Japan 115 women, 29-78 y, dietary history 16 <1 47 63
Arai et al, 
2000
Germany
(Bavaria)
119 adults, 19-49 y,
7 day dietary protocols 12 13.2 8.3 2.7 54
Lin.sei.sen 
et al, 1997
Table 4: Estimated dietary intake of flavonoids In different countries.
Estimates are based on (incomplete) tables of flavonoid content in foods in mg (aglycones)/day. No study provides 
values for all subclasses of flavonoids, hence all listed values are likely to be underestimates. Method of dietary 
assessment: Food frequency questionnaire (FFQ), dietary history, and/or weight dietary intake.
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Country quercetin  intake (mg/d) source
Wales, U.K. 14.2 Hertog et al, 1997
Scotland, UK 14.0 Duthie et al, 2000
Boston, USA 15.4 Rimm et al, 1996
Iowa, USA 9.7 Yochum et al, 1999
Finland 3.3 Knekt et al, 2002
Table 5: Estimated quercetin intake in different countries.
Food Sources quercetin content (mg /lOO g)
apples 4.4
black tea, brewed 2.0
broccoli, raw 3.2
capers, canned 180.8
cocoa, dry powder 20.1
cranberries, raw 14.0
elderberry, raw 42.0
fennel leaves, raw 48.8
red grapes 3.5
red onion, raw 19.9
yellow onion, raw 13.3
Table 6: Quercetin rich foods.
Quercetin content in edible portions of selected foods 
derived from the USDA Database for the Flavonoid 
Content of Selected Foods (http://www.nal.usda.gov/fnic/ 
foodcomp/Data/Flav/flav.html, April, 2004).
1.3. The flavonol quercetin
Certain, dietary flavonoids are particularly bioactive and have pronounced effects 
on mammalian cells. Quercetin, 3, 3', 4 \ 5, 7-pentahydroxyflavone (Figure 3) is one of 
the most abundant flavonoids in our diet, and estimates of human consumption range 
from 3 to 15 mg/day (Table 5). Some flavonoid families are only present in selected food 
groups (e.g. isoflavones in soy products, flavanones in herbs, anthocyanidins in red 
coloured fruit and vegetables). Quercetin however is ubiquitously distributed throughout 
most plant foods and can be found in onion, apples, berries, grapes, lemons, nuts, grains, 
tomatoes, broccoli, lettuce, beans, green and black tea, red wine (see Table 6). Quercetin 
displays a wide range of biological effects (reviewed in paiagraph 3) and epidemiological 
studies conclude that quercetin may play a role in disease prevention (reviewed in 
paragraph 2). In foods quercetin naturally occurs conjugated to sugar molecules, with
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quercetin-4'-giucoside and quercetin-3,4'-di-glucoside (Figure 3) accounting for 80% of 
the total flavonoid content in onion, a major source of dietary quercetin (Hakkinen 1999; 
Rhodes and Price, 1996).
(A)
(B)
(C)
OH
HO,
OH
OH
HO,
HO
OH
OH
HO.
HO
OH OH
HO
Figure 3: Molecular structures of quercetin and quercetin g lycosides.
Structure of quercetin agtycone (A), quercetin-4'-0-p-D-glucoside (B) and 
quercetin-3,4'“di-0-p'D- glucoside (C).
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2. Flavonoids and human health: Epidemiological evidence
Epidemiological studies consistently show inverse relationships between fruit and 
vegetable consumption and many degenerative diseases, such as cancer and heart disease 
(Hu et al, 2003; Riboli and Norat, 2003; World Cancer Res. Fund, 1997; Ness and 
Powles, 1997; Steinmetz and Potter, 1996). However, epidemiological studies can only 
point to associations and can not prove which compounds in fruit and vegetables were 
responsible for the observed health effects. Foods rich in flavonoids also contain other 
known or unknown nutrients and phytochemicals and it may not be possible to 
statistically separate their individual effects from effects caused by flavonoids (De 
Stefani et al, 2000). However, in the past 10 years, the correlation between flavonoid 
intake and disease incidence was investigated in a number of epidemiological studies 
(Tables 7, 8, 9 and 10). This chapter focuses on the effects of flavonol consumption, 7
particularly quercetin consumption. Epidemiological findings on health protective effects 
of isoflavones were not included in this chapter, because the main dietary source of :>
isoflavones, soy and soy products, are rarely consumed in European populations. 
Epidemiological findings on the correlation of catechin intake and disease prevention 
were recently reviewed by Arts et al. (2001) and Blot et al. (1997). Confounding factors f
of ‘flavonoid epidemiology’ are discussed in paragraph 2.5..
2.1. Cardiovascular disease
Four out of eight relevant studies report that a high intake of dietary flavonoids 
(flavonols, flavones and flavanones) was associated with reduced incidence of heart 
disease (Table 7) (Knekt et al, 2002; Geleijnse et al, 2002; Arts et al, 2001; Hertog et al,
1993). In two studies the consumption of tea was negatively correlated with heart disease 
(Geleijnse et al, 2002; Arts et al, 2001), however Hertog et al. (1997) reported that in 
Welsh tea drinkers the intake of >1.2 litres tea /day was correlated with an increased 
risk, rendering inconsistent results for the association of tea consumption and heart 
disease. The “Seven Country Study” by Hertog et al (1995) found that 8% of the between 
country variation of coronary heart disease (CHD) mortality was correlated with a high 
intake of dietary flavonols (smoking and consumption of saturated fat explained 9% and 
73% of the between country variation). In conclusion, the reviewed epidemiological 
studies suggest that a diet high in flavonoids reduces the incidence of CHD.
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2.2. Cerebrovascular disease
Two out of five studies report a significant decline of stroke incidence and 
mortality in population segments with a high intake of flavonoids (Knekt et al, 2002; 
Keli et al, 1996) (Table 8). The other three studies report no or only a very weak non­
significant associations, suggesting that a diet high in flavonoids (namely flavonols, 
flavones and flavanones) may reduce stroke incidence.
2.3. Cancer
Knekt et al, 2002 reports that dietary intake of flavonoids (flavonols, flavones and 
flavanones) was inversely correlated with cancer incidence, particularly lung cancer 
(Table 9). Two earlier studies, however, found no correlation between flavonoid intake 
and cancer incidence (Goldbohm et al, 1997; Hertog et al, 1993). Elevated cancer 
incidence was observed in a Welsh population with high dietary intake of flavonols and 
tea (Hertog et al, 1995). High quercetin intake led to a significant reduction of the 
incidence of esophageal and stomach cancer (De Stefani et al, 1999; Garcia-Closas et al,
1999), however no effect was observed for lung cancer (Garcia-Closas et al, 1998). In 
conclusion, epidemiological studies on potential effects of flavonoids in cancer 
prevention are not yet convincing, and further research is needed to clarify this issue. I
2.4. Other diseases
A diet rich in quercetin appeared to reduce the incidence of asthma and diabetes 
(Table 10) (Knekt et al, 2002). The putative protective effect of quercetin against the f
development of diseases, such as heart disease, stroke, cancer, asthma and diabetes, 
implies that 1) beneficial effects of quercetin are caused by multiple pathways or 2) that 
the pathologies of the different diseases are based on a similar starting point, e.g. pro- 
oxidative imbalance in cells and tissues (Halliwell, 1994).
2.5. Confounding factors of epidemiological studies
All epidemiological studies investigating the relationship between food intake and
disease development critically depend on an accurate measurement of the consumption of
specific foods. In flavonoid epidemiology naturally it is important that major flavonoid
rich foods are recorded in the initial dietary snapshot (food frequency questionnaire,
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dietary history). In some of the above reviewed studies however, the consumption of 
some flavonoid rich foods such as onion, berries tea and red wine was not recorded 
(Knekt et al, 2002; Yochum et al, 1999), which compromises the final results.
Due to the vast number of individual flavonoids, and a lack of adequate food 
composition data, it is almost impossible to quantify the daily flavonoid intake of humans 
(paragraph 1.2.), In all the above reviewed epidemiological studies only a very small 
number of flavonoids, mostly the three flavonols, quercetin, kaempferol and myricetin, 
have been quantified and the consumption of other flavonoid groups, e.g. anthocyanidins 
were completely neglected. However, even if adequate food composition data was 
available, dietary intake of flavonoids does not directly translate into bioavailability. 
Therefore the correlation of disease outcomes with plasma or tissue levels of flavonoids 
may focus the outcomes of epidemiological studies.
In conclusion, caution is warranted in the interpretation of epidemiological studies, 
however, current epidemiological evidence is suggestive that flavonoids including 
quercetin may play a role in disease prevention, particularly in the prevention of heart 
disease and stroke.
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Flavonoids and CHD -  epidemiological data
C ountry S tudy  pop ulation F lavonoidintakc/d
C om pared
w ith Incident
R elative  R isk  
(95% C I) R eference
Holland
The Rotterdam Study 
4807 subjects >55 y
> 375 ml tea no tea
Myocardial infarction 
Fatal myocardial infarction 
Nonfatal myocardial 
infarction
0 .57 (0 .3 3 ,0 .9 8 ) o  
0 .3 0 (0 .0 9 ,0 .9 4 )  •
0 .6 8 (0 .3 7 ,1 .2 6 )  o G eleijnse 
et al, 
2002
(mean 67.4±7.8  y) 
5.6 y follow  up 
(1990/93-1997) >32.9 mg 
flavonols ^ <  22.8 mg
Myocardial infarction 
Fatal myocardial infarction 
Nonfatal myocardial 
infarction
0 .76  (0.49, 1.18) 0 
0.93  (0.57, 1.52) o  
0 .35 (0 .1 3 ,0 .9 8 ) •
Holland
The Zutphen Elderly 
Study, data re- 
evaluation  
806 men, 65-84 y 
1985, 10 y follow  up
> 85.9 ing 
total catecliins < 4 9 .1  mg
Ischemic heart disease 
mortality
Ischemic heart disease 
incidence
0 .49  (0.27, 0 .88) # 
0 .70  (0.39, 1.26) 0
Arts 
et al, 
2001
Holland
The Zutphen Elderly 
Study,
805 men aged 65-84 y, 
1985, 10 y follow  up
>  30 mg 
flavonols and 
flavones
< 19 mg
CHD mortality
First myocardial infarction
0 .47 (0.27,0.82) # 
0 .6 2 (0 .2 4 , 1.05) o
Hertog 
et al, 
1993, 
and 1997
The Caerphilly Study 
1900 men aged 45-59 y 
10-14 y follow  up from 
1979-83
>  34 mg 
flavonols ' < 19 mg Ischemic heart disease 1.1 (0.6, 1,6) o
U.K.
(W ales)
> 18 mg 
quercetin <  10 mg Ischemic heart disease 1.1 (0.7, 1.7) 0
H eitog  
et al, 
1997
> 1200  ml tea <  300 ml Ischemic heart disease 2.3 (1.0, 5.1) •
Finland
Finnish M obile Clinic 
Health Examination 
Survey 
10,054 subjects >15 y
>27 m g total ' 
flavonols (4) 
flavones (2) 
llavanones (3)
< 4 mg Ischemicheart disease mortality 0 .93  (0.74-1.17) 0 Knekt 
et al. 
200228 y follow  up (1967-
94) > 4 mg 
quercetin <  1.5 mg
Ischemic
heart disease mortality 0.79 (0.63, 0 .99) •
USA
(Boston)
W om an’s Health Study 
38,445 women > 4 5  y 
6.9 y follow  up 
(1992-ongoing)
47 mg 
flavonols and 
flavones  ^
(m edian)
9 mg 
(median) Cardiovascular disease 0 .88  (0.68, 1.14) o Sesso  
et al,
>  32.8 mg 
quercetin 
(median)
< 6.5 mg 
(median) Cardiovascular disease 0.96 (0.74, 1.25) o
2003
U SA
(Iowa)
Postmenopausal wom en  
34,492 55-69 y
>28.6 mg 
(median) 
flavonols and 
flavones ’
<  4  mg 
(m edian)
Cardiovascular disease, 
fatal 0 .62  (0.44, 0,87) o
Yochum  
et al.
1986, lOy follow  up
> 1 8 .7  mg 
quercetin 
(m edian)
<  3.3 mg 
(median)
Cardiovascular disease, 
fatal 0 .74  (0.52. 1.06) o
1999
USA
(Boston)
Health professionals 
follow  up 
34,789 men, 40 -75y 
5 y follow  up (1986- 
1992)
> 40  mg 
flavonols and 
flavones ^
<  7.1 mg
Myocardial infarction, 
non-fatal
Non-fatal myocardial 
infarction in men with 
history o f CHD
1,08 (0.81, 1.43) o 
0,63 (0 ,33-1.20) o
Ri mm 
et al, 
1996
Table 7: Effect of dietary flavonoids on CHD incidence - epidem iological data.
The legend for this table is on the next page.
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Flavonoids and stroke - epidemiological data
Country Study population Flavonoidintake/d
Compared
w ith Incident
R elative risk  
(95%  C l) Reference
Holland
The Zutpen Elderly 
Study, data re- 
evaluation  
806 men, 65 -84  y 
1885, 10 y follow  up
> 85.9 ing 
total catechins < 4 9 ,1  mg
Stroke incidence
Stroke mortality
0 .9 2 (0 ,5 1 ,1 ,6 8 )  o
0.81 (0.36, 1.83) o
Arts 
et al, 
2001
The Zutpen Study 
Holland 552 men 50-69 y
1960-70; 15 y follow  up
>28.6  mg 
flavonols and 
flavones ^
< 18.3 mg Stroke incidence 0 .2 7 (0 .1 1 ,0 .7 0 )
5  587 g tea 
(4.7 cups)
< 330 g 
(2 .6  cups) Stroke incidence 0,31 (0 .1 2 ,0 .8 4 ) »
Keli 
et al, 
1996
Finland
Finnish M obile Clinic 
Health Examination 
Survey 
10,054 subjeets >15y  
28 y follow  up (1967- 
94)
>27 mg total ' 
flavonols (4) 
flavones (2) 
flavanones (3)
< 4  mg Cerebrovascular disease 0 .79 (0.64, 0 .98) • Knekt
et al.
>  4  mg 
quercetin < 1 .5  mg Cerebrovascular disease 0 .8 6 (0 .7 0 -1 .0 5 ) o
2002
Finland
Alpha Tocopherol Beta 
Carotene Cancer 
Prevention Study 
26,593 male smokers 
50-69y  
6.1 y follow  up
> 16.4 mg 
(median) 
flavonols and 
flavon es’
< 4 .2  mg  
(m edian) Cerebral infarction 0.98 (0.80-1.21) o
Hirvonen 
et al, 
2000
USA
(Iowa)
Postmenopausal women  
34,492 55-69 y 
1986, lOy follow  up
>28.6 mg 
(median) 
flavonols and 
fla v o n es’
<  4  rag 
(median) Stroke mortality 1.02 (0.59, 1.79) o
Yochum  
et al. 
1999
.1
Table 8: Effect of dietary flavonoids on stroke incidence - epidem iological data.
Results are adjusted for dietary and non-dietary confounding factors, however methods of adjustment varied in different 
studies. 1 Total flavonoids = sum of kaempferol, quercetin, myrlcetin, Isorhamnetin (flavonols), apigenln, luteolln (flavones), 
hesperetin, naringenin and eriodlctyol (flavanones).3Sum of quercetin, kaempferol, myrlcetin, luteolln and apigenln.
•  significant result o  not significant result.
I
Legend for Table 7 on previous page:
Table 7: Effect of dietary flavonoids on CHD incidence - epidem iological data.
Results are adjusted for dietary and non-dietary confounding factors, however methods of adjustment varied in different studies. 
HIrvionen et al, 2001 and The Seven Country study (Hertog et al, 1995) is not included because statistical significance of the data 
was not shown and due to different statistical analysis and data collection.^Total flavonoids = sum of kaempferol, quercetin, 
myrlcetin, Isorhamnetin (flavonols), apigenln, luteolln (flavones), hesperetin, naringenin and eriodlctyol (flavanones). ^Sum of 
quercetin, kaempferol and myrlcetin.  ^Sum of quercetin, kaempferol, myrlcetin, luteolln and apigenln.
•  significant result o  not significant result.
«■
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Flavonoids and cancer -  epidemiological data
C ountry Study pop ulation F lavon oidin takc/d
C om pared
w ith Incident
R elative risk  
(95% C I) R eference
Finland
Finnish M obile Clinic 
Health Examination 
Survey
>27 m g total ’ 
flavonols (4) 
flavones (2) 
flavanones (3)
< 4  m g
all cancers 
lung
colorectuin 
breast (in women)
0 .8 9 (0 .7 4 ,1 .0 6 )  o  
0 .6 4 (0 .3 9 , 1.04) e  
0 .8 4 (0 .4 3 ,1 .6 4 )  o 
1 .2 3 (0 .7 2 ,2 .1 0 )  o Knekt et al, 
200210,054 subjects >15y  28  y follow  up (1967- 
94) >  4 mg quercetin < 1.5 mg
all cancers 
lung
colorectum  
breast (in women)
0 .77 (0.65, 0 .92) •  
0.42  (0.25, 0.72) e  
0 .62 (0.33, 1.17) o  
0 .62 (0.37, 1.03) o
U.K.
The Caerphilly Study 
1900 men aged 45-59  
y 14 y follow up 
from 1979-83 
FFQ and weighed  
dietary intake
>  34 mg 
flavonols " <  19 mg all cancer mortality 1.3 (0.7. 2.3) • Hertog 
et al.(Wales)
> 1200 ml tea <  300 ml all cancer mortality 2.2 (1.0. 5 .0) #
1997
Holland
The Netherlands 
Cohort Study on Diet 
and Cancer, 120,852 ■ 
subjects, 55-69, 1986, 
4.3 y follow up, FFQ
43.5  mg 
median 
flavonols and 
luteolin
12.7 mg 
median
stomach cancer 
colorectal cancer 
lung cancer 
breast cancer
0 .86  (0.47, 1.57) o 
0.97  (0.71, 1.32) o 
0 .9 9 (0 .6 9 , 1.42) o 
1.02 (0.72, 1.44) o Goldbohm  et al, 
199730.3 mg 
quercetin 
(m edian)
8.4 mg 
median 
quercetin
stomach cancer 
colorectal cancer 
lung cancer 
breast cancer
1.08 (0.56, 2.05) o 
1 .0 6 (0 .7 7 ,1 .4 5 ) o 
0 .8 1 (0 .5 7 ,1 .1 7 )  o 
1.00 (0 .7 0 ,1 .4 1 ) o
Holland
The Zutpen Elderly 
Study,
738 men aged 65-84 y. 
1985, 5 y follow  up. 
FFQ
> 29.9  mg 
flavonols and 
flavones ’
<  19 mg
all cause cancer incidence 
lung cancer incidence 
all cause cancer death
1.21 (0 .6 6 ,2 .2 1 ) o 
1.13 (0 .3 8 ,3 .4 0 ) o 
1.43 (0 .5 8 ,3 .5 4 ) o
Hertog 
et al, 
1994
Holland
The Zutpen Elderly 
Study,
728 men aged 65-84  y, 
1985, 10 y follow  up, 
FFQ
>  86 mg 
catechins (6) ’ < 49 mg
epithelial cancer 
(oropharynx, esophagus, 
stomach, colon, rectum, 
liver, gallbladder, pancreas, 
kidney, bladder, bronchus 
and lung)
0.94  (0.56, 1.59) o
Arts 
et al, 
2001
Spain
Case control study 
(354 cases, 354  
controls,)
highest quartile 
o f flavonol and 
luteolin intake
low est
quartile stomach cancer 0.44  (0.25. 0.78) * Garcia-
Closas
highest quartile 
o f  quercetin 
intake
low est
quartile stomach cancer 0 .6 2 (0 .3 5 , 1.10) *
et al, 
1999
Spain
Case control study 
(103 cases, 206  
controls, mean age: 63
y)
highest tertile 
of flavonol and 
luteolin intake
low est
tercile lung cancer 0 .98  (0 .4 4 ,2 .1 9 ) o Garcia- Closas 
et al.
> 6.58 mg 
quercetin
< 2 .50  mg  
quercetin lung cancer 0.99 (0 .4 4 ,2 .2 3 ) o
1998
Uruguay
Case control study 
(111 c a se s ,444  
controls)
highest quartile 
o f  quercetin 
intake
lowest
quartile esophagus cancer 0.47  (0.23, 0 .93) #
De Stefani 
et ai, 
2000
Table 9: Effect of dietary flavonoids on cancer incidence - epidemiological data.
Results are adjusted for dietary and non-dietary confounding factors, however methods of adjustment varied in different 
studies. ^Total flavonoids = sum of kaempferol, quercetin, myricetin, isorhamnetin (flavonols), apigenin, luteolln (flavones), 
hesperetin, naringenin and eriodlctyol (flavanones).%um of quercetin, kaempferol and myricetin. ^Sum of quercetin, 
kaempferol, myricetin, luteolin and apigenin. '‘Sum of quercetin, kaempferol, myricetin and luteolln. ^Sum of catechin, 
epigallocatechin, epicatechin, epigallocatechin, epicatechin gallate and epigallocatechin gallate.
•  significant result o  not significant result.
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Flavonoids and other diseases -  epidemiological data
C ountry Study p op ulation F lavonoidintake/d
C om pared
w ith Incident
R elative  R isk  
(95% C I) R eference
Finland
Finnish M obile Clinic  
Health Examination 
Survey 
10,054 subjects >15y  
28 y follow  up (1967- 
94)
>27 m g total ‘ 
flavonols (4) 
flavones (2) 
flavanones (3)
>  4  mg 
quercetin
< 4  mg 
< 1 .5  mg
Rheumatoid arthrifis 
Diabetes 
Cataract 
Asthma
Rheumatoid arthritis 
Diabetes 
Cataract 
Asthma
1.18 (0 .6 2 ,2 .2 6 ) o 
0.98 (0 .7 7 ,1 .2 4 ) o 
1.36 (0.84, 2 .21) o 
0.65 (0.47, 0 .90) # 
2 .6 4 (1 .3 0 ,5 .3 6 )  o 
0.81 (0.64, 1.02) •  
0 .94  (0.57, 1.56) o  
0.76  (0.56, 1.01) •
Knekt 
el al, 
2002
Table 10: Effect of dietary flavonoids on asthma, cataract, diabetes and rheumatoid arthritis - epidem iological data.
Results are adjusted for dietary and non-dietary confounding factors. ‘Ttotal flavonoids = sum of kaempferol, quercetin, myricetin, 
isorhamnetin (flavonols), apigenin, luteolin (flavones), hesperetin, naringenin and eriodictyol (flavanones).
•  significant result o  not significant result.
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3. Experimental evidence: Biological activity of Quercetin
I
Epidemiological evidence suggests that dietary intake of quercetin rich foods may 
contribute to a better maintenance of physiologic function and to a lower prevalence of 
many degenerative conditions, such as heart disease and cancer. Understanding how 
dietary quercetin affects the pathogenesis of chronic disease may contribute to the 
development of alternative therapeutic treatments and new guidelines for dietary intake 
of flavonoids.
In this chapter three major areas of quercetin bioactivity are reviewed: 1) its 
antioxidant capacity, 2) its potential role in the prevention of atherosclerosis and heart 
disease, and 3) its impact on cancer pathogenesis. In addition to these bioactivities, a 
large number of other pharmacological properties have been ascribed to quercetin, such 
as antiviral, anti-microbial, anti-inflammatory and anti- or pro-estrogenic effects, which 
are reviewed elsewhere (Middleton et al, 2000; Ross and Kasum, 2002, Havsteen; 2002).
3.1. Antioxidant activity of quercetin
Free radicals are produced in the body as part of normal metabolism (Table 11) 
and mammalian organisms have developed a complex defence system (Table 12) to 
protect cellular components such as nucleic acids, lipids, carbohydrates and proteins 
against oxidative damage. Dietary antioxidants are “substances in foods that significantly 
inhibit adverse effects caused by reactive oxygen and nitrogen species in the body”
(Dietary Reference Intakes, Institute of Medicine, Food and Nutrition Board, USA) and 
oxidative stress is defined as a shift of the fine physiological balance of pro-oxidants and 
antioxidants towards an excess of pro-oxidants, causing oxidative damage in tissues and 
cells (Sies et al, 1985). Oxidative damage appears to be involved in the aetiology of 
degenerative diseases, such as cataract, age related macular degeneration, cancer, 
diabetes meilitus, cardiovascular disease, several neuro-degenerative diseases and the 
aging process (Lindsay and Astley, 2002; Halliweil, 1994; Zoch, 1995). Therefore 
avoidance of oxidative stress may contribute to human health.
3.1.1. Direct and indirect antioxidant mechanisms of quercetin
Quercetin and other flavonoids can function as antioxidants due to their ability to
stabilize unpaired electrons within their molecular stracture after having donated one or
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Pathways of free radical formation in vivo
M itochondiral respiration
Enzym atic oxidation (e.g. by mono- and dioxigenases and cyclooxygenase)
A utoxidation (e.g. o f catecholamines)
D uring im m une defence by activated phagocytic cells (monocytes, neutrophiles, macrophages)
D rug m etabolism  (doxorubin, dithranol and paraquat)
Sm oking  
U V -ir radiation
Environm ental pollutants (80%, O3, Pba^)
Progression o f certain diseases (e.g. haemochromatosis)_______________________________________
Table 11 : Pathways of free radical formation in vivo.
Data adapted from Bablor and Woodman (1990) and Zoch (1995).
.
Antioxidant defence network
Endogenous Exogenous
Enzym atic L-ascorbate
calalase tocopherols/tocotrienols
glutathione peroxidase carotenoids
superoxide dismutase dietary phenolics
Cellular
glutathione
a-lipoie acid
ubiquinone
uric acid
Protein
ceruloplasmin
ferritin
transferrin
Table 12; Antioxidant defence network in mammalian 
organism s.
Data adapted from Miibury and Blumberg (2003).
more electrons to free radicals. Giving away an electron makes quercetin itself a reactive 
molecule (free radical), however, due to its aromatic stmcture the quercetin radical 
remains relatively stable via de-locating the unpaired electron within its 31-electron 
system (Duthie et al, 2003). Three principal structural properties of quercetin contribute 
to its antioxidant activity: the O-dihydroxy (catechol) structure of ring B, the 2,3 double
bond in conjugation with the 4-oxo group of ring C, and hydroxyl groups at position 
3,5,7,3’ and 4' (Bors et al, 1990). In vitro, quercetin can inactivate peroxyl radicals, alkyl 
radicals, superoxide, hydroxyl radicals, nitric oxide and peroxynitrite in aqueous and 
organic environments (Duthie and Crozier 2000). Flavonoids like quercetin and catechin 
can be more potent antioxidants than vitamin C and E (Gardener et al, 1997), however it
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is unclear if flavonoids are equally effective in the human body (O’Reilly et al, 2000; 
O’Reilly et al, 2001).
Quercetin and other flavonoids can also act indirectly as antioxidants by forming a 
“redox inactive complex” with metal ions like Cu^'^and Fe^ "^ , thus preventing free radical 
generation through Fenton type reactions (Duthie et al, 2000; Ferrali et al, 1997; Zoch, 
1995). Quercetin may also interact synergistically with the cellular antioxidant defence 
network by recycling, sparing or inducing other antioxidants, such as glutathione, a- 
tocopherol, glutathione-S-transferase, SOD and catalase (Molina et al, 2003; Miibury et 
al, 2002; Rimbach et al, 2001; Fiander and Schneider, 2000; Middleton et al, 2000; De 
Whalley et al, 1990). Synergy with other antioxidants implies additional mechanisms 
beyond stoichiometric quenching of free radicals or sparing of other antioxidants 
(Miibury et al, 2002), however, the nature of these mechanisms are unclear to date. '1
■-I
3.1.2. Pro-oxidant activity of quercetin ?
Quercetin was reported to induce the formation of free radicals in cell culture 
environments (Metodiewa et al, 1999; Dickancaite et al, 1998; Hodnick et al, 1986). If 
quercetin can form free radicals in vivo, it could act as pro-oxidant with potential 7
detrimental effects on DNA integrity and carcinogenesis. Indeed, quercetin induced 
recombinational DNA mutations in cell culture environments (Caria et al, 1995; Rueff et 
al, 1986; Suzuki et al, 1991; Jurado et al, 1991), hence promoting carcinogenesis. In 
mammalian organisms however, dietary or supplemented quercetin appears in body 
tissues almost exclusively as glucuronated, sulfated and methylated quercetin 
metabolites. Metabolism can significantly alter biological effects of the parent 7
compound, e.g. 3'-0-methylation of quercetin renders a non-mutagenic methyl-quercetin 
(isorhamnetin) (Zhu et al, 1994). Such metabolic transformation of quercetin in vivo, 
may explain why the vast majority of in vivo studies did not confirm the hypothesis that 
quercetin has carcinogenic properties (Walle et al, 2004).
In addition, quercetin concentrations required to induce mutations and cytotoxicity 
may not be physiologically achievable through dietary sources. It is a common 
misconception that if a little of something is good, then more is better. In cell culture 
experiments often very high doses of quercetin are used. Metabolizing enzymes in both 
cultured cells and mammalian organisms may be saturated by large doses, and un­
metabolized free quercetin may cause unwanted adverse effects. Therefore, commercially 
available supplements containing mega doses of quercetin or other flavonoids may have
biological activities that could adversely affect human health (Skibola et al, 2000) and
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Antioxidant activity of quercetin in vivo and ex vivo
O bserved effects How was it measured Reference
t resistance o f LDL against 
oxidation
Length o f lag time before LDL particle gets 
oxidised.
Chopra et al, 2000  
Hayek et al, 1997
\  plasma antioxidant capacity
ORAC (oxygen radical absorbance capacity) 
FRAP (ferric reducing antioxidant power) 
TEAC (trolox equivalent antioxidant 
capacity)
TRAP (total radical trapping parameter)
Moon et al, 2001 
McAnlis et al, 1999 
Teraoetal, 1999 
Morand 1998
1 lipid peroxidation
Malondialdehyde (MDA) concentration in 
urine, plasma or liver 
p 2 isoprostane concentration in urine or 
plasma
Pavanato et al., 2003 
Su et ai, 2003 
Fremont et al. 1998 
Rathi el al, 1984
1 DNA damage
8-hydroxy-deoxy-guanine concentration in
plasma and urine
DNA strand breaks: Comet assay
Kim et al, 2003  
Lodovici et al, 2000 
Boyle et al, 2000  
Lean et al, 1999
1 Protein damage Protein carbonyl concentration in liver and kidney
Kahraman et al, 
2003
Funabiki et al, 1999
Table 13: Antioxidant activity of quercetin in vivo.
Estimates of the in vivo antioxidant activity after ingestion of quercetin as determined by biomarkers of oxidative 
stress.
quercetin supplements should not be taken by the public until toxicological issues are 
clarified.
3.1.3. Measuring the antioxidant activity of quercetin in vivo
The pro/anti-oxidant balance in human cells and tissues is difficult to analyse. 
Therefore the antioxidant capacity of dietary compounds is indirectly characterized by 
measuring biomarkers of oxidative stress in urine and plasma (summarized in Table 13), 
LDL particles in plasma are susceptible to oxidation, and a common method to 
measure the efficacy of dietary antioxidants is to isolate plasma LDL and measure its 
resistance to oxidative stress ex vivo. Consumption of quercetin rich foods and quercetin 
supplements prolonged the resistance of LDL particles against oxidation (Chopra et al, 
2000; Hayek et al, 1997). Oxidised, electronegative LDL has been linked to the 
development of arteriosclerosis with its clinical manifestations, myocardial and cerebral
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infarction, therefore increased resistance of LDL to oxidation following consumption of 
dietary quercetin may slow the initiation and progression of arteriosclerosis.
The ability of blood plasma to withstand artificially generated oxidative stress in 
vitro is defined as plasma “antioxidant capacity” or “total antioxidant power” . Using 
various assay methods, a number of authors reported an increase of plasma antioxidant 
capacity after the consumption of quercetin rich foods or quercetin supplements (Moon et 
al, 2001; McAnlis et al, 1999; Terao 1999; Morand 1998). It is generally assumed that an 
elevated plasma antioxidant capacity is desirable, however it may also reflect a 
physiological response to oxidative stress. Therefore caution is warranted and plasma 
antioxidant status alone is not sufficient for determining the antioxidant status on an 
individual (Prior and Cao, 1999).
Quercetin also affects biomarkers of lipid peroxidation, e.g. malondialdehyde
(MDA) and F2-isoprostanes. F2-isoprostanes are free radical derived, cyclo-oxygenase
■independent, oxidation products of arachidonic acid (Natarajan et al, 1999). Plasma and 
urinary isoprostanes are currently regarded as the most specific measure of lipid 
peroxidation compared with MDA formation (Morrow and Roberts, 1996). Several 
studies have reported that ingestion of quercetin reduced the level of biomarkers of lipid 
peroxidation in vitro (Kahraman and Inal 2003; Pavanato et al, 2003).
3.1.4. Conclusion
Current evidence strongly suggests, but does not prove, that quercetin is a causative 
agent in maintaining human health via antioxidant mechanisms. Therefore, while 
quercetin may fit the definition of a dietary antioxidant, further work is necessary to 
determine its true physiological relevance and bio-availability.
3.2. Quercetin and cancer
3.2.1. Oxidative damage to DNA and lipids
Oxidative DNA damage is thought to play a significant role in the initiation and 
progression of cancer (Toyokuni et al, 1995; Feig et al, 1994; Ames, 1983). Cancer tissue 
contains higher concentrations of oxidised DNA than adjacent healthy tissue (Olinski et 
al, 1992). Consumption of dietary quercetin or quercetin supplements may reduce 
oxidative DNA damage and lipid peroxidation (Kim et al, 2003; Lodovici et al, 2000). 
Lipid peroxidation products like MDA can both damage and oxidise DNA. A pro­
oxidant milieu in the cytosol also affects the expression of proteins involved in regulating
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Putative anti-cancer mechanisms of quercetin
Observed effects Proposed mechanism Source
I tumour size, number and 
incidence in rats and mice
possibly a combination o f all observed 
effects listed underneath
Khanduja et al, 1999 
Elangovan et al, 1994 
Panelletti et al, 1992 
Deschner et al, 1991 
Verma et al, 1988 
Mukhtar et al, 1988
I carcinogen formation inhibition or activation o f enzymes which metabolise carcinogens Coughtrie et al, 1998
I oxidative DNA damage decrease of mutation
Kim et al, 2003 
Lodovici et al, 2000  
Boyle et al, 2000 
Lean et al, 1999 
Kuo et al, 1996
1 cell proliferation
Î apoptosis o f tumour cells
reduced DNA synthesis in cancer cells
inactivation or down regulation of pro­
oxidant enzymes and signal transduction 
enzymes
cell cycle arrest at G 1 phase
Spencer et al, 2004 
Shen el al, 2003 
Plaumann et al, 1996 
Uddin and Choudhry, 
1995
Ranelletti et al, 1992
1 metastasis reduced ability o f breast adeno-carcinoma cells to migrate on a collagen layer Lii et al, 1996
Table 14: Putative anti-cancer m echanism s of quercetin.
cell proliferation and differentiation (Toyokuni et al, 1995) (e.g. MAP kinases and RTK 
signal transduction pathways) (Benhar et al, 2002; Chiarugi and Cirri, 2003). Dietary 
components that help maintain a healthy balance of pro and anti-oxidants are therefore 
potential anti-cancer agents.
3.2.2. Modulation of enzyme activities
Quercetin and other flavonoids have been suggested to affect carcinogenesis via 
modulation of the activity and expression of diverse enzyme systems, such as the P450 
superfamily, phase II metabolising enzymes or quinone reductase (Duthie et al, 2000).
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3.2.3. Apoptosis, malignant transformation and anti-proliferative effect
Quercetin may prevent or reverse carcinogenesis by inducing the apoptosis of 
transformed ceils (Dong et al, 1997). The proposed mechanisms for this are the 
modulation of gene expression and the regulation of protein activities relevant for 
apoptosis (such as caspase 3, Mcl-1, NF-kB, AP I, p53 and others) (Plaumann et al, 
1996; Shen et a l, 2003; Lee et a l, 2003). Quercetin and other flavonoids inhibited 
malignant transformation in cell culture by 50% (Franke et al, 1998). It is remarkable that 
quercetin and other flavonoids appear to specifically inhibit cell growth of carcinoma cell 
lines, compared to cell growth of normal cell lines (Duthie et al, 2000; Kuntz et al, 1999).
3.2.4. Conclusion
Experimental data suggests that quercetin may play a role in cancer prevention, 
however more studies are required to confirm cancer preventive qualities of quercetin.
3.3. Quercetin and atherosclerosis
3.3.1. LDL oxidation
High plasma concentrations of LDL, particularly oxidised LDL are associated with 
increased development of arteriosclerosis and its clinical manifestations, myocardial and 
cerebral infarction (Holvoet et al, 1998; Holvoet et al, 1995). Proteins and 
polyunsaturated fatty acids in LDL particles are susceptible to free radical mediated 
oxidation. The consumption of dietary quercetin or quercetin supplements have reduced 
the susceptibility of LDL to oxidation ex vivo (Chopra et al, 2000; Hayek et al, 1997). 
This suggests that a diet high in quercetin may reduce the development and progression 
of atherosclerosis via its protective effects on LDL.
3.3.2. Plasma lipids
Apart from its protective effect on LDL, quercetin may also influence the 
homeostasis of plasma lipids. Reduced serum triglyceride levels were measured in 
humans and animals after ingestion of quercetin and other flavonoids (Hasumura et al, 
2004; Arai et al, 2000; Kaku et al, 1999). The potential clinical significance of these 
observations is obvious.
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Putative anti-atherosclerosis mechanisms of quercetin
Observed effects Proposed m echanism s Source
1 LDL oxidation antioxidant mechanisms
Chopra et al, 2000 
De Whalley et al, 1990 
Hayek et al, 1997
1 plasma cholesterol and 
triglycerides unknown
Hasumura et al, 2004 
Arai el al, 2000 
Kaku et al, 1999
1 platelet aggregation and 
thrombus formation 
in vivo and in vitro
I cyclooxygenase: inhibition of  
arachidonic acid metabolism
I thromboxane formation
antagonism to thromboxane receptors 
and other mechanisms......
Middleton et al, 2000 
Gryglewski et al, 1987
1 atherosclerotic plaques 1 LDL oxidation Hayek et al, 1997
1 inflammation modulation of cytokines and prostanoid synthesis
Morikawa et al, 2003 
Larrick and Wright, 1990
1 adhesion molecule expression 1 upregulation o f cytokine induced genes
Kobuchi et al, 1999 
Gerritsen et al, 1995
1 blood pressure t endothelial function enhancing nitric oxide release Ibarra et al, 2003 Taubert et al, 2002
Table 15: Putative m echanism s of quercetin to help prevent atherosclerosis.
3.3.3. Platelet aggregation and thrombus formation
Platelets are key participants in thrombus formation, which can lead to acute 
myocardial or cerebral infarction. Quercetin and rutin may prevent the formation of 
platelet thrombi and have been shown to disperse pre-formed platelet thrombi at 
physiological plasma concentrations (under 0.05 pM) (Gryglewski et al, 1987). Thus, 
quercetin and other flavonoids may be potent blood “thinning” agents, similar to aspirin, 
reducing the incidence of infarction in older adults. Mechanisms for quercetin’s 
inhibition of platelet adhesion to the endothelium and platelet aggregation may include 
its inhibition of arachidonic acid metabolism by cyclooxygenase, inhibition of 
thromboxane formation, and its antagonism to thromboxane receptors (Middleton et al, 
2000). Consequently, flavonoids may be potentially useful anticoagulant drugs.
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3.3.4. Inflammation and adhesion molecules
The development of inflammatory processes requires the activation of the vascular 
endothelium and the expression of adhesion molecules on the cellular surface. 
Circulating monocytes in plasma attach to adhesion molecules, roll along the vascular 
endothelium and migrate into the inflammatory site/intima (Aplin et al, 1998) where they 
transform into macrophages after ingesting a large number of oxidised LDL particles. 
The increased expression of adhesion molecules is the first morphological change in the 
development of atherosclerosis (Ross, 1995). Flavonoids, including quercetin can inhibit 
adhesion molecule expression (Gerritsen et al, 1995) and the adherence of leucocytes to 
the endothelium (Larrick and Wright, 1990). Thus flavonoids may have the potential to 
intercept atherogenesis at a very early stage.
3.3.5. Conclusion
A diet rich in quercetin may help reduce the progression of atherosclerosis via 
various antioxidant and non-antioxidant mechanisms, e.g. by affecting the plasma lipid 
homeostasis, elevating the resistance of LDL against oxidation and inhibiting blood 4
clotting and thrombus formation.
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4. Bioavailability -  Key for biological relevance
4.1. The concept of bioavailability
The journey of dietary micronutrients from food into organs and tissues begins 
with their oral ingestion. Micronutrients are released from the food matrix by “food 
processing” in the mouth, stomach and intestine. Micronutrients must be presented to the 
enterocytes in a particular condition to ensure absorption. Absorption into the enterocytes 
may occur either by passive diffusion or by active transport mechanisms. Once uptaken 
into enterocytes, lipid soluble micronutrients are packaged into chylomicrones which are 
secreted into the lymph system, arrive in the blood stream via ductus thoracicus and are 
further distributed by the liver, responsible for lipid metabolism and distribution of lipid 
soluble micronutrients within the body. Enterocytes secrete water soluble micronutrients 
directly into portal blood. However, prior to their secretion, enterocytes metabolize some 
of these compounds into more “biocompatible molecules” (Stahl et al, 2002).
In pharmacology, the term ‘bio-availability’ is used to describe the “rate and extent 
of a drug to reach its site of action”. The bioavailability of micronutrients in humans, 
however, can not be determined according to this concept as it is usually impossible to 
collect human tissues for this purpose. Therefore, micronutrient bioavailability is 
commonly estimated from plasma concentrations and has been re-defined as “the fraction 
of an oral dose (parent compound or active metabolite) that reaches the systemic 
circulation” (Lin et al, 1999; Schumann et al, 1997).
After its appearance in plasma, the micronutrient’s journey through the body, 
however, continues and 1) it may be ubiquitously distributed throughout the entire 
organism, 2) it may be transported to specific organs and tissues, 3) it may remain for a 
different length of time in the blood stream before it is excreted (urine, bile), or 4) it may 
be sequestered by organs or tissues. Some micronutrients, e.g. folic acid, enter the 
enterohepatic circulation, where the compound is excreted via the bile into the intestine 
and subsequently re-absorbed to re-enter the systemic circulation. Therefore, the plasma 
concentration of a micronutrient, e.g. quercetin, does not sufficiently describe its true 
bioavailability in vivo.
The final mission of a bioactive nutrient is to arrive at the site of action in a 
bioactive form. The bioactive form can be its natural molecular structure as present in 
food, or its metabolites. At present we know little about the active forms of many 
micronutrients, including quercetin. It is important to note that micronutrients do not
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always need to enter the systemic circulation to be bioactive (Walle 2004; Stahl et al,
2002). Unabsorbed antioxidant micronutrients may play an important role in limiting 
oxidative stress in the Gl-tract, an important site for immune and inflammatory functions.
In summary, the bioavailability of flavonoids and other micronutrients depends on 
food processing, composition of the meal, digestion, presence of bile acids and metabolic 
transformation. Considering all these variables, databases of the micro nutrient content in 
food only provide an estimate of the amount ingested, and the true availability of 
bioactive compounds at target tissues remains unclear for many micronutrients.
4.2. Methods to determine bioavailability
In humans, it is normally not possible to determine the micronutrient concentration 
in target tissues. Therefore, the micronutrient concentration or the concentration of its 
active metabolites is determined in accessible fluids or tissues and the concentration at 
target tissues is an estimate.
Many investigators regard peak plasma concentrations as a indicator of 
micronutrient absorption. These values however can not reflect the true absorption or 
bioavailability, as some compounds are absorbed gradually and have a low peak plasma 
concentration over a long period of time, whereas other compounds are absorbed rapidly 
with a high peak plasma concentration for only a very short time. The peak plasma 
concentration however, is useful to determine physiological micronutrient concentrations 
in human plasma and is important for the design of in vitro and cell culture studies.
The area under the plasma concentration time curve (AUC) is most commonly used 
as a tool to determine bioavailability after oral administration. For this approach it is 
essential to consider plasma clearance, e.g. the rate and extent of urinary and bilary 
excretion and the rate of exchange of the micronutrient between the plasma compartment 
and storage or target compartments. If either the plasma clearance or the tissues 
sequestration is unclear, the AUC calculation can not be used to determine micronutrient 
bioavailability.
In some studies bioavailability is determined by quantifying the urinary excretion
of the ingested and absorbed compound. However, this method is only applicable for
selected micronutrients that are exclusively excreted via urine, that are not metabolised
and not retained in the body (Rechner et al, 2002). As quercetin is found almost
exclusively in conjugated and oxidised (degraded) forms in urine, and since bilary
excretion of flavonoids has been reported to be significant (Rechner et al, 2002), the
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quantification of quercetin conjugates in urine is an insufficient method to determine 
quercetin bioavailability.
Radiolabelled micronutrients or stable isotopes have been the method of choice for 
bioavailability studies. The body-distribution of labelled compounds, reflects un­
ambiguously the absorption of the ingested compound including its potentially unknown 
metabolites. Whole-body auto-radiography or timed sample collection can help to 
identify target tissues (Deprez and Scalbert, 1999). Due to the radiation hazard, 
radiolabelled micronutrlents are usually administered only to animals, however, stable 
isotopes can be used in human intervention studies, although the detection of small 
quantities or unknown metabolites is easier if the compound under investigation is 
radiolabelled. In both cases the number and positioning of labelled atoms within the 
micronutrient molecule is crucial, as it determines the strength of the signal, and the 
metabolite fraction which can be identified after metabolic catabolism. In conclusion, by 
using labelled micronutrients, definite information on the absorption and body 
distribution can be obtained, especially for heavily metabolised compounds. However the 
synthesis of both stable isotopes and radiolabelled compounds, is expensive and time 
consuming and the radiation hazard can be problematic.
In summary, no common approach can be recommended for measuring the 
bioavailability of micronutrients. This is due to substantial differences in absorption 
mechanism, metabolism, body distribution and excretion pathways. Each micronutrient 
may require an individually tailored strategy for the correct determination of its 
bioavailability (Schumann et al, 1997). Many commonly used methods for the 
determination of bioavailability are likely to give incomplete results.
4.3. Absorption
4.3.1. How much is absorbed?
In recent years the absorption of dietary quercetin has been controversially
discussed. Studies with ileostomy patients, where ileal fluid was analysed, suggested that
over 50% of ingested quercetin was absorbed from a meal containing fried onion (Walle
et al, 2000; Hollman et al, 1995). However, much less than 10% of ingested quercetin is
found in plasma and urine, which suggests a much lower absoiption (Goldberg et al,
2003; Graefe et al, 2001; Erlimd et al, 2000; Manach et al, 1998). There are three
possible explanations for the high disappearance of quercetin from the small intestine in
the ileostomy studies and the low quercetin recovery in plasma, and urine: 1) only a
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small amount of quercetin is absorbed, but whilst in the Gl-tract most of the quercetin is 
metabolised into other compounds, 2) substantial quantities of quercetin are absorbed and 
rapidly metabolised by internal tissues, or 3) large amounts of quercetin are absorbed and 
rapidly sequestered by body tissues.
4.3.2. Factors affecting quercetin absorption
Pre-absorption events are important as they determine if and in what form a 
nutrient reaches the enterocytes where it may be absorbed. Quercetin glycosides, like 
other micro nutrients in plants, need to be released mechanically from plant cells where 
flavonoids accumulate in the cell wall and cell vacuole (Markham et al, 2000). 
Differences in chewing time or the ingestion of puree and juices can therefore affect the 
level of quercetin release and its subsequent bioavailability.
Quercetin absorption seems to be greatly influenced by its solubility in the food 
matrix. Data from Azuma et al (2002) indicates that a combination of lipids and 
emulsifiers can elevate the absorption of quercetin aglycone in rats. This assumption is 
supported by findings from Cermak et al (2003) where quercetin absorption in pigs was 
increased when ingested with beef, suggesting that quercetin bioavailability depends on 
the composition of the meal.
Quercetin can react irreversibly with proteins (Walle et al, 2003; Zsila et al, 2002), 
however, reports on the bioavailability of tea flavonoids from black tea, consumed either 
with or without milk, are controversial (Kyle et al, 2003; Hollman et ai 2001; Hertog et 
al, 1997; van het Hof et al, 1998).
The position and type of the sugar moiety attached to the quercetin molecule not 
only determines the speed and the site of absorption (as described in the next section), it 
also affects the total amount that is absorbed. The reason for the preferred absorption of 
particular quercetin glycosides (quercetin-4'-glucoside > quercetin-3-glucoside > 
quercetin > rutin) remains to be determined. (Murota and Terao, 2003; Cermak et al, 
2003; Morand et al, 2000; Day et al, 2003, Olthof et al, 2000). Also, whether the rate of 
quercetin absorption is dependent on the dose remains to be determined, as reports are 
controversial (Cermak et al, 2003; Erlund et al, 2000). In summary, the chemical 
structure, degree and postion of glycosylation and solubility in dietary matrix may 
determine the bioavailability of quercetin.
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4.3.3. Mechanism of absorption
Three mechanisms for the absorption of quercetin and its glycosides have been 
proposed in recent years; active transport via SGLT-1 (Walgren et al, 2000; Gee et al,
1998), hydrolysis by lactase phloridzin hydrolase (LPH) or by colon micro flora (Day et 
al, 2000; Macdonald et al, 1983) followed by subsequent absorption of the released 
aglycone via passive diffusion into the enterocytes (Williamson et al, 2000; Day et al, 
2003; Murota and Terao, 2003). The timing of the hydrolysis affects both bioavailability 
and pharmacokinetics, as quercetin from rutin (quercetin-3-(3-0-rhamnosylglucoside) 
reaches its peak plasma concentrations at 6-8 h after ingestion presumably due to its 
hydrolysis by colonic micro-flora and subsequent absorption from the colon (Graefe et 
al, 2001; Hollman et al, 1999; Hollman et al, 1997; Griffiths and Barrow, 1972). 
Quercetin glycosides such as quercetin-4'-glucoside and quercetin-3-glucoside however 
appear to be absorbed from the upper GI-tract, as peak plasma levels are reached after 
15-45 minutes (Cermak et al, 2003; Graefe et al, 2001; Hollman et al, 1999). It has been 
postulated that LPH, a p-glucosidase located on the outside of the enterocyte brush 
border (Day et al, 2000) releases quercetin from quercetin-4'-glucoside and quercetin-3- 
glucoside, and the aglycone is subsequently absorbed by passive diffusion (Williamson et 
al, 2000; Day et al, 2003). Only quercetin-4'-glucoside (not rutin and quercetin-3- 
glucoside) was transported into intestinal enterocytes with the involvement of the 
NaTglucose co-transporter SGLT-1. (Walgren et al, 2000; Gee et al, 1998; Day et al, 
2003). A greater understanding of the absorption mechanism of quercetin and its dietary 
quercetin glycosides is essential to customise supplements or flavonoid rich meals to 
achieve maximal quercetin bioavailability.
4.4. Metabolism
4.4.1. Metabolism -  the enemy of bioavailability?
The term metabolism embraces all processes that change the molecular structure of
the parent compound. This may be degradation of its molecular structure or the addition
of other molecules. Metabolic transformation may considerably change the function and
activity of a compound, as they may become more water soluble, less toxic or more
suitable for excretion (Coughtrie et al, 1998). Enzyme catalysed detoxification reactions
are one of the primary defence mechanisms against toxic or xenobiotic compounds, and
are classified into phase I and phase II metabolites. The cytochrome P-450 complex, the
most important phase I metabolising enzyme family, primarily hydroxylates, de­
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hydroxylates, or de-methylates compounds, generally to activate compounds for 
subsequent phase II metabolism.
Phase II metabolising enzymes are widely distributed among tissues, including 
liver, lung, intestine and kidney. Glucuronidation occurs on the luminal side of the 
endoplasmatic reticulum by uridine-5'-diphosphate-glucuronyl-transferases (UGTs), a 
large family of enzymes (Donovan and Waterhouse, 2003). Cytosolic phenol-sulfo- 
transferases (SULTs) transfer sulfate groups from 3'-phosphoadenosine-5'- 
phosphosulfate to phenolic compounds (Duffel et al, 2001). Catechol-O- 
methyltransferases (COMTs), also located in the cytosol, catalyse the S-adenosyl-L- 
methionine-dependent methyl group transfer to OH groups of flavonoid acceptor 
molecules (Willits et al, 2004). The addition of a sulfate or glucuronyl group results in 
metabolites that are negatively charged at physiological pH (Donovan and Waterhouse,
2003).
The amount of orally administered micronutrients or drugs to reach the systemic 
circulation can be reduced by both intestinal and hepatic metabolism, called first-pass or 
pre-systemic metabolism. It is believed that the liver is the major site for pre-systemic 
metabolism due to its size and high content of metabolising enzymes. However, in recent 
years the role and contribution of intestinal metabolism has been increasingly recognized 
(Lin et al, 1999). In the classic view, pre-systemic metabolism is regarded as mechanism 
of the body to limit the bioavailability of xenobiotic and potentially toxic compounds 
(Coughtrie et al, 1998). Recent studies indicate that all absorbed quercetin underwent 
phase II metabolism, raising the question whether phase II metabolism activates or 
inactivates absorbed quercetin. Therefore, knowledge about metabolism and the 
identification of quercetin metabolites is vital in the effort to explore mechanisms of 
bioactivity and ultimately the identification of active compounds.
4.4.2. Characterisation of quercetin metabolites in the body
Absorbed quercetin appears in plasma conjugated with glucuronide, sulfate and 
methyl moieties (Ueno et al, 1982). Plasma quercetin concentrations are therefore 
routinely measured after the release of free quercetin from its conjugates by enzymatic or 
acid hydrolysis. This indirectly proves the presence of phase II quercetin metabolites in 
plasma, even if individual quercetin metabolites were not characterised by LC-MS/MS 
analysis (Moon et al, 2000; Manach et al, 1999; Spencer et al, 1999). In recent years, 
several investigators have identified various quercetin metabolites and results are 
summarized in Table 16. A convincing number of studies report that no or very little free
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quercetin is detected in human or animal plasma and phase II metabolites of quercetin are 
clearly the dominating form of absorbed quercetin in vivo (Crespy et al, 2003; Terao, 
1999; Manach et al, 1999; Morand et al, 1998).
Absorbed forms of quercetin in vivo: quercetin metabolites
Quercetin m etabolites Sample
Adm inistered  
form  of  
quercetin
Reference
Quercetin-3'-sulphate
QLiercetin-3-mono-glucuronide
Quercetin-4'-mono-gliicuronide
Quercetin-3'-mono-glucLironide
3'-Methyl-quercetin-3-mono-glucuronide
3'-Methyl-quercetin-4'-mono-glucuronide*
Quercetin-di-glucuronides
Sulfated quercetin mono-glucuronide
human plasma onion Day et al, 2001
Quercetin-3 -mo no-gl ucuronide 
Quercetin-4'-mono-gluciironide
rat
plasma quercetin
Moon et al, 
2001
5 isoforms
of quercetin mono-glucuronide, 
no sulfates
human plasma food or herbal medicine
Witting et al, 2001
Table 16; Absorbed forms of quercetin in vivo: quercetin metabolites.
Positive identification of pfiase II metabolites of quercetin by LC-MS/MS analysis. The conjugation position of 
methyl, sulfate or glucuronide moieties were determined by ‘ H NMR analysis or by comparison of the HPLC 
retention time with an authentic standard. * clear identification of this compound was not possible
"S,.S:.
4.4.3. First step in metabolising quercetin: hydrolysis of quercetin glycosides
While dietary anthocyanidins appear to be absorbed intact, e.g. complete with 
various sugar moieties that are attached to the anthocyanidin structure (Miibury et al, 
2002; Rechner et al, 2002; Cao et al, 2002), most other flavonoids are extensively 
metabolised prior to their distribution throughout the body. The first step in metabolism 
is most likely de-glycosylation of quercetin glycosides (Walle, 2004; Day et al, 2003; 
Murota and Terao, 2003). Flavonoid glycosides don’t seem to be hydrolysed in the acidic 
environment of the stomach (Crespy et al, 2002; Rechner et al, 2002; Hollman et al,
1999). However hydrolysis occurs either before, during or after absorption from the 
small intestine or colon (Aura et al, 2002; Williamson, 2000; Day et al, 2003; Walle et al,
2000). Indeed, recent studies clearly showed (3-glycosidase activity (cytosolic [3-
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(Gibson and Skett, 1996). In comparison to humans, microflora in the rat stomach may
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glycosidase and LPH which is attached to the luminal side of enterocytes) in the small 
intestinal epithelium and in cultured liver and intestinal cells (Day et al, 2000; Lambert et 
al, 1999; loku et al, 1998; Day et al, 1998).
Despite these findings, there has been considerable debate over whether or not 
quercetin glycosides are absorbed intact. Some reports claim the presence of intact 
quercetin glycosides in human plasma (Aziz et al, 1998; Paganga and Rice Evans, 1997; 
Hollman et al, 1997). Initially it was hypothesised that in these studies glucuronides were 
mistaken for glycosides due to their similar absorption spectrum and HPLC retention 
time. However, two studies positively identified small amounts of quercetin glycosides in 
plasma using MS technology (Oliveira et al, 2002; Mauri et al, 1999). While absorption 
of some quercetin glycosides may be possible, most studies report that no quercetin 
glycosides were found in plasma or intestinal mucosa (Day et al, 2003; Manach et al, 
1998).
4,4.4. Phase I and II metabolism of quercetin
In analogy with the metabolism of drugs and other foreign compounds, flavonoids 
are metabolised by phase I and phase II metabolising enzymes. After the initial de- 
glycosylation step, free quercetin appears to be re-conjugated with glucuronide, methyl 
and sulfate moieties (Crespy et al, 1999; Vargas et al, 1997), presumably in the 
enterocytes directly after absorption (Crespy et al, 1999; Spencer et ai, 1999). It has been 
shown that quercetin is a substrate for UDP-glucuronyl transferases (Oliveira and 
Watson, 2000), catechol-O-methyltransferases (De Santi et al, 2002; Okushio et al, 
1999b) and phenol sulfotransferases which are present in human and animal small 
intestine and liver (Donovan et al, 2001 ; Kuhnle et al, 2000; Piskula et al, 1998).
Human and animal liver cytochrome P-450 mono-oxygenases can de-methylate 
and hydroxylate flavonols in vitro (Breinholt et al, 2002; Nielsen et al, 1998). To date 
however there is no in vivo evidence of quercetin metabolism by cytochrome P-450 
enzymes (Walle, 2004) therefore, conjugation of quercetin with glucuronide, methyl and 
sulphate groups appears to be the most likely metabolic route (Walle 2004; Williamson 
et al, 2000).
Significant inter species differences have been reported for phase II metabolism. 
Sulfation appears to be a minor pathway in the rat small intestine, in humans however, 
the intestinal SULT activity is much higher then in rats (Dunn et al, 1998; Pacifici et al, 
1988). Pigs can not form sulfate conjugates at all, and in cats glucuronidation is rare
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cause microbial degradation of compounds prior to their entry into the small intestine 
(Williamson et al, 2000). Therefore an informed choice of the model organism and 
cautious interpretation of the results are important.
4.4.5. Site of quercetin metabolism
The liver was always considered to be the chief organ for xenobiotic metabolism 
including flavonoid metabolism (Griffiths, 1982; Graefe et al, 1999; Williamson et al,
2000). The abundance and activity of the three main families of metabolising enzymes 
(cytochrome P-450 complex, UDP glucuronyl-transferases and sulfo-transferases) is 
superior in the liver in comparison to other tissues, e.g. kidney and intestinal mucosa (Lin 
et al, 1999). However metabolic transformation of flavonoids in the intestinal mucosa 
and enterocytes (Crespy et al, 1999) has been reported.
4.4.6. Quercetin catabolism
The extent of the absorption of quercetin and other dietary polyphenols from the small 
intestine appears to be relatively small (estimates range from <1% to 50%) (Erlund et al,
2000; Walle et al, 2000; Hollman et al, 1995). Therefore it is expected that the majority 
of the ingested quercetin reaches the large intestine either im-metabolised or in the form 
of quercetin conjugates. In humans, colon microflora holds a high degree of bio-catalytic 
power, with lO'^ micro-organisms per g tissue, in comparison with 10^  in the small 
intestine and 10^  in the stomach (Frank, 1992). Colonic micro flora has enormous 
potential to transform flavonoids into lower molecular weight phenolics, which may be 
bio-active in the colon. Initially, the aglycone is released from quercetin glycosides or 
quercetin conjugates by microbial (3-glycosidases, a-rhamnosidases and |3-glucuronidases 
(Aura et al, 2002; Manach et al, 1995; Bokkenheuser et al, 1987; McDonald et al, 1983). I
Colon microflora can open the C ring of the flavonol structure via hydrolytic cleavage of 
the ether bond at the 1,2 position, to catabolise quercetin into phenolic acids (Figure 4)
(Rechner et al, 2002; Justesen et al, 2000). Phenolic acids are derived from the B ring 
therefore the type of phenolic acid depends on the hydroxylation pattern of the B ring 
(Justesen et al, 2000). Phenolic acids derived from quercetin are phenyl-acetic and 
phenyl-propionic acids (Table 17). The major A ring product is phloroglucinol (1,3,5 |
trihydroxybenzene), which is thought to oxidise further forming butyrate and acetate 
(Pillai et al, 2002).
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Colonic ring fission of quercetin
OH
-OH
HO.
OH
OH
Figure 4: Ring cleavage positions in quercetin catabolism by 
colon microflora.
Colonic micro flora oxidises quercetin by opening the C ring. The 
figure shows the three possible types of ring fission. Adapted 
from Justesen et al,( 2000).
Ring fission products of quercetin
colonic m etabolites of quercetin identified by
3.4-di-hydroxy-toluol
3.4-di-hydroxy-benzaldehyde
3- or 4- hydroxy-phenyl-acetic acid
3 ,4-di-hydroxy-phenyl-acetic acid 
(homo-proto-catechuic-acid)
3- or 4- hydroxy-phenyl- 
propionic acid _____
Justesen et al, 2000
Justesen et al, 2000 
Schneider et al, 1999
Aura et al, 2002 
Justesen et al, 2000 
Kim et al, 1998 
Gross et al, 1996 
Winter et al, 1989
Aura et al, 2002 
Justesen et al, 2000 
Schneider et al, 1999 
Kim et al, 1998 
Gross et al, 1996 
Winter et al, 1989
Justesen et al, 2000
Table 17: Colonic ring fission products of quercetin.
It has been shown that phenolic acids, such as phenyl-propionic-acid are absorbed 
from the colon (Sawai et al, 1987; Jacobson et al, 1983), and may be further metabolised 
in the liver (Rechner et al, 2002). The plasma concentrations of phenolic acids can be up 
to 10 times higher than for conjugated quercetin metabolites (Rechner et al, 2002). It has
p ag e  35
Literature Review
also been reported that these phenolic acids may have potential health beneficial effects 
in vivo, hence they might be in part responsible for the reported health beneficial effects 
of quercetin (Kim et al, 1998; Merfort et al, 1996).
4.5. Quercetin excretion
Absorbed flavonoids are quickly eliminated from plasma. Few studies are able to 
detect appreciable levels of quercetin in plasma 24 h after consumption. Three major 
mechanisms for the excretion of flavonoids including quercetin have been reported: 1) 
elimination by the kidneys via urine, 2) elimination by the liver in bile and 3) elimination 
by the small intestine by active efflux transport mechanisms. The unabsorbed (majority 
of) ingested quercetin is are excreted via faeces. Before excretion, the quercetin content 
in the large intestine is subject to ring fission and further metabolism by colonic micro 
flora.
4.5.1. Urinary excretion of quercetin
After consumption of foods containing quercetin glycosides, 1-10% of the dose is 
typically recovered in urine as phase II metabolites (Graefe et al, 2001; Hollman et al, 
1997). Urine contains no or very little un-metabolised free quercetin (Rechner et al, 
2002; Petrakis et al, 1959). Quantifying urinary quercetin metabolites with intact ring 
structure (e.g. phase II metabolites) cannot be considered a reliable indicator for 
absorption as 1) urinary excretion may be only a minor route of excretion and 2) ring 
fission products constitute a large proportion of the urinary metabolites. The presence of 
ring fission products in urine appears to be dependent on microbial action in the lower 
intestine, therefore their presence in urinary may be an indicator of gut micro flora status. 
If quercetin absorption is to be quantified by urinary excretion, both phase II metabolites 
and ring fission products of quercetin need to be taken into account.
4.5.2. Quercetin in bile and enterohepatic circulation
A major route of flavonoid and quercetin excretion may be the secretion of
quercetin conjugates (particularly glucuronides) via the bile into the small intestine
(Donovan and Waterhouse, 2003; Rozman et al, 1996). Excretion from liver into the bile
depends partly upon molecular weight, and usually compounds above 350 kDa are
filtered from the blood stream (Spencer et al, 2004), Once excreted with the bile into the
intestine, quercetin conjugates may reach the colon where gut micro flora could release
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the aglycone, which may be re-absorbed and participate in enterohepatic cycling 
(Scalbert and Williamson, 2000; Scheline, 1973).
4.5.3. Quercetin in faeces
Studies using radiolabelled quercetin have reported that after an oral dose of ''Re­
labelled quercetin (1%) by rats, 45% of the administered radioactivity appeared in faeces 
and two thirds of the radiolabelled compounds in faeces were identified as unchanged 
quercetin (Ueno et al, 1983). Human volunteers also excreted radiolabelled compounds 
in faeces, both, after oral ingestion and i.v. administration of '"^0 labelled quercetin, 
however in both cases faeces contained only 5% of the administered radioactive dose 
(Walle et al, 2001). Other studies report that quercetin or rutin was completely degraded 
by colonic microflora (Aura et al, 2002; Justesen et al, 2000). The rate of orally ingested 
quercetin which is excreted unchanged in faeces, may depend on the activity of colonic 
microflora and the ingested dose.
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5. Aims of this thesis
The aims of this thesis were to address following questions: 
A. What is the true bioavailability of dietary quercetin?
o Estimates of quercetin absorption in humans range from 1% to 50%.
Which of these estimates are realistic? 
o How is absorbed quercetin distributed within the body? 
o Does quercetin accumulate in specific organs?
B. In what form is dietary quercetin bio-available?
o Does dietary quercetin-4'-glucoside appear in plasma unchanged? 
o What metabolites are found in plasma?
o Could unknown metabolites explain controversial reports of quercetin 
absorption?
o Are different metabolites found in different organs?
C. What are the active forms of quercetin in vivo?
o Is dietary quercetin contributing to human health? 
o What are the mechanisms?
o Can we formulate recommendations for dietary intake?
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Abstract
B ackground: Quercetin is a bioactive food compound whose intestinal
absorption and subsequent biological fate are still 
controversial.
Objective: To investigate the absorption, body distribution and bio­
transformation of dietary quercetin using radiolabelled 
quercetin-4'-giucoside, a major flavonol glucoside in 
onions.
Design:
Results:
Conclusions;
Twelve rats received an oral dose of 3 mg radiolabelled 
quercetin-4'-glucoside and were sacrificed at 0.5, 1, 2 and 5 
hours after the meal. The distribution of radioactivity 
within the whole body (brain, Gl-tract, heart, kidneys, 
liver, lungs, muscle, plasma, red blood cells, spleen and 
testes) was determined at 0.5, 1, 2 and 5 hours after the 
meal. Radiolabelled compounds were extracted from 
plasma and tissues and identified using HPLC with online 
radioactivity detection and tandem mass spectrometry.
Two hours after dosing all ingested quercetin-4'-glucoside 
had been metabolised. Over 85% of the ingested
radioactivity was present in the Gl-tract at all time points. 
Only extremely small amounts of radiolabelled metabolites 
of quercetin-4’-glucoside were detected in blood and 
internal organs, mainly in the liver and kidney. Over 95% 
of the absorbed quercetin was in the form of over 20 
different methylated glucuronated and/or sulfated quercetin 
conjugates. The main metabolic end products, 5 h after 
ingestion of [2-^‘^ C] quercetin-4'-glucoside, were quercetin 
di-glucuronides in liver, kidney and the Gl-tract, and
glucuronated sulfates of methylated quercetin in plasma.
About 10% of dietary quercetin-4'-glucoside was absorbed 
in rats. Quercetin occurs in the body almost exclusively as 
conjugates with the attachment of one or more methyl, 
sulfate or glucuronide groups. The main site of quercetin 
metabolism appears to be the Gl-tract. Thus the
metabolism of dietary quercetin may be primarily pre-
systemic, e.g. a defence strategy. Any systemic biological 
effects previously attributed to free quercetin must be due 
to its metabolites.
Key words: [2-^"^C]quercetin-4'-glucoside, absorption, body-
distribution, metabolism, rat-tissues, HPLC-tandem mass 
spectrometry.
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1. Background and Aim
The inferred benefits of dietary quercetin depend on its consumption, its intestinal 
absorption and subsequent distribution of active compound(s) throughout body tissues, 
where anti-carcinogenic and anti atherogenic effects may occur at a cellular level (Stahl 
et al, 2002). In recent years the absorption of dietary quercetin has been controversially 
discussed. Studies with ileostomy patients suggested that over 50% of ingested quercetin 
was absorbed from fried onion (Waile et al, 2000; Hollman et al, 1995), however the vast 
majority of studies report that < 10 % of the ingested quercetin is found in plasma or 
urine, suggesting a much lower absorption (Goldberg et al, 2003; Graefe et al, 2001; 
Erlund et al, 2000; Manach et al, 1998).
There are three possible explanations for the high disappearance of quercetin from 
the small intestine in ileostomy patients and a low quercetin recovery in plasma, and 
urine; 1) only a small amount of quercetin is absorbed, but whilst in the Gl-tract most of 
the quercetin is metabolised into other compounds, 2) large amounts of quercetin are 
absorbed and rapidly metabolised by internal tissues, or 3) large amounts of quercetin are 
absorbed and rapidly sequestered by body tissues.
The focus of this study was to determine the dynamics of quercetin absorption, 
metabolite formation, distribution and accumulation in plasma and body tissues using 
radiolabelled quercetin-4'-glucoside, a quercetin glycoside naturally present in onion.
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2. Materials and Methods
2.1. Materials
[2-"^C]quercetin-4'-0-p-D-glucoside (Figure 1) was synthesised by S.T. Caldwell 
and R. C. Hartley (Department of Chemistry, University of Glasgow, Glasgow G 12 
8 QQ) using the previously reported method for the synthesis of [2 -'‘^ C]quercetin 4 - 0  ^- 
D-glucoside (Caldwell et al, 2000). The specific activity of [2-'"^C]quercetin-4'-glucoside 
was 3.75 mCi/mmol. The standards quercetin and kaempferol were purchased from 
Sigma-Aldrich Co. Ltd. (Poole, Dorset, U.K.). Isorhamnetin was obtained from Apin 
Chemicals Ltd. (Abingldon, Oxon, U.K.). A sample of quercetin-3-glucuronide was 
kindly supplied by Prof. Gary Williamson (Food Research Institute, Norwich, UK.) 
Quercetin-4'-glucoside was generously provided by Dr. T. Tsushida (National Food 
Research Institute) Ibaraki, Japan. All other chemicals were of analytical grade and 
solvents were of HPLC grade purchased from Rathburn Chemicals Ltd. (Walkerburn, 
Peebleshire, U.K.).
OH
O-Glucose
HO
OH
OH O
Figure 1: Radiolabelled [2-’<C]quercetln-4'-glucoside.
[2-i‘’C]quercetin-4'-glucosid was synthesised by S.T. Caldwell 
and R. Hartley, Department of Chemistry, University of 
Glasgow (specific activity 3.75 mCi / mmol).
2.2. Animals and oral administration of [2-i^C]quercetin-4’-glucoside
After an overnight fast, 12 male rats (Rowett Hooded Lister strain; mean weight 
430 ±  4 g) were offered 1 g of stock rat feed (CRM, Special Diet Services, Witham, 
Essex, UK) containing 3.26 mg (7.6 mg/kg body weight) of [2-'"^C]quercetin-4'-glucoside 
to give a radioactivity dose of 58.5 x lO^dpm. The rats consumed all of the ration within 
2 min (as they were very hungry, after the overnight fast). The rat feeding and sample 
collection was carried out at the Rowett Research Institute by Phil Morrice and Dr. Garry 
G. Duthie.
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2.3. Sample collection and preparation
After 0.5, 1, 2 and 5 h, three rats were terminally anaesthetised with isofluorane 
and blood was removed by cardiac puncture into heparinised evacuated tubes (Beeton 
Dickinson, Oxford, U.K.). Plasma was obtained by centrifugation at 1000 g for 10 min at 
4 °C. The pelleted red blood cells were re-suspended in 9 ml of phosphate buffered saline 
(pH 7.4). Livers were perfused in situ with chilled 0.15 M KCl and then removed along 
with brain, heart, kidney, lung, muscle (gastrocnaemius), spleen, and testes. The 
gastrointestinal tract (Gl-tract) was removed intact including its contents. The sample 
collection was carried out at the Rowett Research Institute by Phil Morrice and Dr. Garry 
G. Duthie. All samples were immediately frozen in liquid nitrogen and stored at -80 
Upon arrival in Glasgow, all organs were freezedried and ground to a powder using 
mortar and pestle and again stored at -80  °C. The weights of the fresh and freezedried 
organs are summarized in the appendix (Appendix, Table 1).
2.4. Measurement of radioactivity
Aliquots of the freezedried and homogenized tissues (10 mg), whole Gl-tract (50 
mg) plasma (200j.il) and red blood cell suspension (150pl) were digested in 0.5 ml Biosol 
tissue solubilizer (National Diagnostics, Hull, UK) for 3 h at 50 °C in a shaking water 
bath. With the exception of red blood cells, which were bleached using 1.75 ml of a 25% 
solution of sodium hypochlorite, the solublization treatment produced clear solutions. 
Aliquots of the solubilized tissue were added to scintillation fluid (Optiflow Safe One, 
Fisons, Loughborough, UK) and the radioactivity was determined using a Wallac 1409 
liquid scintillation counter (Pharmacia, Uppsala, Sweden). Representative samples of all 
analysed tissues were assayed for quench interference. The tissue-scintillation fluid mix 
was diluted six fold with additional scintillation fluid and the radioactivity was measured 
by liquid scintillation counting. When the measured radioactivity was equivalent in 
diluted samples and undiluted samples, it was assumed that quenching had not interfered 
with the measurement.
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2.5. Extraction of metabolites from tissues, red blood cells and plasma
2.5.1. Method development
Aliquots of lyophilised and homogenised liver tissue (from liver samples collected 
at 0 . 5  h) were extracted under continuous shaking using different extraction solvents 
(Figure 2). After 30 min, the mixture was centrifuged at 2000 g for 20 min, the 
supernatant was collected and the pellet re-extracted with the same solvent two more 
times. The recovery of radiolabelled compounds was determined by the choice of the 
extraction solvent. 99% of the radioactivity, which was originally present in the tissue 
sample, went into solution when a 50% methanol/50% phosphate extraction buffer was 
used (Figure 2). The phosphate buffer was made up by adding a solution of 0.1 M 
K2 HPO 4  to a solution of 0 .1 M KH 1 PO 4  until a pH of 7.0 was obtained. The phosphate 
buffer was diluted by 50% with methanol and 20 mM sodium diethyldithiocarbamate 
was added as an antioxidant. To obtain a clear separation of the individual radiolabelled 
compounds by HPLC analysis the extracts were further purified as described in the next 
section.
Extraction solvents determine the extraction efficiency
100% acetone 
100% ethylacetate 
50% acetone / 40% methanol /10%  diethylether 
50% methanol containing 0.83 M acetic acid 
50% methanol / 50% acetone 
100% methanol 
80% methanol 
65% methanol 
50% methanol / 50% phosphate buffer 
50% methanol 
30% methanol 
10% methanol
0% 20% 40% 60%
radiolabelled compounds
80% 100%
Figure 2: Extraction of radiolabelled com pounds with different solvents.
Lyophilised and homogenised liver tissue was extracted with different extraction solvents under continuous 
shaking. After centrifugation, the supernatant was collected and the pellet was extracted with the same 
solvent for two more times. The graph shows the sum of the recovered radioactivity from three consecutive 
extractions.
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2.5.2. Final tissue and plasma extraction method
Freezedried and homogenised tissues from rats sacrificed at the same timepoint 
were pooled, and 1 g aliquots were extracted (Figure 3) by continuous shaking with 15 
ml of 50% methanol in 0,1 M phosphate buffer (pH 7.0) containing 20 mM sodium 
diethydithiocarbamate as an antioxidant. After 30 min, the mixture was centrifuged at 
2000g for 20 min. The methanolic supernatant was decanted and the pellet re-extracted a 
further two times. The three methanolic supernatants were combined, and the methanol 
was removed in vacuo. The remaining aqueous phase was adjusted to pH 3 using 25% 
H2 SO 4  and partitioned three times with an equal volume of ethyl acetate.
Extraction protocol
plasma freeze-dhed tissue
protein predpltatlon I X Li extraction with
with acetone U 50% methanol 1XI 50% phosphate buffer
addition of (pH7)
phosphate buffer a
- organic solvent was dried off
- resulting aqueous phase was addtfled to pH 3 
and partitioned against ethyl acetate (3 times)
aqueous phase ethyl acetate phase
a filtered, dried and compounds were reconstituted in methanolsep pak cartridge 
eluted with methanol
V
concentrated and purified 
aqueous extract
concentrated and purified ethyl 
acetate extract
a  j }
separation and Identification of 
radiolabelled compounds using 
HPLC analysis with RC and MS-MS
Figure 3: Extraction and purification of radiolabelled com pounds 
from rat t issu es  and plasma. Schematic depiction of the extraction 
protocol.
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Extraction efficiency in %: 
Radiolabelled compounds extracted from rat tissues and plasma
extraction a queou s p h ase ethyt acetate  ph ase
I I - III r drying organic  so lven t off
after after elution
partitioning from se p  pak
after
partitioning
average: 8 9 '
Section
extraction
efficiency
final recovery
Gl-tract 68 (±6) 19 (±3) 5(±1) 92 (±10) 78 (±16) 14 (±10) 8 (±7) 56 (±10) 64 (±14)
liver 75 (±6) 10 (±4) 4 (±2) 94 (+11) 70 (±8) 43 (±8) 28 (±8) 19 (±11) 46 (±9)
kidney 84 (±7) 16 (±6) 4 (±3) 104 (±12) 94 (±11) 34 (±8) 18 (±4) 24 (±18) 42 (±20)
plasma 65 (±11} 0(±1) 0(±0) 66 (±11) 66 (±13) 51 (±14) 42 (±9) 6 (+4) 48(±9)
average: 50 ‘
Table 1 : Extraction efficiency of radiolabelled com pounds from rat tissue and plasma.
Quercetin and its metabolites were extracted from rat tissue (Gl-tract, liver and kidney) and plasma collected at 0.5,1, 
2 and 5 h after oral ingestion of [2-i''C]quercetin-4'-glucoside. The table shows the extraction efficiency (recovery of 
radiolabelled compounds in the extracts) at various stages of the purification and concentration process (Figure 3). 
The extraction efficiency (in %) is calculated as the ratio: activity in the extract / initial activity In each sample x 100. All 
radioactivity measurements were carried out in duplicate, by adding a 50 pi aliquot of the extract to 5 ml scintillation 
fluid followed by liquid scintillation counting. Values in the table are the mean (±SD) of four extractions.
I
:
■'I
■I
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The ethyl acetate extracts were combined and reduced to dryness in vacuo, then re­
suspended and stored in methanol at -80  °C. A gentle stream of nitrogen was used to 
remove residual ethyl acetate from the aqueous phase before it was loaded onto a 2  g C i8 
Sep Pak cartridge (Waters, Milford, Massachusetts, USA). The cartridge was washed 
with 15 ml of distilled water adjusted to pH 3.0 (with H 2 SO 4 ) and the radiolabelled 
compounds were eluted with 30 ml of methanol. The methanolic eluent was reduced to 
dryness in vacuo, re-suspended in methanol, and stored at -80  °C.
To precipitate proteins, plasma was treated twice for 10 min with 2.5 volumes of 
acetone. After centrifugation the two acetone extracts were combined, 20 ml of 0.1 M 
phosphate buffer (pH 7.0) was added and in vacuo reduced to the aqueous phase. The 
ethyl acetate and aqueous extracts were obtained as described above. Over 89% of the 
radioactivity, which was originally present in the tissues/plasma, went into solution 
during the extraction process (Table 1). The concentrated purified extracts contained on 
average 50% of the radioactivity originally present in the tissues and plasma.
The concentrated ethyl acetate and aqueous extracts were analysed individually 
(extracts from organs collected at 1 and 5 h), or were combined before analysis (extracts 
from organs collected at 0.5 and 2 h). The samples were dissolved in the HPLC mobile 
phase and analysed as described below.
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2.6. Identification of radioiabelied compounds by LC-MS/MS analysis
Aliquots of plasma and tissue extracts containing ca. 30,000 dpm of radioactivity, 
were analysed on a P4000 high performance liquid chromatograph (HPLC) fitted with an 
AS 3000 autosampler and with the initial detection by a UV6000 diode array absorbance 
monitor scanning from 250 to 700 nm (Thermo Finnigan, San Jose, CA, USA). 
Separation of the radiolabelled compounds was carried out using a 240 x 4.6 mm i.d. 4 
\xM Synergy RP-Max column (Phenomenex, Macclesfield, UK), eluted with a 60 min 
gradient of 5-40% acetonitrile in 1% formic acid at a flow rate of 1 ml/min at 40 °C. 
After passing through the flow cell of the UV absorbance monitor, the column eluate was 
split by 50%, and simultaneously directed to a radioactivity monitor (Reeve Analytical 
Model 9701, Lab Logic, Sheffield, UK), and to a Finnigan LCQ Duo tandem mass 
spectrometer with an electrospray interface in negative ion mode operating in full scan 
mode from 150 to 2000 amu. The parallel connection of the radioactivity monitor with 
the tandem mass spectrometer was set up by Mr. Bill Mullen, who also maintained the 
equipment and injected the samples. The radiolabelled compounds were identified by 
MS-MS analysis, comparison of HPLC retention times, the elution pattern, UV 
absorption values at 365 nm and their UV diode array spectra. The MS-MS data was 
analysed by Mr. Bill Mullen and Brigitte A. Graf using LCQ™ Deca XP (Revision 1.2) 
software for Xcalibur™ (Thermo Finnigan, San Jose, CA, USA).
2.7. Quantification of radiolabelled compounds
2.7.1. Initial peak quantification
Our MS/MS software package did not include integration software for peak 
quantification, therefore all radiolabelled compounds (=peaks) were quantified by 
measuring peak heights in HPLC-RC chromatograms (Figure 6).
The measured peak heights (in cm) were converted into ‘y-axis-scale’ units, 
considering the individual scales of the y-axis’ of each chromatogram (Table 2, step 1, 2 
and 3). The ‘y-axis-scale’ units were transformed into dpm (disintegrations per minute), a 
standard measure for radioactivity, based on the assumption that the sum of all peaks in 
one chromatogram, was identical with the injected radioactivity in dpm (Table 2, step 4). 
The radioactivity (in dpm) represents the number of molecules which contain a 
radiolabelled C atom, e.g. 1 pmol of [2-^"^C]quercetin-4'-glucoside or any [2- 
^^C]metabolite has a radioactivity of 8.3 x 10  ^dpm.
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The result of the quantification calculation at this stage (Table 2, step 4) is the 
actual quantity of each metabolite (in dpm which is convertible into qmol) in the 
analysed aliquot of the extract. To calculate the total amount of metabolites per whole 
organ (Table 2, step 5), the amount of radioactivity which was recovered in the final 
extract was considered, together with the weights of the freezedried and fresh organs 
(Appendix, Table 1).
The final quantification results (Appendix, Table 4) are the amounts of the 
individual metabolites per whole organ. On average 50% of the original radioactivity was 
present in the purified and concentrated extracts. However for every extracted organ the 
recovery rate varied slightly (Table 1 and Appendix, Table 2). In order to compare the 
quantities of the individual metabolites between different organs, in Table 6 , 8  and 9; 
Figure 7 the metabolite quantities are given as a percentage of the extracted and analysed 
radioactivity (radioactivity present in the purified concentrated extract ~ 50% of the 
original radioactivity = analysed radioactivity = 100%). This way the results reflect 
accurately our data but remain comparable. We assume that the losses of radioactive 
compounds during the purification and concentration process were ubiquitous not 
specific, e.g. not selected compounds, but a small quantity of all compounds were lost 
equally in the purification process.
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Five step metabolite quantification
step 1 : Measurement of peak height:
e.g. peak 5 in chromatogram obtained from liver 0.5 h after dosing: 
peak 5 = 8.50 cm (on an A4 print out of the chromatogram)
Step 2: Conversion of peak height into y-axis-scale' units:
8.50 cm = 0.15758 'y-axis-scale' units /  injection of 75,385 dpm
Step 3: Adjustment of injected radioactivity:
peak 5 = 0.15758 ‘y-axis-scale’ units /  injection of 75,385 dpm ^  
peak 5 = 0.06303 'y-axis-scale' units / injection of 20,000 dpm
Step 4: Convert radioactivity units into dpm:
The sum of all peaks in this chromatogram ~ 0.54431 ‘y-axis-scale’ units. 
=> 0.54431 ‘y-axis-scale’ units = 20,000 dpm
peak 5 = 0.06303 ‘y-axis-scale’ units = 2,316 dpm
Step 5: Quantity of metabolites per whole organ:
The whole organ contained 1,126,615 dpm,
50% of the original activity was present in the purified concentrated extract. 
100% = 1,126,615 dpm 
50 % = 563,307.5 dpm
=>
if the whole tissue would have been extracted (recovery 563,307.5 dpm), 
peak 5 would have a quantity of 65,231 dpm
Table 2: Five step peak quantification.
All individual radiolabelled compounds (=peaks in chromatograms obtained with the radioactivity detector) were 
quantified by measuring their peak heights. Subsequently, the quantity of each metabolite per whole organ was 
calculated using a 5 step quantification method as shown above. The calculation is demonstrated for metabolite peak 
5 detected in liver, 0.5 h after dosing. For the final peak quantification, an abbreviated quantification method was used 
as described underneath and a calculation example is shown in Table 3.
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Table 3: Abbreviated method for metabolite quantification (by Bill Mullen).
All individual radiolabelled compounds (=peaks in chromatograms obtained with the radioactivity detector) were 
quantified by measuring their peak heights. Subsequently, the quantity of each metabolite per whole organ was 
calculated using the abbreviated three step quantification method (devised by Bill Mullen). The calculation is 
demonstrated for metabolite peak 5 detected in liver, 0,5 h after dosing.
2.7.2. Abbreviated method for metabolite quantification
The peak heights were directly converted into metabolite quantity per whole organ, 
using a simple 3 step method, devised by Mr. Bill Mullen. The sum of the measured peak 
heights (in cm) was assumed to be 100% (Table 3, step II), and each peak was given a 
percentage value reflecting its quantity in the analysed sample. This percentage value 
was directly used to calculate the amount of the radiolabelled compound per whole organ 
(Table 3, step III), assuming that the extracted aliquot of freezedried tissue represented 
the metabolite spectrum in the whole organ. The abbreviated 3 step quantification 
method gave identical results as the above described 5 step method, hence the shorter 
method was used for the final peak quantification of all samples. %
Three step metabolite quantification
step I: Measurement of peak height:
e.g. peak 5 in chromatogram obtained from liver 0.5 h after dosing: 
peak 5 = 8.50 cm (on an A4 print out of the chromatogram)
Step II: Conversion of peak height into a percentage of the injected sample:
Sum of all peak heights = 73.40 cm = 100%
peak 5 = 8.50 cm = 11.58 %
Step 111: Quantity of metabolites per whole organ:
The whole organ contained 1,126,615 dpm,
50% of the original activity was present in the purified concentrated extracts. 
100% = 1,126,615 dpm 
5 0 % =  563,307.5 dpm
=>
if the whole tissue would have been extracted (recovery 563,307.5 dpm), 
peak 5 would have a quantity of 11.58% = 65,233 dpm
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3. Results
3.1. Distribution of radioactivity in body tissues and piasma
The distribution of the radioactivity in the rats was determined at 0.5, 1, 2 and 5 h 
after the meal. At all time points, 86%-93% of the ingested radioactivity was present in 
the Gl-tract (Figure 4), which included the stomach, small and large intestine, and their 
contents. Thirty minutes after the meal, 7.2% of the ingested radioactivity was present in 
internal organs (liver, kidneys, heart, lungs, spleen, testes and brain) and blood (Table 4), 
indicating early absorption from the upper Gl-tract. The absorbed radioactivity was 
distributed throughout all analysed organs, but the amounts present in the spleen, red 
blood cells and the brain were minute. Highest levels were detected in the plasma, liver 
and kidney with a peak concentration of 2.9% (14 p.M), 1.9% and 1.0% of the ingested 
radioactivity at 0.5 hours (Table 4). The total radioactivity present in internal organs and 
plasma was highest at 0.5 h and decreased thereafter over the time course of the 
experiment, indicating no retention and quick excretion of radiolabelled compounds.
3.2. Separation and identification of radioiabeiied metaboiites
HPLC-RC analysis of methanolic extracts of the rat feed confirmed that the only 
radiolabelled compound present in rat feed was [2-*"^C]quercetin-4'-glucoside, and no 
metabolites had formed prior to dosing (Figure 5). The HPLC-RC profiles obtained from 
tissue and plasma extracts (Figure 6) show a complex pattern of radiolabelled 
metabolites with 27 major peaks heing detected. Using negative ion, electrospray, 
tandem mass spectrometry, 22 of the 27 detected metabolites were identified as quercetin 
conjugates with one or two glucuronyl, methyl or sulfate groups attached as detailed in 
Table 5.
3.2.1. Ingested [2-i4C]quercetin-4'-glucoside:
Peak 18 (retention time 33.87 min) was identified as the ingested [2-*'^C]quercetin- 
4'-glucoside on the basis of its co-elution with an authentic standard and MS analysis. 
MS analysis detected a molecular ion (M“) with a mass to charge ratio (m/z) of 463, 
which disintegrated into a fragment ion at m/z 301. Hence, a neutral molecule of the size 
of 162 atomic mass units (amu) was split from the molecular ion, corresponding to the
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Body distribution of [2-i4C]quercetin-4'-glucoside or its metabolites
1 0 0 %II
T3I 1%
I  0.1%
0 5  1 2
hours after the meal □
Figure 4: Body distribution of [2-^'>C]quercetin 4 ' glucoside or its metabolites in rats.
Graphical depiction of data given in Table 4 (underneath). The y-axis has a logarithmic scale.
Tissuv/fluid 0.5 hours 1 hour 2 hours 5 hours
plasma 1.696 ±401 (2.90 %) 1.644 ± 157 (2.81 %) 1,460 ± 3 5 (2.50 %) 982 ± 149 (1 .68% )
Red blood cells 7 ± 2 (0.01 %) 4 ± 4 (0.01 %) 5 ± 2 (0.01 %) 5 ± 2 (0.01 %)
Kidneys 595 ± 3 4 6 ( 1.02 %) 468 ± 295 (0.80 %) 104 ± 12 (0 .18% ) 163 ± 8 5 (0.28 %)
Liver 1,127 ± 623 (1.93 %) 684 ± 2 4 0 (1 .17% ) 304 ± 7 8 (0.52 %) 155 ± 2 2 (0.27 %)
Spleen 5 ± 1 (0.01 %) 6 ± 1 (0.01 %) 5 ± 1 (0.01 %) 18 ± 3 0 (0.03 %)
Brain 0 ± 0 (0.00 %) 1 ± 1 (0.00 %) 1 ± 2 (0.00 %) 1 ± 2 (0.00 %)
lungs 25 ± 3 (0.04 %) 38 ± 10 (0.07 %) 27 ± 7 (0.05 %) 14 ± 3 (0.02 %)
Heart 15 ± 2 (0.03 %) 18 ± 2 (0.03 %) 16 ± 4 (0.03 %) 9 ± 3 (0.02 %)
Muscle 753 ± 2 8 9 (1.29 %) 839 ± 3 1 0 (1.43 %) 471 ± 7 6 (0.81 %) 130 ±51 (0.22 %)
testes 7 ± 3 (0.01 %) 25 ± 3 (0.04 %) 33 ± 6 (0.06%) 24 ± 7 (0.04 %)
Sum 4.230 ± 1.376 (7.23 % ) 3.727 ± 405 (6.37 %) 2,426 ± 193 (4 .15% ) 1,501 ± 315 (2.57 %)
Gastro-intestinal-tract 
(including contents) 50,303 ± 4,460 (85.99 %) 54,530 ± 4,728 (93.21 %) 51,494 ±8.091 (88.02 %) 53 870 (92.09 %)
Recovered radioactivity 
from rats 54.533 ± 5,569 (93.22 %) 58,257 ±4.804 (99.58 %) 53,920 ±8,143 (92.17% ) 55 371 (94.65 %)
Table 4: Body distribution of [2-i^C]quercetin 4'-glucoside or its metabolites in rats.
Distribution of radioactivity in rats 0.5, 1, 2, and 5 h after ingestion of [2-’‘*C]quercetin 4'-glucoside (58.5 x 10  ^dpm). 
Radioactivity was measured by liquid scintillation counting after treating tissues/plasma with tissue solublizer. 
Radioactivity is expressed as dpm x 10  ^per tissue/fluid per whole rat ± standard deviation (n = 3), and in parenthesis 
as a percentage of the administered radioactivity.
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molecular weight of the glucosyl unit of [2- C]quercetin“4'-glucoside. The fragment ion 
at m/z 301 corresponds with the molecular weight of quercetin: 302 amu less 1 amu due 
to the ionisation process during the MS analysis. The specific activity of the [2- 
*‘^ C]quercetin-4'-glucoside was 3.75 mCi/mmol, indicating that only about 8 % of the 
quercetin-d'-glucoside molecules were radiolabelled, thus heavier by 2 amu. Therefore in 
the MS analysis, the major ions come from the “cold” quercetin-4’-glucoside not the 
radiolabelled quercetin-4’-glucoside, which would display a m/z value of 303 (molecular 
weight; 302 amu + 2 amu for the heavier C atom -  1 amu due to ionisation = m/z value of 
303).
[2-"^C]quercetin-4'-glucoside was essentially present only in the Gl-tract at 0.5 and 
1 h after ingestion (Table 6). No intact [2-‘"^C]quercetin-4'-glucoside was detected in the 
kidney and plasma, however the liver contained a very small amount at 0.5 h.
3.2.2. Quercetin
Free quercetin (peak 24, retention time 43.73 min) was identified on the basis of its 
coelution with an authentic standard and MS analysis. A molecular ion (M‘) at m/z of 301 
was detected and no fragments were formed. Quercetin was present in the Gl-tract at all 
time points. No free quercetin was detected in plasma, although small amounts were 
present in liver and kidney at some time points.
3.2.3. Mono-glucuronides
Seven different radiolabelled compounds (peak 12, 15, 19, 20, 21, 22 and 23) were 
identified as glucuronide conjugates of quercetin and methyl-quercetin. Quercetin mono­
glucuronides (peak 12, 15, 22 and 23) had a M' at m/z 477 which fragmented into m/z of 
301, indicating that a neutral molecule with a molecular weight of 176 amu had been 
attached to quercetin. According to its molecular weight, it was concluded that the 
attachment was a glucuronyl group. Peak 12 was identified as quercetin-3-glucuronide on 
the basis of its coelution with an authentic standard. To further confirm that a neutral loss 
of 176 resembled the cleavage of a glucuronyl group, tissue extracts were treated with p- 
glucuronidase, which would selectively split glucuronyl units from the main molecule. If 
the enzyme treatment would release free quercetin or methyl quercetin, (which would 
have been readily detectable using HPLC-RC) the 176 unit could have been only a 
glucuronyl group. Unfortunately, the hydrolysed samples were lost in the Bower 
Building fire, and it was not possible to repeat the experiment.
Peaks 19, 20 and 21 had a M" at m/z 491 which fragmented into a m/z ion of 315.
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The cleaved neutral molecule had a molecular weight of 176 amu indicating that a 
glucuronyl unit had been attached. From previous analysis of flavonol standards we 
know that isorhamnetin (S'-O-methyl-quercetin) and tamarixetin (4'-0-methyl-quercetin) 
has a M' of m/z 315, therefore peaks 19, 20 and 21 were identified as glucuronides of 
methylated quercetin. The different retention times of the mono-glucuronide metabolites 
indicated different positioning of the methyl and/or glucuronide groups on the quercetin 
molecule, changing the polarity and the elution behaviour of that molecule.
Mono-glucuronides were present in all organs, but only at 0.5, 1 and 2 h after the 
ingestion of [ 2 - quercetin-4'-glucoside. After 5 h mono-glucuronides were found only 
in the liver in relatively small amounts.
3.2.4. Di-glucuronides
Nine of the radiolabelled metabolites (peak 3, 5, 6 , 7, 8 , 9, 10, 11, 14) were 
identified as di-giucuronide conjugates of quercetin and methyl-quercetin. Quercetin di- 
glucuronides (peak 3, 6 , 7, 9, 10 and 11) had a M‘ at m/z 653 which fragmented to 
produce ions at m/z 477 and 301. Two neutral molecules have been cleaved from the M', 
both with a molecular weight of 176 amu, indicating that two glucuronyl have been 
attached to the quercetin molecule. Mullen et al, 2002 assumed that the two glucuronyl- 
units were attached at two different positions on the basis of previous results showing 
that disaccarides conjugated to anthocyanins fragmented with a loss of the intact 
disaccaride unit (Giusti et al, 1999). Peak 5, 8  and 14, were identified as methyl- 
quercetin with the attachment of two glucuronyl units, as they displayed a M' at m/z 667 
which fragmented to produce ions at m/z 491 and 315.
Di-glucuronides were the major group of metabolites in liver and kidney at all 
timepoints, and in the Gl-tract at 5 h. In plasma the quantity of di-glucuronides was 
highest at 0.5 h and decreased thereafter.
3.2.5. Sulfates
Five different radiolabelled compounds contained a sulfate moiety. Peaks 13,16 
and 17 were identified as glucuronated and sulfated quercetin or methyl-quercetin. With 
a M at m/z 557 which fragmented to produce ions at m/z 477, 381 and 301, peaks 13 and 
17 were identified as conjugates of quercetin with a glucuronyl unit and a sulfate unit 
attached. A sulfate (SO3) adduct is characterised by a neutral loss of 80 amu. The 
fragmentation pattern indicates that the glucuronyl unit and the sulfate unit are cleaved
off separately (see Table 1-3). Peak 16 had a M at m/z 571 which fragments at m/z 491,
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395 and 315, revealing that it was a conjugate of methyl-quercetin with the attachment of 
a sulfate and a glucuronyl unit. Small amounts of glucuronated sulfates were present in 
liver, kidney and the Gl-tract at most timepoints. In plasma, the quantity of glucuronated 
sulfates increased with time, and after 5 hours, 76% of all metabolites present in plasma 
were glucuronated sulfates. Peak 25 was a methyl-quercetin sulfate (M" at m/z 395 which 
fragmented to m/z 315) and peak 26 was a quercetin sulphate (M" at m/z 381 which 
fragmented to m/z 301). Both of these sulphated metabolites were found only in the 
intestine at 0.5, 1 and 2 h.
3.2.6. Un-identified metabolites
Metabolite peaks 1, 2 and 4 were not identified, as they did not yield recognisable 
mass spectra. All three metabolites had relatively short HPLC retention times indicating 
that they are relatively polar molecules. Metabolite peak 4 appears in small quantities in 
intestine, liver and kidney. Metabolites 1 and 2 appear only in the intestine 5 h after 
ingestion.
3.3. Metabolite spectra In tissues and plasma
3.3.1. Gl-tract
At 0.5 h half of the total ingested dose was metabolised (Table 4 and 8). At this 
early stage, mono-glucuronides, di-glucuronides and sulfated quercetin and/or methyl- 
quercetin conjugates were detected in the Gl-tract together with free quercetin and its 
methylated derivative isorhamnetin. At one and two hours after the meal, mono­
glucuronides formed a major portion of the metabolites. Five hours after the meal the 
mono-glucuronides had disappeared and di-glucuronides formed the major class of 
metabolites.
3.3.2. Plasma
Neither quercetin nor the ingested quercetin-4’-glucoside were detected in plasma
at any time point. In plasma, the amount of di-glucuronides decreased over the time
course of the experiment and mono-glucuronides were present only at 0.5 and 1 h after
the meal. However, the amount of glucuronidated sulfates increased steadily and 5 h after
the meal glucuronated sulfates form the major group of metabolites in plasma in the form
of peak 13, a sulfated quercetin glucuronide, and peak 16 a methylated, sulfated
quercetin glucuronide. Peak 16 was the predominant metabolite in plasma at 5 hours,
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representing 62% of the radioactivity in plasma at that time point.
3.3.3. Liver and kidney
In both liver and kidney the most abundant group of metabolites were di- 
glucuronides followed by mono-glucuronides and sulfated glucuronides. The amount of 
di-glucuronides increased steadily over the time of the experiment. Small amounts of free 
quercetin were detected in the liver, and in kidney. In the liver a small amount of 
quercetin-4*-glucoside was present at 0.5 h.
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Figure 5; HPLC-RC trace of rat feed containing 
[2-i‘’C]quercetin-4'-glucoside.
The rat feed was extracted and analysed by gradient, reverse 
phase HPLC-RC to confirm that [2-i4C]quercetin-4'-glucoside was 
stable in the food matrix and that no metabolites had formed prior to 
dosing.
Gl-tract (0.5 fi)
0 10 20 30 40 50 60
Liver (0 .5  h)
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Figure 6: HPLC-RC traces of plasma and tissu e  extracts after oral ingestion of [2-^'*C]quercetin 4'-glucoside by 
rats.
Extracts were analysed by gradient, reverse phase HPLC-MS/MS with online radioactivity detection. The above 
chromatograms show radiolabelled compounds in the Gl-tract and liver at 0.5 h and in plasma at 2 h after ingestion of 
[2-i'‘C]quercetin 4'-glucoside by rats. HPLC retention times and MS-MS data on these and other metabolite peaks are 
given in Table 5.
I
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Identification of radioiabeiied compounds by tandem mass spectrometry
peak UT (min) compound [M-H]' (m/z) MS^ fragment ions (m/z)
1 9.30 Not identified
2 12.04 Not identified
3 17,22 Quercetin di-gluciironide 653 477 ([M-H]--GlcUA) 301 ([M-H]--GlcUA -GlcUA)
4 20.05 Not identified
5 21.32 Methylated quercetin di-glucuronide 667 491 ([M-H]--GlcUA) 315 ([M-H]--GlcUA -GlcUA)
6 23.10 Quercetin di-glucuronide 653 477 ([M-H]--GlcUA) 301 ([M-H]--GlcUA-GlcUA)
7 24,24 Quercetin di-gUicuronide 653 477 ([M-H]--GlcUA) 301 ([M-H]--GlcUA -GlcUA)
8 24.40 Methylated quercetin di-glucuronide 667 491 ([M-H]--GlcUA) 315 ([M-H]--GlcUA -GlcUA)
9 24.92 Quercetin di-glucuronide 653 477 ([M-H]--GlcUA) 301 ([M-Hl'-GlcUA-GlcUA)
10 26.27 Quercetin di-glucuronide 653 477 ([M-Hr-GlcUA) 301 ([M-H]--GlcUA-GlcUA)
! 1 27.95 Quercetin di-glucuronide 653 477 ([M-H]'-GlcUA) 301 ([M-H]--GlcUA -GlcUA)
12 29.38 Quercetin-3-glucttronide 477 301 ([M-H]--GlcUA)
13 29.54 Quercetin mono-glucuronide sulfate 557 477 ([M-Hj -SOO 381 ([M-H]--GlcUA) 301 ([M -H]-SOi-GlcUA)
14 30.26 Methylated quercetin diglucuronide 667 491 (tM-H]--GlcUA) 315 {[M-H]--GlcUA -GlcUA)
15 31.12 Quercetin mono-glucuronide 477 301 (tM-Hj-GlcUA)
16 31.77 Methylated quercetin mono-glucuronide sulfate 571 491 ([M-HJ--SO,) 395 ([M-H]--GlcUA) 315 ([M -H]-SO,-GlcUA)
17 33.16 Quercetin mono-glucuronide sulfate 557 477 ([M-H]--SO,) 381 ([M-H]--GlcUA) 301 ([M -H]-SO,-GlcUA)
18 33.87 Quercetin-4'-glucoside 463 301 ([M-H]'-Glc)
19 35.01 Methylated quercetin mono-glucuronide 491 315 ([M-H]--GlcUA)
20 35.89 Methylated quercetin mono-glucuronide 491 315([M-H]--GlcUA)
21 36.70 Methylated quercetin mono-glucuronide 491 315 ([M-H]-GlcUA)
22 36.74 Quercetin mono-glucuronide 477 301 ([M-H]--GlcUA)
23 38,70 Quercetin mono-glucuronide 477 301 (fM-H]-GlcUA)
24 43.73 Free quercetin 301
25 50.36 Methylated quercetin sulfate 395 315([M -Hr-SO,)
26 50.56 Quercetin sulfate 381 301 ([M-Hl-SO,)
27 52.38 Isorhamnetin (methylated quercetin)
Table 5: Identification of metabolites of [2- '^‘C]quercetin-4'-glucoside isolated from rat plasma and tissu es .
Extracts were analysed by gradient, reverse phase HPLC with online radioactivity detection and paraleil MS/MS 
detection. The above table shows HPLC retention times, negative ion MS-MS fragmentation patterns and identification 
of metabolites isolated from rat tissues and plasma after oral ingestion of [2-i'<C]quercetin 4'-glucoside. Peak numbers 
refer to the order of elution from the column. (RT = retention time, [M-H]- = molecular ion, m/z = mass to charge ratio, 
GlcUA = glucuronyl unit, Glc = glucosyl unit). The identity of quercetin-3-glucuronide (peak 12) was confirmed by an 
authentic standard kindly provided by Prof. Gary Williamson. Examples of typical MS trances of quercetin metabolites 
are shown in Appendix Figure 1.
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Relative quantity of radiolabelled metabolites in rat tissues and plasma
peak Compound 0.5 hours 1 hour
2 hours 5 hours
iiuost'mc pliisma tUdneys inlcstinu pla.sm;i liver kidneys iiilcsllnn plasma kidneys iniestiin; plasma kidncy.s
1 Not identified - - - - - - - - - - - - 10.6 - - -
2 Not identified - - - - ■ - - - - - - - 10.8 - - -
3 Quercetin di-glucuronide - - 3.8 6.3 0.8 - 6.4 7.4 - - - 25.4 - - 35.5 40.3
4 Not identified 1.8 - - 3.4 0.8 - - 4.5 3,0 - - - - - 4.7 3.4
5 Methylated quercetin di-glucuronide - - 11.6 15.7 1.3 - 13.0 17.0 5.5 - 4.8 15.3 - - - -
6 Quercetin di-glucuronide - 1.2 - 3.1 0.2 6.4 - - 2.9 9.7 3.1 - 2.4 7.8 42.5 17.4
7 Quercetin di-giucuronide - 4.4 - - - - - - - - - - - 3.2 - -
8 Methylated quercetin di-glucuronide - - 6.8 12.1 0.6 - - 12.5 7.2 - - 3.6 2.1 - - 2.5
9 Quercetin di-glucuronide - 6.2 - 5.4 - 3,7 - - - 5.4 6.8 16.6 - 3.2 - -
10 Quercetin di-glucuronide 2.2 30.0 15.0 1.3 2.5 20.5 33.5 11.7 14.9 14.9 29.9 19.1 66.7 2.1 8.4 33.7
11 Quercetin di-glucuronide 4.5 10,6 7.1 5.9 0.6 8.2 4.0 8.4 3.6 5.7 7.7 3.4 - 1.8 - -
12 Quercetin-3-glucuronide - 9.2 - 5.9 10.6 2.1 6.9 7.9 8.6 - - - - - - -
13 Quercetin glucuronide sulfate - 1.6 6.8 - 6.9 13.8 3.0 - 7.0 16.8 8.3 - 1.2 14.1 - -
14 Methylated quercetin di-glucuronide - - - - - - - - - - - - - 5.7 - -
15 Quercetin mono-glucuronide - 16.0 - - - - - - - - - - - - -
16 Methylated quercetin glucuronide sulfate - 9.4 22.5 2.3 0.7 43.6 12.8 3.1 7.1 47.5 20.1 - - 62.2 - -
17 Quercetin glucuronide sulfate - 3.3 - - - - - - - - - - - - 1.7 1.0
18 Quercetin-4'-glucoside 49.0 - 1.8 - 26.2 - - - - - - - - - - -
19 Methylated quercetin mono-glucuronide - 1.1 10,5 9.1 6.5 0.5 13.4 7.7 7.2 - 8.3 7.8 - - 2.9 -
20 Methylated quercetin mono-glucuronide 2.5 2,1 8.3 22.4 4.9 0.4 5.6 16.8 7.0 - 3.9 8.9 - - - -
21 Methylated quercetin mono-glucuronide - 2.6 5.9 7.0 12 2 0 8 - 3 1 9.2 - 7.1 - - - - -22 Quercetin mono-glucuronide 3.3 - - - - - - - - - - - -
23 Quercetin mono-glucuronide - 2,3 - - - - - - - - - - - - - -
24 Free quercetin 25.1 - - - 7.2 - 1.5 - 6.7 - - - 6.1 - 4.3 1.8
25 Methylated quercetin sulfate - - - - 17 9 - - - - - - - - - - -26 Quercetin sulfate 6.5 - - - - - - 9.1 - - - - - - -
27 Isorhamnetin 5.1 - - - - - - - 1.0 - - - - - - -
■f
Table 6: Relative quantity of radiolabelled m etabolites in rat plasma and t issu es  after oral ingestion of [2- 
i''C]quercetin-4'-glucoside.
Radiolabelled metabolites were extracted from the Gl-tract, plasma, liver and kidney, and identified using HPLG-RC- 
MS. The quantity of each metabolite is expressed as a percentage of the total recovered radioactivity from each organ 
(given in Table 4).
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Section
Four types of quercetin conjugates
Di-glucuronides (6 isoforms) Quercetin + Glucuronic acid + Glucuronic acid
Di-glucuronides (9)
Methylated Di-glucuronides (3 isoforms) Quercetin
+ Methyl group 
4- Glucuronic acid 
+ Glucuronic acid
Mono-glucuronides (4 isoforms) Quercetin + Glucuronic acid
Mono-glucuronides (7)
Methylated mono-glucuronides (3 isoforms) Quercetin + Methyl group + Glucuronic acid
Glucuronated sulfates (2 isoforms) Quercetin + Sulfate group + Glucuronic acid
Glucuronated sulfates (3)
Methylated glucuronated sulfate (1 isoform) Quercetin
f  Methyl group 
+ Sulfate group 
+ Glucuronic acid
Sulfate (1 Isoform) Quercetin + Sulfate group
Sulfates (2)
Methylated sulfate (1 isoform) Quercetin + Methyl group + Sulfate group
i4:
f
t
I
Table 7: Four major types of quercetin conjugates found in rat tissu es and plasma.
Using HPLC with on line radioactivity detection and tandem mass spectrometry, 22 different quercetin conjugates were 
detected (Table 5) which were classified into four major groups of quercetin conjugates (methyl-quercetin, peak 27 not 
included), The number of Individual metabolites belonging to each group is given in parenthesis.
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Metabolite types in rat tissues and plasma
Gl-tract plasma
90 %
■s
2.5 %
■s
0.5 1 2 5
time after administration (hours)
kidney
0.5 1 2 5
time after administration (hours)
liver
0.6 % 1 %
0.5 1 2 5
time after administration (hours)
H  quercetin-4'-glucoside 
I  quercetin
I I Isorhamnetin (methyl-quercetin) 
I I  di-glucuronides
0.5 1 2 5
time after administration (hours)
H  mono-glucuronides 
B  sulfated mono-glucuronides 
B  sulfates
I  I  unknown com pounds
Figure 7: Metabolite types found in rat Gl-tract, plasma, liver and kidney.
Using HPLC-RC with MS/MS, 27 different radiolabelled compounds were 
detected in rat tissues and plasma after oral ingestion of [2-’ '‘C]quercetin-4'- 
glucoside and classified into 8 major groups (Table 7). The relative quantities 
of each metabolite group are shown in relation to the administered dose.
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Section
Abundance of different metabolite types in rat tissue and piasma
% of ingested dose % of tissue content
Gl-tract Gl-tract
Types of metabolites 0.5 h I h 2 h 5 h 0.5 h 1 h 21, 51,
Quercetin-4'-glucoside 42 .2 24.4 - “ 4 9 .0 26.2 - -
Quercetin 21.6 6.7 5.9 5 .6 25.1 7 .2 6.7 6 .1
Isorliainnetiii 4.4 - 0.8 - 5.1 - 1.0 -
Di-glucuronides 5.7 5.6 30.0 65.6 6.7 6.0 34.1 71.2
Mono-glucuronides 5.1 31.9 28.2 - 5.9 34.2 32.1 -
Glucuronated sulfates - 7.2 12.4 1.1 - 7.7 14.1 1.2
Sulfates 5.6 16.7 8.0 - 6.5 17.9 9.1 ~
unknown 1.5 0.8 2,6 19.8 1.8 0.8 3.0 21.5
sum 86.1 93.3 87.9 92.1 100 100 100 too
plasma plasma
Types of metabolites 0.5 h 1 h 2h 5 h 0.51, 11, 21» 5 h
Quercetin-4'-glucoside - - - - - - - -
Quercetin - - - - - - - -
Isorhamnetin - - - - - - - -
Di-glucuronides 1.5 1.1 0.9 0.4 52.3 38.8 35.6 23.7
Mono-glucuronides 1.0 0.1 - - 33.3 3.8 - -
Glucuronated sulfates 0.4 1.6 1.6 1.3 14.4 57.4 64 .4 76.3
Sulfates - - - - - - - -
unknown - - - - - - - -
sum 2.9 2.8 2.5 1.7 100 100 100 100
livei liver
Types of metabolites 0.5 h I h 2 h 51, 0.5 h 11, 2 h 51,
Quercetin-4'-glucoside - - - - 1.8 - - -
Quercetin - trace - trace - 1.5 - 4.3
Isorhamnetin - - - - - - - -
Di-glucuronides 0.9 0.7 0.3 0 .2 44.3 56.9 52.3 86.5
Mono-glucuronides 0.5 0.3 0.1 trace 24.7 25.8 19.3 2.9
Glucuronated sulfates 0.6 0.2 0 .2 trace 29.3 15.8 28.4 1.7
Sulfates - - - - - - - -
unknown - - - trace - - 4.7
sum 2.0 1.2 0 .6 0 .2 100 100 100 100
kidneys kidneys
Types of metabolites 0.5 h I h 2 h 5 h 0.5 1, 1 h 2 h 51,
Quercetin-4'-glucoside - - - - - - - -
Quercetin - - - trace - - - 1.8
Isorhamnetin - - - - - - - -
Di-glucuronides 0.5 0.5 0.2 0.3 49.8 56.9 83.1 93.9
Mono-glucuronides 0.5 0.3 trace - 44.5 35.5 16.6 -
Glucuronated sulfates trace trace - trace 2.3 3.1 - 1.0
Sulfates - - - - - - - -
unknown trace trace - trace 3.4 4.5 - 3.4
sum 1.0 0.80 0.2 0.3 100 100 100 100
Table 8: Abundance of different metabolite types in rat tissu es and plasma.
This table shows the large difference between the amounts of metabolites present in the Gl-tract and the other organs, 
including plasma. Using HPLC-MS-RC, 27 different radiolabelled compounds were detected in rat tissues and plasma 
after oral ingestion of [2-iC]quercetin-4'-glucoside (Table 5), The radiolabelled compounds were classified into 8 
major groups (Table 7). The quantity of each group of metabolites is given as a percentage of the ingested dose (left 
column) and as a percentage of the radioactivity in the respective tissues and plasma (right column).
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Methylated quercetin metabolites In rat tissue and plasma
of inficstcd dose of tissue content
Gl-tract Gl-tract
Types of metabolites 0.5 h I h 2 h 51, 0.5 h 1 h 21, 5 1,
Methylated metabolites 6.6 13.1 38.9 1.9 7.6 14.1 44.2 2.1
Un-methylated metabolites 33.7 33.0 46.6 70.4 41.6 39.0 52.9 76.3
Unchanged or unknown ® 43.7 23.2 2.6 19.8 51.0 27,0 3.0 21,5
S l i m 86.0 93.3 88.1 92.1 100 100 100 100
plasma plasma
Types of metabolites 0.5 h 1 h 2 h 5 h 0.51, 1 h 21, 5 h
Methylated metabolites 0.4 1.3 1.2 1.1 15.2 43.3 47,3 67.8
Un-methylated metabolites 2.3 1.3 1.3 0.3 84.8 34.7 52.5 32.2
Unchanged or unknown *= - - - - - - -
sum 2.9 2,8 2.3 1.6 100 100 100 100
liver liver
Types of metabolites 0.5 h I h 2 h 5 h 0.51, 1 h 21, 5 h
Methylated metabolites 1.3 0.3 0.2 trace 63.3 44.8 44.2 2.9
Un-methylated metabolites 0.6 0,7 0.3 0.3 32.7 33.2 33.8 92.4
Unchanged or unknown * trace - - trace 1.8 - - 4.7
sum 1.9 1.2 0.3 0.3 100 100 100 100
kidneys kidneys
Types of metabolites 0.5 h I h 2h 5 h 0.5 h I h 21, 5 h
Methylated metabolites 0.7 0.5 0.1 trace 68.7 37.0 35.3 2.3
Un-methylated metabolites 0.3 0.3 0.1 0.3 28.0 38.3 64.3 94.1
Unchanged or unknown * trace trace - trace 3.4 4.5 - 3.4
sum 1.0 0.8 0.2 0.3 100 100 100 100
Table 9: Abundance of methylated quercetin metabolites in rat t issu es and plasma.
Radiolabelied compounds from rat tissue and plasma were extracted and 27 different compounds were detected using 
HPLC-RC-MS/MS (Table 5). The data shown in Table 8 was assembled without considering the méthylation status of 
the metabolites. Therefore, the table above shows the abundance of methylated quercetin metabolites as a 
percentage of the administered dose (left column) and as a percentage of the total radioactivity in tissues and plasma 
(right column). The 27 radiolabelled compounds were grouped into methylated metabolites (8 metabolites) and un- 
methylated metabolites (15 metabolites) and ^unchanged or unknown compounds (quercetin-4'-glucoside and 3 un­
identified compounds).
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4. Discussion
4.1. Absorption: less then 10%
The administered dose of 3 mg [2-^"^C]quercetin-4'“gliicoside to rats corresponds 
with the quercetin-4'-glucoside content in 250 g fresh onion consumed by a 70 kg human 
subject (Crozier et al, 2000; Tsushida et al, 1995). About 10% of the administered 
radioactivity was absorbed into internal organs or blood (peak plasma concentration: 14 
pM at 0.5 h). This is in keeping with human and animal studies which report low peak 
plasma concentrations of quercetin conjugates, suggesting a low absorption of quercetin 
or its metabolites from supplements or quercetin rich foods (Graefe et al, 2001 ; Erlund et 
al, 2000; Hollman et al, 1997). In contrast, two studies with ileostomy patients (Waile et 
al, 2000; Hollman et al, 1995) found that over 50% of the ingested quercetin (in fried 
onion) disappeared between oral ingestion and ileostomy effluent collection. As 
quercetin proved to be relatively stable in ileal fluid (only 5% degraded), it was 
concluded that the ‘missing quercetin’ must have been absorbed (Hollman et al, 1995). 
Our data show that up to 44% of the quercetin metabolites in the Gl-tract of the rats were 
methylated (Table 9). The méthylation of quercetin, presumably to isorhamnetin, or 
tamarixetin, and its further conjugation with glucuonic acid/sulfate groups has been 
described in a number of human and animal studies (DuPont et al, 2002; Manach et al, 
1999; Manach et al, 1997). The ileal fluid however was only analysed for the presence of 
quercetin or quercetin conjugates, not for the presence of methylated quercetin or its 
conjugates (Walle et al, 2000; Hollman et al, 1995). The metabolism of quercetin into 
methylated quercetin and its conjugates might therefore provide an explanation for the 
high disappearance of quercetin in the ileostomy model (Waile et al, 2000; Hollman et al, 
1995) and the absorption of quercetin might be substantially lower then suggested by 
these two studies.
High absorption of quercetin has also been reported by Walle et al (2001), on the 
basis of a study where human volunteers ingested [^"^Cjquercetin aglycone. The 
absorption of radiolabelled quercetin was estimated to be 36-53% of the ingested dose 
(100 mg) by calculating the “area under the curve” of the total radioactivity present in 
plasma over 72 h. During this period 4.2 % of the orally ingested radioactivity was 
excreted in urine, while 52% was exhaled as ’"^C02. It was assumed that the exhaled 
originated from the portion of [^'^C]quercetin which was not absorbed from the
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small intestine but underwent bacterial degradation in the colon (Ueno et al, 1983; 
Petrakis et al, 1959). About 70% of the CO2 in venous blood is usually transported in the 
form of H C O 3 " ions which are dissolved in plasma (Rehner and Daniel, 1999). Therefore, 
radioactivity detected in plasma by Walle et al (2001) is likely to include "^^ C02, en route 
to the lungs for exhalation, together with other radiolabelled products of intermediary 
metabolism derived from hydroxy-phenylacetic acids (Aura et al, 2002) and related ring 
fission products of [^'^Cjquercetin. Consequently, we believe that quercetin absorption of 
36-53%, based on the “area under the curve” calculation of plasma radioactivity by 
Walle et al (2001) was an overestimate.
4.2. Site of metabolite formation: the Gl-tract ?
The catalytic activity of drug metabolising enzymes in the small intestine are 
generally lower then the corresponding values in the liver (Lin et al, 1999). Therefore, it 
is usually assumed that the liver is the major site for metabolism of xenobiotics such as 
quercetin (Griffiths, 1982; Hackett, 1986). However, from our results we conclude that 
most of the metabolites must have been formed in the Gl-tract. This conclusion is based 
on following observations: 1) all ingested radio label led quercetin-4'-glucoside had 
undergone metabolic changes within 2 h, and 2) at all timepoints most of the 
radiolabelled compounds were present in the Gl-tract (86%-93% of administered dose) 
(Table 4 and Table 6). If the liver were the main site of quercetin metabolism, and the 
metabolites were immediately excreted into the intestine via the bile, the liver should 
contain higher levels of radioactivity, at least at one time point. In practice, the liver 
contained no more than 2% of the ingested radioactivity at any time point (Figure 8).
Our hypothesis is supported by Crespy et al, (2003) who perfused rat intestine in 
situ with quercetin and collected intestinal eluent and bile separately. Bile contained only 
10% of the quercetin conjugates, intestinal eluent contained 90% of the quercetin 
conjugates, indicating that the majority of the metabolism had occurred in the gut not in 
the liver. Preliminary data by Cermak et al. (2003) supports our conclusion, as it was 
reported that portal blood of pigs contained exclusively quercetin metabolites, and that 
quercetin was metabolically transformed before reaching the liver.
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Gut
90% I ^  f  LiverAbsorption I 1%
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2.5%Bile
Cldney0 .6%
Figure 8; Is the Gl-tract the main site of quercetin metabolism in vivo?
Although the primary function of the small intestine is to absorb nutrients and 
water, it also has the ability to metabolise food constituents and drugs by numerous 
pathways (Suzuki et al, 2(XX)). From our results and other reports we conclude that most 
of the ingested dietary quercetin is metabolised directly in the Gl-tract. Thus 
gastrointestinal quercetin metabolism may be a pre-systemic mechanism to reduce the 
bioavailability of quercetin, e.g. a defence strategy (Schuelz and Schinkel, 1999).
4.3. Quercetin metabolism by internal tissues
In agreement with previous reports (O ’Leary et al, 2003; Donovan et al, 2001; Day 
et al, 2000; Manach et al, 1999) our data suggests that internal tissues were capable of 
quercetin metabolism.
Glucuronidation: At 0.5 h, the Gl-tract contained two quercetin di-glucuronides 
(peak 10 and 11) whereas kidneys contained seven different di-glucuronides (peak 3, 5, 
6, 8, 9, 10 and 11) and liver and plasma contained both five different di-glucuronides 
(liver: peak 3, 5, 8, 10 and 11, plasma: peak 6 , 1 , 9 ,  10 and 11) (Table 6). This indicates 
that internal tissues, most likely the liver and kidney, may further modify absorbed 
quercetin mono glucuronides.
Méthylation: Methylated forms of different types of quercetin metabolites (mono­
glucuronides, di-glucuronides, glucuronated sulfates, sulfates) were predominant in liver 
and kidney at 0.5 h, whereas the Gl-tract contained only a small proportion of methylated 
metabolites at this timepoint (Table 9). This either indicates selective absorption and/or 
transport of methylated metabolites into liver and kidney tissues or post-absorptive
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méthylation as previously suggested by a number of studies (De Santi C et al, 2001, 
Piskula and Terao 1998; Zhu et al, 1994).
In conclusion, our data suggests that internal tissues can metabolise quercetin. 
However, m vivo, quercetin metabolism in the liver and kidney may only play a minor 
role since only small amounts of the ingested dose appears to be absorbed.
4.4. Types and isoforms of quercetin metabolites
In most previous studies the presence of quercetin metabolites in human and 
animal plasma has been shown indirectly, by releasing free quercetin and methyl- 
quercetin from glucuronyl and sulfate moieties via enzymatic or acid hydrolysis before 
HPLC analysis (Manach et al, 1999; Spencer et al, 1999; Crespy et al, 1999; Manach et 
al, 1998). In this study the advantage of radio labelled metabolites, good compound 
separation on the HPLC column, and on line radioactivity detection in parallel with 
tandem mass spectrometry (HPLC-RC-MS/MS) allowed us to characterize 22 different 
types and isoforms of glucuronated, sulfated and/or methylated quercetin conjugates: 
Seven different quercetin mono-glucuronides and nine different quercetin di- 
glucuronides have been detected together with three glucuronated sulfates, two quercetin 
sulfates and isorhamnetin (methylated quercetin) (Table 6 and 7).
It has been previously reported that glucuronidation of quercetin may occur at 
different and multiple hydroxyl groups within the quercetin molecule (Day et al, 2000). 
Quercetin conjugates and isomers have identical molecular mass and fragmentation 
patterns on mass spectrometry, therefore positional isomers could only be distinguished 
by their different elution times from the HPLC column (e.g. column retention time).
Assuming that all 5 OH groups on the quercetin molecule are possible binding 
positions for glucuronyl units, and OH groups at 3' and 4' position are possible binding 
positions for methyl groups, 8 isoforms of methylated quercetin mono-glucuronide and 4 
isoforms of quercetin mono-glucuronide could theoretically occur (Figure 9). In 
agreement with our findings, two other laboratories have recently detected 3 methylated 
quercetin mono-glucuronides and 4 un-methylated quercetin mono-glucuronides which 
were formed in liver cell free extracts and by HepG2 cells (Day et al, 2000; O ’Leary et 
al, 2003). In addition Oliveira et al, (2002) also reported the formation of 4 un-
methylated quercetin mono-glucuronides by rat hepatocytes in suspension. The fact that 
all four laboratories report the same number of isoforms despite the use of different
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Binding sites and theoretical number of isomers of quercetin conjugates
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Figure 9: Theoretical number of isom ers of quercetin 
conjugates.
Red arrows highlight putative binding positions of glucuronide, 
sulfate and methyl moieties to the quercetin molecule. Current 
literature suggests that methyl groups only bind to positions 3' 
and 4'. On the x axis of the figures: binding positions (3, 5, 7, 3', 
4‘), y axis: number of possible isoforms, blue = methyl group, 
black = glucuronide group, green = sulfate group.
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chromatographic conditions and equipment, suggests that glucuronyl transferases 
(UGTs) and methyl transfereases (COMTs) selectively conjugate particular hydroxyl 
groups on quercetin and that not all possible isomers are formed.
4.5. Pathways of metabolite formation
4.5.1. Cleavage of the glycoside
Plasma or tissue metabolites did not contain the original glucose moiety of 
quercetin-4'-glucoside, therefore it is evident that the glucose unit was efficiently 
hydrolysed before or during absorption and before further metabolism. Two enzymes are 
believed to hydrolyse quercetin glycosides in the small intestine: lactase phloridizin 
hydrolase (LPH) on the enterocyte brush border and cytosolic p-glucosidases inside 
enterocytes (Day et al, 2000; Day et al, 2003). These findings support the view that 
ingested quercetin-4'-glucoside is hydrolysed in the small intestine, before, during or 
immediately after the absorption step.
4.5.2. Glucuronidation: part of the absorption process?
All quercetin metabolites found in plasma and internal tissues (liver and kidney) 
contained a glucuronyl unit. This may suggest that glucuronidation either (1) permits or 
is part of the absorption process of quercetin, or (2) occurs immediately after absorption. 
This conclusion is supported by Inoue et al (1999), reporting that both naphthyl glucoside 
and p-nitrophenol glucoside are metabolised to the corresponding glucuronides during 
passage through rat intestinal mucosa.
4.5.3. Is sulfation only occurring in the Gl-tract?
Quercetin sulfates (without the attachment of a glucuronide moiety) were only 
present in the Gl-tract at 0.5, 1 and 2 h. Plasma, kidney and liver only contained 
quercetin sulfates with the attachment of a glucuronide group. Thus it is hypothesized 
that in the rat, quercetin or methyl-quercetin might be first sulfated in either the lumen or 
enterocytes of the Gl-tract, followed by glucuronidation either during absorption or 
immediately after absorption.
4.5.4. Are metabolites further metabolised?
The distribution of metabolite types and numbers in tissues and plasma changed
dramatically over the monitored 5 h period (Table 6, Figure 7). In the Gl-tract, the
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Peak Metabolite Gl-tract Plasm a Liver Kidney Sum
3 Quercetin di-glucuronide - - 0.1 (35.5) 0.1 (40.3) 0.2
6 Quercetin di-glucuronide 2.2 (2.4) 0.1 (7.8) 0.1 (42.5) 0.0 (17.4) 2.4
10 Quercetin di-glucuronide 61,5 (66.7) 0.0 (2.1) 0.0 (8.4) 0.1 (33.7) 61.6
16 Methylated quercetin giucuronide sulfate - 1.0 (62.2) - - 1.0
Table 10: Four predominant m etabolites at 5 h.
The quantity of each metabolite is given as a % of the ingested dose, and in parenthesis as a percentage of the 
radioactivity, which was extracted from each organ.
4.5.5. Catabolism of quercetin metabolites in the colon?
Two major radiolabeiled metabolites, accounting for 21 % of the radioactivity in the 
Gl-tract at 5 h after [2-^‘*C]quercetin-4'-glucoside administration, were not identified as 
they did not yield recognisable mass spectra. Their relatively short HPLC retention times 
suggested that they were polar molecules, possibly phenolic acids which may have been 
formed by colonic microflora (Rechner et al, 2002; Justesen et al, 2000). Catabolism of
Section I
number of individual metabolites increased from 8 to 15 at 0.5 and 1 h, and decreased to 
14 and 7 at 2 and 5 h. The increased number of metabolites may be due to prolonged 
exposure to metabolising enzymes and possibility differences of pH and enzyme activity 
as the chymus moves down the Gl-tract. In this short time frame, it is unlikely that the 
increased number of metabolites was due to quercetin induced upregulation of phase II 
enzymes (Galijatovic et al, 1999).
However at 5 h, the number of metabolites was drastically reduced to 4 main 
quercetin conjugates (peaks 3, 6, 10, 16) (Table 10). The explanation that in an 
absorptive organ, the metabolites disappeared because they had been absorbed and then
;subsequently sequestered by tissues, must be excluded, as radioactivity levels in all 
internal organs continually decreased. The only logical explanation seemed to be that 
quercetin conjugates underwent further metabolism, e.g. de-conjugation with subsequent 
re-conjugation at a different binding position.
This hypothesis is in agreement with recent studies (O’Leary et al 2003; Crespy et 
al, 2003; Oliveira et al, 2002; Donovan et al, 2001) therefore it is assumed that the main 
metabolite at 5 h, (60% of total radioactivity dose) had been formed in the lower Gl-tract ;after de-conjugation and subsequent re-conjugation to form the quercetin di-glucuronide 
isoform which elutes as peak 10.
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quercetin into phenolic acids would therefore be expected to occur in the caecum and 
colon of the rat at timepoints around 5 h after the oral dose (Manach et al, 1997; Brown 
et al, 1988). The present study was focussed on quercetin absorption and metabolism 
from the small intestine, and for the investigation of quercetin metabolism and/or 
catabolism in the large intestine it would have been necessary to collect samples at later 
time points.
4.6. Discussion of the applied methods
4.6.1. Extraction of quercetin metabolites from biological samples
In a number of studies acidified solvents were used for the extraction of flavonoid 
metabolites from biological samples (Manach et al 2000, Alder et al 2000, Boulton et ai 
1999, Manach et al 1999). Therefore this approach was tested (materials and methods. 
Figure 2), however, when our extraction solvent (50% methanol/phosphate buffer) was 
acidified, the extraction efficiency of radiolabelled quercetin metabolites from liver was 
only 20% compared to > 95% when the extraction solvent (50% methanol/phosphate 
buffer) was kept at pH 7.0.
It is evident, that both the extraction solvent and technique determines the 
extraction efficiency, and low findings of plasma metabolites in previous studies may be 
due to inadequate extraction techniques. Internal standards, added to plasma samples 
before the extraction, may not reflect the true extraction efficiency, as virtually all plasma 
quercetin is metabolised and bound to plasma proteins (Walle et al, 2003; Zsila et al, 
2002, Boulton et al, 1998). Thus the true value of absorbed quercetin may be 
significantly higher as previously reported.
4.6.2. 50% recovery
Using 50% methanol/phosphate buffer as extraction solvent, over 95% of the 
radiolabeiled quercetin metabolites were released from the tissue matrix and went into 
solution. During the subsequent multi step purification and concentration process 
(Figure 2), on average 50% of the original radioactivity was lost (Table 1), however the 
final extract was sufficiently concentrated and pure for MS/MS analysis. It was assumed 
that a similar quantity of all compounds was lost equally, and no specific compound was 
lost selectively.
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4.6.3. Metabolites in urine and faeces ?
As the main focus of this study was the investigation of absorption and metabolism 
of [2-’"'^C]quercetin-4’-glucoside, urine and faeces samples had not been collected. 
However, as >92% of the ingested radioactivity was accounted for by measuring the 
radioactivity concentration in plasma, whole Gl-tract and eight other tissues we assume 
that up to 5 h post ingestion no significant amounts of [2-^"^C]quercetin-4'-glucoside or its 
metabolites were excreted in urine or faeces.
5. Conclusion
This study supports the view that ~iO% of dietary quercetin is absorbed from the
Gl-tract. Absorbed quercetin occurs in the body almost exclusively metabolised with one 
or more methyl, sulfate or glucuronide groups attached. We hypothesise that most of the 
ingested dietary quercetin is metabolised directly in the Gl-tract. Thus the metabolism of 
dietary quercetin is primarily pre-systemic, e.g. may be a defence strategy. Any systemic 
biological effects previously attributed to free quercetin must be due to its metabolites.
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Abstract
Background:
Objective:
Design:
Results:
Conclusions:
Previous results suggested that quercetin is extensively 
metabolised before or during its absorption. It was 
hypothesized that the Gl-tract was the major organ of 
quercetin bio-transformation.
Determine where in the Gl-tract quercetin metabolites may 
have been formed by comparing the metabolite profiles of 
physiologically distinct Gl-tissues and contents.
Rat Gl-tracts were divided into 5 physiologically distinct 
segments (stomach, proximal small intestine, distal small 
intestine, caecum and colon), and separated from their 
luminal contents, Radiolabelied compounds were extracted 
and stored for LC-MS/MS analysis.
Half an hour after ingestion >90% of the radioactivity was 
found in the stomach and small intestine and at 5 hours 
>80% was found in caecum and colon. Small intestinal 
tissue held the highest concentration of radiolabeiled 
compounds (4.3% of the ingested dose at 0.5 hours) 
compared to other body tissues. Data on the identity of 
radiolabeiled compounds in different Gl-segments were 
lost in the Bower Building fire.
The time-dependent distribution of radiolabeiled 
compounds throughout the Gl-tract confirms our 
hypothesis that metabolites at 0.5 hours after oral ingestion 
of [2-^ 't] quercetin-4'-glucoside were located in the 
stomach and small intestine. Similarly, the metabolite 
composition found in the Gl-tract at 5 hours reflected the 
situation in caecum and colon.
Key w ords: [2-^ "^ C] quercetin-4'-glucoside, radioactivity-distribution,
Gl-tissues, chymus.
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1. Background and Aim
Epidemiological and experimental studies suggest that dietary quercetin may 
reduce the risk of heart disease and certain cancers, but an incomplete understanding of 
the bioavailability and metabolism of dietary quercetin confounds the interpretation of 
these results. Results in Section I suggest that dietary quercetin is completely 
metabolised before its entry into systemic circulation, implying that the Gl-tract may be 
the major site of quercetin metabolism.
Due to the early appearance of quercetin metabolites in the Gl-tract at 0.5 h after 
the oral ingestion (Section I, Table 6, Figure 7) it was hypothesized that quercetin 
metabolites had been formed in the upper Gl-tract. However, the speed of passage of 
ingested [2-^'^C]quercetin-4’-glucoside through the rat Gl-tract was not known. In Section 
I, complete Gl-tracts (Gl-tissues and contents) were analysed as one homogenized unit, 
and the distribution of radiolabeiled compounds between Gl-tissues and luminal contents 
was not determined.
To explore the metabolic fate of dietary quercetin in different Gl-segments, the Gl- 
tracts of two rats were divided into five physiologically distinct gut segments and the Gl- 
tissues were separated from their luminal contents. The aim of the study was to identify 
and compare quercetin metabolites in Gl-tissues and their respective luminal contents, to 
test the hypothesis that specific Gl-tissues are the primary location of quercetin 
metabolism in vivo.
2. Materials and Methods
2.1. Materials, animals and sample collection
Two Gl-tracts that had been collected in the previous experiment (Section I) were
used for this study. As described in Section I, rats received an oral dose of 3.26 mg [2-
'"^C]quercetin-4'-glucoside (7.6 mg/kg body weight) (radioactivity dose: 58.5 x 10  ^dpm).
The Gl-tracts were snap frozen in liquid nitrogen and stored at -8 0  °C. The animal
feeding and sample collection was carried out at the Rowett Research Institute by Phil
Morrice and Dr. Garry G. Duthie. After their arrival in Glasgow, the Gl-tracts were
divided into stomach, proximal small intestine (first 1/3 of the small intestine), distal
small intestine (second 2/3 of the small intestine), caecum and colon (Figure 1). Luminal
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stomach
proximal small intestine
distal small intestine
caecum
colon
Figure 1 : Rat Gl-tract.
The rat Gl-tract was divided into 5 physiologically distinct segments, as 
shown in the figure..
contents were collected by gently squeezing out the segments and Gl-tissues were rinsed 
with PBS until the rinsing solution was free of radioactivity, which indicated that luminal 
contents were completely removed from Gl-tissues (the radioactivity content of the 
rinsing solution was monitored by liquid scintillation counting). Gl-tissues were 
homogenized in extraction buffer, and luminal contents were first freezedried and then 
homogenized using mortar and pestle.
2.2. Measurement of radioactivity content
Aliquots of tissue homogenates (300 mg) and luminal contents (30 mg) were 
digested using Biosol tissue solubilizer, and analysed by liquid scintillation counting as 
previously described in Section I, paragraph 2.4,
2.3. Extraction of radiolabeiled metabolites
All samples containing >100.000 dpm were extracted following the same 
extraction protocol as described in Section I, paragraph 2.5.2. Samples containing 
<100.000 dpm did not contain a sufficient amount of radiolabeiled compounds for 
extraction and HPLC-RC analysis. The recovery of radiolabeiled compounds from 
tissues and luminal contents (extraction efficiency) was 50%±15% and 66%±12%,
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respectively, with exception of 94% for radiolabelied compounds from luminal contents
of the stomach at 0.5 h after oral ingestion of [2- ' quercetin -4' - glucoside.
3. Results
3.1. Distribution of radioactivity within Gl-tissues and luminal contents
The distribution of radiolabeiled compounds within the Gl-tract of rats was 
determined at 0.5 and 5 hours after oral ingestion of [2-*"*^C]quercetin-4'-glucoside 
(Figure 2). At both time points -92%  of the ingested radioactivity was associated with 
the whole Gl-tract, which included the stomach, small intestine, caecum, colon and their 
contents (Section I, Table 4). When the Gl-tract was divided into physiological segments, 
at 0.5 h after ingestion, 91% of the ingested radioactivity was found in the stomach and 
small intestine, with 6% present in tissues and 85% in luminal contents. Compared with 
all other analysed body tissues (liver, kidney, lung, heart, testes, spleen brain, muscle and 
plasma, Section I, Table 4), small intestine tissue held the highest concentration of 
radiolabeiled compounds (4.3% of the ingested dose at 0.5 h, 2,513 x 10  ^ dpm/3.6 g wet 
tissue) (Table 1).
Five hours after oral ingestion of [2-^'^C]quercetin-4'-glucoside 80% of the ingested 
radioactivity was associated with caecum and colon, e.g. present in the lower Gl-tract. 
Tissues of the stomach and small intestine did not retain the amounts of radiolabeiled 
compounds which they held at 0.5 h (Table 1).
2.4. Identification of radiolabelied compounds by LC-MS analysis
It was intended to analyse the extracts containing radiolabeiled compounds from 
Gl-tissues and their respective luminal contents by HPLC-RC-MS/MS as described 
previously (Section I, paragraph 2.6). Unfortunately, however, all extracts were lost in 
the Bower Building fire, (October 24^ *' 2001), and it was not possible to repeat the animal 
experiments in the time frame of this PhD.
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Figure 2: Distribution of radioactivity in G l-tissues and luminal contents.
Distribution of radioactivity in the Gl-tract of rats, 0.5 and 5 h after ingestion of 3 mg [2-^'*G]quercetin-4'-glucoside. Gl- 
tissues and luminal contents were collected separately, and tissues were thoroughly washed to completely remove 
luminal contents (until the wash was free of radioactivity). Radioactivity was measured by liquid scintillation counting 
after solubilising samples with tissue solubilizer. This figure graphically shows data given in Table 1. Abbreviations; 
prox.s.int = proximal small intestine, dist.s.int.= distal small intestine.
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Distribution of [2-i4C]quercetin-4'-giucosïde and its metabolites 
in Gl-tissue and its luminal contents
0.5 h after oral ingestion % of % of
dpm ± SD whole Gl-tract oral dose
.stomach 896 ± 5 6 1.66 1.53
proximal small intestine 807 ± 2 3 1.50 1.38
3 distal small intestine 1,706 ± 4 5 3.17 2.92
^  caecum 73 ± 3 0.14 0.13
colon 131 ± 6 0.24 0.22
mesentery 140 ± 0 .6 0.26 0.24
Sum: Gl-tissues 3,753 6.97 6.42
stomach 32,086 ± 4 2 4 59.65 54.85
a proximal small intestine 3,469 ± 7 3 6.45 5.93
'g distal small intestine 14,323 ± 2 0 5 26.63 24.48
^  caecum 113 ± 1 0 0.21 0.19
colon 42 ± 4 0.08 0.07
Sum: Gl-contents 50,033 93.02 85.52
Sum: Gl-tissues + contents 53,786 100.00 91.94
5 h after oral ingestion % of % of
dpm ± SD whole Gl-tract oral dose
stomach 35 ± 0 .3 0.06 0.06
proximal small intestine 36 ± 3 0.07 0.06
3  distal small intestine 250 ± 2 0.46 0.43
Æ caecum 805 ± 12 1.49 1.38
colon 447 ± 5 2 0.83 0.76
mesentery 473 ± 51 0.88 0.81
Sum: Gl-tissues 2,046 3.79 3.50
stomach 302 ± 2 3 0.56 0.52
a  proximal small intestine 472 ± 1 1 0,88 0.81
■g distal small intestine 4,607 ± 8 4 8.55 7.87
( j  caecum 37,461 ± 8 ,0 9 2 69.54 64.04
colon 8,981 ± 3 6 9 16.67 15.35
Sum: Gl-contents 51,823 96.20 88.59
Sum: Gl-tissues + contents 53,869 100.00 92.09
'I
I
I
Table 1: Distribution of radioactivity in G l-tissues and luminal contents.
Distribution of radioactivity in the Gl-tract of rats, 0.5 and 5 h after ingestion of 3,26 mg [2- '^’C]quercetin-4‘-glucoside 
(58.5 X 10  ^dpm). Gl-tissues and luminal contents were collected separately, and tissues were thoroughly washed to 
completely remove luminal contents (until the wash was free of radioactivity). Radioactivity was measured by liquid 
scintillation counting and results are shown in dpm x 10  ^(± SD, n=3) (left column), as a percentage of the radioactivity 
content of the whole Gl-tract (middle column) and as percentage of the administered radioactivity (right column). ;'
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3.2. Identification of radiolabeiled compounds in Gl-tissues and contents
The Identification of radiolabeiled compounds in Gl-tissues and luminal contents 
by HPLC-RC-MS/MS analysis was not possible due to the loss of the samples in the fire.
4. Discussion
4.1. Passage of radiolabeiled compounds through the rat Gl-tract
Half an hour after oral ingestion of [2-'"^C]quercetin-4'-glucoside >90% of the 
ingested radioactivity was found in the stomach and small intestine, and at 5 hours >80% 
of the ingested dose was found in caecum and colon. Therefore, it can be concluded that 
metabolites which were present in the whole homogenized Gl-tract at 0.5 h (Section I, 
Figure 7) were located in stomach or small intestine. Similarly, metabolites extracted 
from the whole homogenized Gl-tract at 5 hours (Section I, Figure 7) most likely reflect 
the situation in caecum and colon. If metabolites were formed in the Gl-tract, those 
metabolites found at 0,5 h must have been formed either in stomach or small intestine.
5. Conclusion
The tissue of the small intestine held the largest concentration of radiolabeiled 
compounds compared with all other analysed body tissues. Thus, intestinal epithelia may 
be the part of the body that is most exposed to ingested flavonoids, such as quercetin-4'- 
glucoside. Dietary flavonoids may play a role in the maintenance of Gl-health.
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Abstract
Background;
Objective:
Design:
Results:
The determination of the putative roles of dietary quercetin 
and its in vivo metabolites in disease prevention requires 
information on its bioavailability and biotransformation. 
Thus, we examined the contribution of the liver and small 
intestine to quercetin metabolism.
To compare the ability of cultured liver and intestinal cells 
to synthesize quercetin metabolites.
Cultured liver (CC-1) and intestinal cells (IEC-6) were 
exposed to 5 pM [2-‘"^C]quercetin-4'-glucoside for 0.5, 2, 
5, 24, 48 and 72 hours. Radiolabeiled compounds were 
collected, extracted, and analyzed by LC-MS/MS with on­
line radioactivity detection.
Both cell lines produced similar types and numbers of 
quercetin metabolites. Eleven of the 16 quercetin 
metabolites were identical with metabolites formed in vivo 
in the rat. Four of the in vitro metabolites not identical to 
rat metabolites were new isoforms of previously detected 
metabolites. The degree of chemical instability of [2- 
^"^C]quercetin-4'-glucoside in cell culture medium was not 
anticipated a priori. Less than 0.2% of [2-^"*^C]quercetin-4'- 
glucoside, its break down products or metabolites were 
associated with the cells. Culture medium contained 
>99.8% of the administered radioactivity, but the presence 
of the cells was essential for the formation of the 
metabolites.
■ t
■3is:
Conclusions;
Key words:
Intestinal and liver cells form similar types and numbers of 
quercetin metabolites. These results support the hypothesis 
that the Gl-tract is involved in quercetin metabolism in 
vivo. We now hypothesize that quercetin metabolites are 
quickly exported from cells after their synthesis. Provided 
the stability of the flavonoid under investigation is ensured 
(e.g., cell independent break down is controlled), in vitro 
experiments can provide a useful tool for investigating the 
effects of quercetin metabolites in vivo.
[2-''"^C] quercetin-4'-gIucoside, liver cells, intestinal cells, 
in vitro metabolism, compound-stahility.
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1. Background and Aim
Ingested dietary quercetin is quickly metabolised in animals and humans (Section I; 
Crespy et al, 2003; Sesink et al, 2001; Graefe et al, 2001). To explore the potential role 
of quercetin metabolites in disease prevention, it is essential to determine where 
quercetin metabolites are formed and which metabolites are produced. The liver is 
regarded as the primary metabolising organ for xenobiotic compounds, including 
flavonoids (Lin et al, 1999; Griffiths, 1982; Hackett, 1986). However, our results 
(Section I of this thesis) support the hypothesis that in rats, the Gl-tract is the major site 
of quercetin metabolite formation, as at 2 h >90% of orally ingested [2-'"^C]quercetin-4'- 
glucoside was found metabolised in the Gl-tract, while the metabolite concentration in 
liver tissues never exceeded 2%. However, the possibility that quercetin metabolites had 
been synthesized in the liver and transported into the small intestine via the bile, could 
not be entirely ruled out by this data. To estimate the individual contribution of the liver 
and the Gl-tract towards quercetin metaholism, the quantity and nature of synthesized 
metabolites must be determined separately. In vivo this question is usually resolved by 
collection and analysis of the bile during bile duct cannulation experiments in animals.
The aim of this study was 1) to investigate whether cultured liver or intestinal cells 
were capable of metabolising quercetin-4'~glucoside in a similar manner to that seen in 
the rat and 2) to investigate whether there is potential for establishing a cell culture 
model for in vivo metabolism of dietary quercetin. Cultured liver and intestinal cells were 
incubated with [2-‘"^C]quercetin-4-glucoside and radiolabeiled compounds were 
collected, purified and analysed following the same metabolite extraction protocol as 
previously used for rat samples.
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2. Materials and Methods
2.1. Cell culture
2.1.1. Cell lines
The cell lines IEC-6 (small intestinal epithelial cells) and CC-1 (liver epithelial 
cells) were purchased from The European Collection of Cell Cultures (ECACC, 
Salisbury, Wiltshire, U.K.) Both cell lines were derived from normal (non-cancerous) 
tissue. Rat cell lines were chosen to allow comparison with previous results from the rat 
feeding study (Section I) without interspecies extrapolation.
2.1.2. Materials and equipment
IEC-6 cells were maintained in Dulbeco’s Modified Eagle Medium (D 5671, 
Sigma, Poole, Dorset, U.K) supplemented with 0.3 lU insulin/ml, 2 mM L-glutamine, 50 
units penicillin/ml, 0.05 mg streptomycin/ml and 5% (v/v) fetal calf serum (Sigma). CC- 
1 cells were cultured in Minimum Essential Medium (M 7278, Sigma) containing 1% 
(v/v) MEM Non Essential Amino Acid Solution (M 7145, Sigma), 2 mM L-glutamine, 
50 units penicillin/ml, 0.05 mg streptomycin/ml and 10% (v/v) fetal calf serum (Sigma). 
All manipulations of CC-1 and IEC-6 cells were carried out under sterile conditions in a 
cIass-2 laminar flow cabinet (BHA 48, Faster, Ferraia, Italy). The cells were incubated at 
37 °C and 5% CO2 in a IG50 Jouan incubator (St.Herblain, France) and kept in uncoated 
plasticware (75 cm^ and 25 cm^ flasks, 6, 12 and 24 well plates) purchased from Greiner- 
bio-one (Frickenhausen, Germany). The morphology of growing and confluent cells was 
closely monitored, under 20 x magnification using a Nikon Microscope (Tokyo, Japan).
2.1.3. Cell passage
At 90% confluence cell monolayers were rinsed twice with PBS and covered with 
1-2 ml 0.25% trypsin/EDTA for 1 min. After removal of excess trypsin, flasks were 
incubated at 37 °C for 10 min and detached cells were dispersed in cell culture medium 
and split by a ratio of 1 to 20.
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2.2. Experiments and sample collection
[2-*"^C]quercetin-4'-glucoside (3.75 mCi/mmol) was solubilized in methanol at a 
concentration of 0.5 g/ml. CC-1 and IEC - 6  cells were seeded into 25 cm^ flasks (at 3 x 
10"^  cells/ml medium, 10 ml medium was used for a 25 cm^ flask) and incubated with 5 
|iM [2-*"^C]quercetin-4'-giucoside (8.3 KBq) immediately after seeding or after reaching 
confluence. The final methanol concentration in culture medium was 0.5% (v/v) which 
had no adverse effect on cell viability. After incubation for 0.5, 2, 5, 24, 48 and 72 hours 
at 37 °C, cell morphology was closely monitored at 20 x magnification, culture media 
was collected and the cell monolayer was rinsed twice with PBS and trypsinised as 
described above. To stop trypsin activity, detached cells were dispersed in 20% (v/v) 
foetal calf serum in PBS. The cell pellet was collected after centrifugation, re-suspended 
in 200 pi 20% (v/v) methanol in PBS and lysed by three repeated freeze-thawing cycles.
For control experiments 5 pM [2-^''^C]quercetin-4'-glucoside was added to fresh cell 
culture medium and incubated at 37 °C for 5 and 72 h.
To determine whether metabolite formation had occurred in the cell culture 
medium by substrates and/or enzymes released from the cells, medium was separated 
from cell monolayers after 72 h co-culture and placed in fresh culture flasks (containing 
no cells). 5 pM [2- C]quercetin-4'-glucoside was added to the culture medium and 
incubated at 37 °C for 24 and 72 h.
2.3, Extraction of radiolabeiled metabolites
The radioactivity content of cell lysate and cell culture medium was determined by 
dissolving the total sample, or an aliquot, in 5 ml of scintillation fluid, and counting the 
radioactivity using a Multi Purpose Liquid Scintillation Counter (LS6500, Beckmann 
Instalments, Fullerton, CA 92634-3100, U.S.A.).
The radioactivity content in the cell lysates (< 0.2% of the administered dose) was 
in-sufficient for extraction and analysis, therefore only radiolabeiled compounds in 
culture medium were extracted and analysed, following the previously developed method 
for the analysis of [2-^"^C]quercetin-metabolites in rat tissues and plasma (Section I). Cell 
culture media was adjusted to pH 3 (using 25% H2SO4) and partitioned three times with 
an equal volume of ethyl acetate. The three ethyl acetate extracts were combined and 
stored at -8 0  °C. Any residual ethyl acetate was removed from the aqueous phase by 
drying it for 1 h using a centrifugal evaporator (GyroVap, Howe, U.K.) at 40 °C, before
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it was loaded onto a 2 g C|g Sep Pak cartridge (Waters, Milford, Massachusetts, U SA ). 
The cartridge was washed with 15 ml of distilled water adjusted to pH 3.0 (with H2SO4) 
and radiolabeiled compounds were eluted with 30 ml of methanol. The methanolic eluent 
was combined with the ethyl acetate extracts and reduced to dryness in  v a c u o ,  re­
suspended in methanol, and stored at -8 0  °C.
■'H
Radiolabeiled compounds extracted from cell culture medium: 
extraction efficiency in %
Sample ID
aqueous phase ethyl acetate phase extraction efficiency
after
partitioning
after elution 
from sep pak
after
partitioning
aqueous phase + 
ethyl acetate phase
CC-1 confluent 0 .5  h 12.4 14.4 7 5 .7 90.1
CC-1 confluent 2  h 9.5 17.8 73.1 90.9
CC-1 confluent 5  h 34.3 3 0 ,9 50 .7 81 .6
CC-1 confluent 72  h 66.4 5 0 .2 40 .0 90.2
CC-1 growing 2 4  h 37,0 3 7 .5 30 .7 68.1
CC-1 growing 48 h 48.8 3 2 .2 3 2 .7 64.9
CC-1 growing 72  h 54.3 54 .6 26 .3 80.8
CC-1 In or out 24  h 32.4 20 .8 48 .9 69.7
CC-1 in or out 72  h 32.8 21 .3 34 .8 56.0
CC-1 control medium  5 h 16.1 14.6 7 1 .7 86.4
CC-1 control medium 72  h 18.6 20 .9 2 7 .7 48.6
IEC-6 confluent 0.5h 14.9 15.8 7 1 ,6 87.4
IEC-6 confluent 2 h 12.2 16.4 61 .5 77.8
IEC-6 confluent 5h 68.7 76 .9 21.8 98.7
IEC-6 confluent 72  h 41.9 39 .5 47.5 87.0
IEC-6 growing 24  h 35.1 30 .2 46 .0 76.1
IEC-6 growing 48  h 28.9 28.1 50 .2 78.3
IEC-6 growing 72  h 21.4 34.1 41.6 75.7
iEC-6 in our out 24 h 19.1 21 .4 73 .4 94.9
iEC-6 in our out 72 h 66 .7 57 .7 17.7 75.4
iEC-6 control medium 5 h 16.8 28.9 48 .3 77 .3
IEC-6 control medium 72 h 68.2 55 .7 9 .5 65.2
average recovery:
-A:
78.2
Table 1: Extraction efficiency of radiolabeiled com pounds from cell culture medium.
Cultured liver and intestinal cells were Incubated with 5 \iM [2-i'’C]quercetin4'-glucoside and after 0.5, 2, 5, 
24, 48 or 72 h radiolabeiled compounds were extracted from cell culture medium, according to the 
extraction protocol which was previously used for extracting quercetin metabolites from rat tissues and 
plasma (Section I, Figure 3 and Table 1). The extraction efficiency (in%) is the ratio: activity in the extract I 
initial activity in each sample x 100. The initial activity in each sample, e.g. cell culture medium was on 
average 90% of the administered dose = 450,000 dpm. Sample ID (left column of the table): Cell type (CC- 
1 I IEC-6), experiment (confluent cells, growing ceils, are metabolites formed inside or outside of cells, 
abbreviated as "in or out", control medium which was never in contact with cells) and incubation times (0.5, 
2, 5,24, 48 and 72 hours).
A
A4'T;3?
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2.4. Separation and Identification of radiolabeiled metabolites
2.4.1. HPLC analysis with online radioactivity detection (HPLC-RC)
Cell culture medium extracts (containing ca. 50,000 dpm) were analysed using a 
P4000 HPLC fitted with an AS 3000 autosampler, a UV 6000 diode array absorbance 
monitor (Thermo Finnigan, San Jose, CA, USA) and a radioactivity monitor (Model 
9701, Reeve Analytical, Glasgow, U.K.) fitted with a 200 pi heterogeneous flow cell. 
Separation was carried out at 1 ml/min using a 250 x 4.6 mm, i.d. 4 pm, Polar-RP 
column (Phenomenex, Macclesfield, U.K.) eluted at room temperature with a gradient of 
5 to 25% acetonitrile/2%formic acid over 60 minutes. Signals from both, the diode array 
and radioactivity monitor were processed using Chromquest 3.0 software (Thermo 
Finnigan).
2.4.2. MS/MS analysis with online radioactivity detection (LC-MS/MS-RC)
Samples were analysed on a Surveyor HPLC system comprising of a HPLC pump, 
diode array absorbance detector, scanning from 250 to 700 nm and an autosampler 
cooled to 4“C (Thermo Finnigan, San Jose, CA, USA). Separation was carried out using 
a 250 X 4.6 mm i.d. 4 pm Synergy RP-Max column (Phenomenex, Macclesfield, U.K.) 
eluted with a gradient over 60 minutes of 5-40% acetonitrile in 1% formic acid at a flow' 
rate of 1 mL/min and maintained at 40 "C. After passing through the flow cell of the 
diode array detector the column eluate was directed to a radioactivity monitor (Model 
9701, Reeve Analytical, Glasgow, U.K.) fitted with a 500pl heterogeneous flow cell 
packed with cerium activated lithium glass scintillant, before being split with 50% 
entering a LCQ DecaXP ion trap mass spectrometer with an electrospray interface 
(Thermo Finnigan, San Jose, CA, USA) operating in negative ion mode and scanning 
from 100-2000 amu.
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Relating retention times in HPLC-RC and LC-MS/MS-RC chromatograms by their Rf values.
HPLC-RC analysis 
gradient 5-25% / 60 mins, 
column; Phenom enex RP Polar
LC-MS/MS-RC analysis 
gradient 5-40% / 60 mins, 
column; Phenom enex RP Max
1
radiolabelled
peaks RT Rf value Rf value RT com pound identity
cells 1 16.17 0.40 0.47 15.88 Quercetin di-glucuronide
cells 5 24.47 0.60 0.61 20.59 Unknown
cells 6 25.81 0.63 0.68 23.00 Methylated quercetin di-glucuronide
cells 10 34.16 0.84 0.77 25.95 Quercetin di-glucuronide
cells 12 35.18 0.87 0.86 28.83 Quercetin di-glucuronide
cells 13 37.00 0.91 0.91 30.50 Quercetin mono-glucuronide
cells 15 43.93 1.08 1.02 34.45 Methylated quercetin mono-glucuronide
cells 16 44.71 1.10 1.04 35.00 Methylated quercetin mono-glucuronide
cells 17 46.85 1.15 1.06 35.74 Quercetin
Table 2 A; R{ values of m etabolites formed by liver cells. Chromatograms are show n in Figure 3.
HPLC-RC analysis LC-MS/MS-RC analysis
radiolabelled
peaks RT Rf value Rf value RT com pound identity
cells 1 21.73 0.53 0.48 16.29 Quercetin di-glucuronide
cells 4 23.30 0.57 0.57 19.08 Unknown
cells 5 25.70 0.63 0.62 20.96 Methylated quercetin di-glucuronide
cells 10 29.00 0.71 0.77 25.98 Quercetin di-glucuronide
cells 11 31.07 0.76 0.82 27.50 Quercetin di-glucuronide
cells 12 34.05 0.84 0.86 28.94 Quercetin mono-glucuronide
cells 15 43.06 1.06 1.02 34.42 Methylated quercetin mono-glucuronide
cells 17 43.95 1.08 1.07 36.00 Methylated quercetin mono-glucuronide
cells 18 47.41 1.17 1.27 42.73 Quercetin
HPLC-RC analysis LC-MS/MS-RC analysis
Table 2 B; Rf values of m etabolites formed by intestinal cells. Chromatograms show n In Figure 3.
radiolabelled
peaks RT Rf value Rf value RT com pound identity
cells 1 20.63 0.51 0.49 16.44 Quercetin di-glucuronide
cells 5 24.84 0.61 0.62 20.82 Methyl-quercetin di-glucuronide
cells 6 28.02 0.69 0.68 23.01 Quercetin di-glucuronide
standard 41.25 1.00 1.00 33.84 Quercetin-4'-glucoside
cells18 52.96 1.30 1.29 43.48 Quercetin
Table 2 C; Rf values of m etabolites formed In cell culture media, pre-exposed to liver cells. Chromatograms 
are show n in Figure 4.
Table 2 A, B and C; Metabolites formed in cell culture - Rf values.
Radiolabelled compounds were extracted from cell culture medium and analysed by HPLC-RC and LC-MS/MS-RC. 
The retention times (RT) of peaks In HPLC-RC and LC-MS/MS-RC chromatograms (Figure 3 and 4) was different due 
to different separation conditions (column and gradient) and different equipment. Radioactive peaks in HPLC-RC and 
LC-MS/MS-RC chromatograms were matched by comparing their R f  values, elution pattern and MS identity. The R f  
value is the ratio of RT (unknown compound) I RT ([2-i4Q]quercetin-4'-glucoside). The reference RT for quercetin-4'- 
glucoside in HPLC-RC chromatograms was 40.67 min, and in LC-MS/MS-RC chromatograms 33.68 min. Calculation 
example: [RT (radiolabelled peak “cells 1” in intestinal cells) = 21.73] I [RT ([2-‘''‘C]querc6tin-4'-glucoside) = 40.67] = R f  
value of 0.53.
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2.5. Data analysis
The relative quantity of radiolabelled compounds was determined by measuring the 
height of peaks in chromatograms obtained from the radioactivity monitor by HPLC-RC. 
The retention time of peaks in HPLC-RC chromatograms and LC-MS/MS-RC 
chromatograms was different due to the use of different separation conditions (column 
and gradient) and equipment. Radioactive peaks in HPLC-RC and LC-MS/MS-RC 
chromatograms were matched by comparison of Rf values, MS/MS identification and 
elution pattern. The Rf value is the ratio of the retention time of the unknown compound 
and the retention time of quercetin-4'-glucoside. The reference retention time for 
quercetin-4'-glucoside in HPLC-RC chromatograms was 40.67 min and in LC-MS/MS- 
RC chromatograms 33.68 min.
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3. Results
3.1. Radiolabelled metabolites formed in cell culture
[2-’‘^ C]quercetin“4'~glucoside was not stable in cell culture medium. When 5 |iM 
[2-^‘^ C]quercetin-4'-glucoside was exposed to cell culture medium for 72 h, it 
decomposed completely into unidentified relatively polar compounds (Figure 1). After 
incubating confluent or growing liver (CC-1) and intestinal (IEC-6) cells for 0.5, 2, 5, 24, 
48 and 72 h with culture medium containing 5 p,M [2-^^C]quercetin-4'-glucoside (8.3 
KBq), < 0.2 % of the administered radioactivity was associated with the cells and > 99.8 
% was found in culture medium either unchanged or as radiolabelled metabolites and 
break down products. The uptake of radiolabelled compounds into cells was not 
increased in sub-confluent, growing cells. In addition, growing cells produced fewer 
metabolites and the formation of break down products was increased, therefore all further 
experiments were carried out using confluent cell monolayers.
When confluent monolayers of liver and intestinal cells were incubated with 5 pM 
[2-*'^C]quercetin-4'-glucoside for 72 h, cell culture medium contained radiolabelled 
compounds which eluted at retention times different to decomposition products and 
unchanged [2-’'^C]quercetin-4'-glucoside (Figure 2). To identify the nature of these 
radiolabelled peaks, samples were analysed using LC-MS/MS with on-line radioactivity 
detection (Figure 4, Table 3). Sixteen radiolabelled compounds were identified as 
different types and isoforms of quercetin conjugates with the addition of one methyl or 
sulfate group and/or one or two glucuronyl groups (Table 3). Eleven of these metabolites 
were identical with metabolites previously detected in the rat (Table 6). Four of the five 
cell culture metabolites not identical with rat metabolites were new isoforms of di- 
glucuronides (metabolite peaks 2, 3 and 9, Table 3 and 5), and a new isoform of 
methylated and sulfated quercetin mono-glucuronide (peak 8). Cultured intestine cells 
produced one minor metabolite with a molecular ion (M ) at m/z 639 which fragmented 
to produce ions at m/z 477, 463 and 301. A neutral loss of 162 amu {m/z 639 -  477 = 162 
amu, and m/z 463 -  301 = 162 amu) indicates the presence of a glycosyl adduct. A 
neutral loss of 176 amu {m/z 639 -  463 = 176 amu, and m/z 477 -  301 ~ 176 amu) 
indicates the presence of a glucuronyl unit (as previously reported in Section I). 
Therefore metabolite peak 7 was identified as glucuronated quercetin glucoside
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(presumably glucuronated quercetin-4'-glucoside), a type of metabolite that was 
previously not detected.
3.3. Time of metabolite formation
After incubating confluent cells for 0.5, 2 and 5 hours, only degradation products 
and unchanged [2-^'^C]quercetin-4'-glucoside were found in cell culture medium (Figure 
2). However, quercetin metabolites were found after 24 hour incubation of sub-confluent, 
growing cells (data not shown), indicating that metabolite formation occurred between 5 
and 24 hours after addition of [2-^"^C]quercetin-4'-glucoside. Thus, metabolic 
transformation of [2-^^C]quercetin-4'-glucoside was significantly slower in the employed 
cell culture model compared with the rat, where 3 mg [2-'"^C]quercetin-4'-glucoside was 
completely metabolised by 2 h after ingestion (Section I).
3.4. Accumulation of radiolabelled metabolites In cell culture medium
At all time points, neither growing nor confluent cells accumulated more then 0.2% 
of the administered radioactivity, casting doubt whether metabolic transformation had 
occurred inside the cells. Therefore it was investigated whether quercetin metabolites 
were formed in cell culture medium by enzymes and substrates released by the cells. Cell 
culture medium was exposed to liver and intestine cell monolayers for 72 hours, 
transferred to fresh flasks and incubated with 5 pM [2-*"^C]quercetin-4'-glucoside for 24 
and 72 h at 37 °C. No metabolites were formed in medium which was pre-exposed to
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3.2. Stability of [2-^4C]quercetm-4'-glucoside in ceil culture medium
[2-^"^C]quercetin-4'-glucoside decomposed completely into unidentified relatively 
polar compounds when exposed to cell culture medium for 72 h (‘control medium’ 
experiment) (Figure 1). The decomposition rate of [2-‘"^C]quercetin-4'-glucoside was 
different in culture medium formulas for liver or intestinal cells. When 5 pM [2- 
^"^C]quercetin-4'-glucoside was incubated with fresh medium for 5 h, all [2-*‘^ C] quercetin- 
4'-glucoside decomposed in medium for intestinal cells, whereas medium for liver cells 
contained intact [2-^"^C]quercetin-4'-glucoside together with degradation products 
(Figure 1), The presence of cells appeared to have an effect on the stability of [2- 
‘"^C]quercetin~4'-glucoside in culture medium (Figure 1 and Figure 2).
Section III
" %
intestinal cells, however, medium which was pre-exposed to liver cells contained very 
low concentrations of three quercetin di-glucuronides after 24 h (<5% of the 
administered radioactivity dose) (Figure 3). The metabolite formation in liver cell 
medium may have been caused by a few detached floating cells that may have been 
present in the medium after its separation from the cell monolayer. However, in both 
experiments over 95% of the administered [2-^'^C]quercetin-4'-glucoside was recovered 
from the cell culture medium either unchanged or in the form of degradation products, 
suggesting that quercetin metabolism occurred on the cell surface or inside the cells with 
immediate excretion of metabolites into the cell culture medium.
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Stability of [2-i^C]quercetin-4'-glucoside in cell culture medium
—aL L
Q4'G
liver cell culture -  control medium
5 hours
72 hours
intestine cell culture -  control medium
[2-’^C]-quercetin-4'-glucoside
^  a  ^
no cells
control medium
Figure 1: [2-^^C]quercetin-4'-glucoside is not stable in culture medium  
formulas for liver and intestinal cells.
Fresh cell culture medium was incubated for 5 and 72 h with 5 pM [2- 
’ ‘*C]quercetin-4'-glucoside. Radiolabelled compounds were extracted from the 
medium and analysed by HPLC-RC.
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Metabolism and break down of [2-i'*C]quercetin-4'-glucoside in cell culture
Q4'G
JL
Q4’G
0.5 hours
L
2 hours
JL I 5 hours
hours
liver cell culture medium intestine cell culture medium
[2-i«C]-quercetin-4'-glucoside
L — L j
cell monolayer
cell culture medium
Figure 2: Radiolabelled com pounds in cell culture medium after 
incubating liver and intestinal cells with [2-^^C]quercetin-4'-glucoside.
Confluent monolayers of liver or intestinal cells were incubated for 0.5, 2, 5 or 
72 h witfi 5 pM [2-i'*C]quercetin-4'-glucoside. Radiolabelled compounds were 
extracted from tfie medium and analysed by HPLC-RC.
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No significant formation of metabolites without cells
. 24 hours
Q4'G  >■
-JU 24 hours
72 hours j l 72 hours
pre-conditioned 
liver cell culture medium
pre-conditioned 
intestine cell culture medium
[2-’'*C]-quercetin-4'-glucoside
transfer of media
lrf>TTï~vnnT7rry>^ ^
&
cell monolayer no cells
pre-conditioned
medium
Figure 3: No significant formation of quercetin m etabolites without cells.
To investigate whether metabolites were formed in the culture medium or inside the cells, culture medium was 
exposed to confluent cell monolayers for 72 h, cells were removed and the “pre-conditioned medium” was incubated 
with [2-’‘‘C]quercetin-4'-glucoside for 24 and 72 h. Radiolabelled compounds were extracted and analysed by HPLC- 
RC and LC-MS/MS-RC.
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LC-MS/MS identification of metabolites formed by cultured cells
peak RT (min) compound [IVI-H]- (m/z) fragment ions (m/z)
1 15.88 Quercetin di-glucuronide 653 477 ([M-H]-G!cUA) 301 ([M-H]-GicUA-GicUA)
2 17.48 Methyiated quercetin di-giucuronide 667 491 ([M-H]--GlcUA) 315 ([M-H]-GicUA-GicUA)
3 18.27 Quercetin di-glucuronide 653 477 ([M-H]--GlcUA) 301 ([M-H]-GlcUA -GicUA)
4 19.08 not identified
5 20.78 Methyiated quercetin di-giucuronide 667 491 ([M-H]-GicUA) 315 ([M-H]-GicUA-GicUA)
6 23,00 Quercetin di-glucuronide 653 477 ([M-H]-GlcUA) 301 ([M-H]-GicUA -GicUA)
7 23.73 Giycosilated quercetin monoglucuronide 639 477 {[M-H]-glucosyl) 463 ([M-H]--GlcUA) 301 ([M-H]--S03-GicUA)
8 24.73 Methylated quercetin mono-glucuronide suifate 571 491 ([M-H]-S03) 395 ([M-H]-GioUA) 315 ([M-H]-SOs-GicUA)
9 25.17 Methylated quercetin diglucuronide 667 491 ([M-H]-GlcUA) 315 ([M-H]-GicUA-GicUA)
10 25.97 Quercetin di-glucuronide 653 477 ([M-H]-GlcUA) 301 ([M-H]-GicUA-GicUA)
11 27.80 Quercetin di-glucuronide 653 477 ([M-H]--GlcUA) 301 ([M-H]-GlcUA-GicUA)
12 28.89 Quercetin mono-glucuronide 477 301 ([M-H]-GlcUA}
13 30.50 Methylated quercetin monoglucuronide sulfate 571 491 ([M-Hl-SOa) 395 ([M-H]--GicUA) 315 ([M-H]-S03-GicUA)
14 31.35 Quercetin monoglucuronide sulfate 557 477 ([M-H]--S03) 381 ([M-H]-GlcUA) 301 ([M-H]--S03-GicUA)
15 34.48 Methylated quercetin monoglucuronide 491 315([M-H]--GlcUA)
16 35.00 Methylated quercetin monoglucuronide 491 315 ([M-H]-GicUA)
17 35.87 Methyiated quercëln mono-glucuronide 491 315 ([M-H]--GlcUA)
18 42.73 Free quercetin 301
Table 3; Identification of labelled m etabolites formed by cultured liver and intestinal cells.
Radiolabelled compounds were extracted from ceil culture medium, and analysed by LC-MS/MS with online 
radioactivity detection. The table shows LG retention times (RT), negative ion MS/MS fragmentation 
patterns and putative identities of the radioiabeiled metabolites. Abbreviations: GicUA = glucuronyl unit, [M- 
H]- (m/z) = mass to charge ratio of the molecular ion).
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Types of quercetin conjugates formed by cultured cells
Di-glucuronides (5 isoform s) Quercetin + Glucuronic acid  + Glucuronic acid
Di-glucuronides (8)
Metfiylated di-glucuronides {3 isoform s) Quercetin
+ Methyl group  
+ Glucuronic acid 
+ Glucuronic acid
Mono-glucuronides (1 isoform) Quercetin + Glucuronic acid
Mono-glucuronides (4)
Methyiated mono-giucuronides (3 isoform s) Quercetin + Methyl group  + Glucuronic acid
Glucuronated sulfates (1 isoform) Quercetin + Sulfate group  + Glucuronic acid
Sulfated Mono-glucuronides (3)
Methylated glucuronated sulfate (2 isoforms) Quercetin
+ Methyl group  
+ Suifate group  
+ Glucuronic acid
Glycosylated Mono-glucuronide (1) no m ethylated com pound found Quercetin + G lu cose  + Glucuronic acid
Table 4: Classification of quercetin m etabolites Into four major groups.
Sixteen different quercetin conjugates were identified as metabolites of [2-i''C]quercetin-4'-glucoside 
formed by cultured liver and Intestinal ceils. The individual metabolites were classified into four 
major groups as shown above and the number of individual metabolites is given in parenthesis).
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Relative quantities of radioiabeiled metabolites formed by cultured cells
I
IEC-6 cells CC-1 cells
peak com pound relative quantity (in %)
relative quantity 
(in %)
cells 1 quercetin di-glucuronide 1.20 3.42
cells 2 methyl quercetin di-giucuronide 1.00 -
cells 3 quercetin di-glucuronide 3.01 0.95
cells 4 unknown 2.41 -
ceils 5 methyl quercetin di-glucuronide 2.41 17.65
cells 6 quercetin di-glucuronide - 2.66
ceils 7 giycosilated quercetin mono-glcuronide 0.40 -
cells 8 methyiated quercetin mono-glcuronide suifate 0.80 -
cells 9 methyl quercetin di-glucuronide 1.00 3.61
cells 10 quercetin di-glucuronide 1.00 6.83
cells 11 quercetin di-glucuronide 2.21 -
cells 12 quercetin mono-glucuronide 7.43 5.12
cells 13 methylated quercetin mono-gicuronide sulfate - 1.90
cells 14 quercetin mono-glucuronide suifate 12.85 8.92
ceils 15 methyl querceitn mono-giucuronide 3.01 6.07
cells 16 methyl querceitn mono-glucuronide - 5.12
ceils 17 methyl querceitn mono-glucuronide 2.61 7.02
cells 18 quercetin 0.60 -
sum 41.94 69.27
di-glucuronides 11.85 35.10
mono-giucuronides 13.05 23.34
glucuronated sulfates 13.65 10.82
glucuronated glucoside 0.40 -
phase II metabolites 38.95 69.26
free quercetin 0.60 -
unknown 2.41 -
break down products 58.03 30.74
sum 100.00 100.00
a
I
I
Table 5: Relative quantities of radioiabeiled m etabolites formed by cultured cells.
Radioiabeiled metabolites In cell culture medium were extracted and analysed by LC-MS/MS with radioactivity 
detection. Relative quantities of individual metabolites were determined by measurement of peak height. 
100% in the table = radioactivity present in cell culture medium = 98.2% of the administered 5 pM [2- 
'^’C]quercetin-4'-glucoside. 0.2 % of the administered radioactivity was associated with the ceils.
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Comparison of metabolite types 
formed by cultured cells and in rat tissue
cultured intestine cells
I>
cultured liver cells
rat Gl-tract rat liver
o>
‘ >
90  %
■§
1 %
0.5 1 2 5
time after administration (hours)
I
0.5 1 2 5
time after administration (hours)
^  quercetin-4-glucoside  
m  quercetin
I I  Isorhamnetin (methyl-quercetin)
I  ] quercetin g lucosid e m ono-glucuronide 
I  I  di-glucuronides
g  m ono-glucuronides 
^  sulfated m ono-glucuronides 
H  su lfates
|~~j unknown com pounds
mm break down products in cell culture medium
Figure 5: Metabolite c la s se s  formed by cultured cells and in rat tissu es .
The graph summarizes relative quantities of formed metabolites and break 
down products formed by cultured cells and in rat Gl-tract and liver. 
Radioiabeiled compounds formed in cell culture and in the rat were classified 
into 10 major groups. Data of rat Gl-tract and liver is taken from Section I, 
Figure 7.
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Comparison of quercetin metabolites in cultured cells and in the rat
8  #  1Î I l  1 i 111 Identity of metabolites
rat 1 unknown
rat 2 unknown
rat 3 cells 1 Quercetin di-glucuronide
cells 2 Methylated quercetin di-glucuronide
cells 3 Quercetin di-glucuronide
rat 4 cells 4 unknown
rats cells 5 Methylated quercetin di-glucuronide
rate cells 6 Quercetin di-glucuronide
rat 7
cells 7 Glycosylated quercetin glucuronide 
Quercetin di-glucuronide ^
cells 8 Methylated quercetin mono-glucuronide sulfate
rats Methylated quercetin di-glucuronide
rat 9 Quercetin di-glucuronide
cells 9 Methylated quercetin di-glucuronide
rat 10 cells 10 Quercetin di-glucuronide
rat 11 cells 11 Quercetin di-glucuronide
rat 12 cells 12 Quercetin mono-glucuronide
rat 13 
rat 14 
rat 15
Quercetin mono-glucuronide sulfate 
Methylated quercetin di-glucuronide ’ 
Quercetin mono-glucuronide i
rat 16 cells 13 Methylated quercetin mono-glucuronide sulfate
rat 17 cells 14 Quercetin mono-glucuronide sulfate
rat 18 Quercetin-4’-glucoside
rat 19 cells 15 Methylated quercetin mono-glucuronide
rat 20 cells 16 Methylated quercetin mono-glucuronide
rat 21 cells 17 Methylated quercetin mono-glucuronide
rat 22 
rat 23
Quercetin mono-glucuronide 
Quercetin mono-glucuronide ’
rat 24 cells 18 Quercetin
rat 25 Methylated quercetin sulfate
rat 26 Quercetin sulfate
rat 27 Isorhamnetin (methylated quercetin)
Table 6: List of quercetin m etabolites formed by cultured cells and in the rat.
Comparison of metabolites formed by cultured cells (Table 3) and in the rat (Section I, Table 5). 
’ = metabolite was only found in plasma
H U  metabolites found in rat liver and rat Gl-tract (Section I, Table 5) 
iJÈl metabolites formed in cell culture by the rat liver cell line CC-1
■ ■ I  metabolites formed in cell culture by the small intestinal cell line IEC-6
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Radioactivity associated with the cells
Sample radioactivity % of quercetin-4'-glucoside
(cell type and confluence, associated  with administered equivalents
incubation time with Q4'G) the cells (dpm) d ose ( n g / 10® CC-1 cells)
IEC-6 cells confluent 0.5 h 304 0.061 3.388
lEC-6 ceils confluent 2h 319 0.064 3.554
IEC-6 cells confluent 5 h 270 0.054 3.008
IEC-6 ceils confluent 72 h 675 0.135 7.522
IEC-6 cells growing 72 h 300 0.060 3.344
CC-1 cells confluent 0.5 h 578 0.116 4.601
CC-1 cells confluent 2 h 421 0.084 3.348
CC-1 cells confluent 5 h 639 0.128 4.537
CC-1 cells confluent 72 h 570 0.114 4.537
CC-1 cells growing 72 h 320 0.064 2.547
average 440 0.088 4.039
Table 7: L ess then 0.2% of the administered radioactivity w as associated  with the cells.
Confluent or growing liver (CC-1 ) and intestinal cells (IEC-6) were incubated with 5 pM [2- 
^4C]quercetin-4‘-glucoside. After 0.5, 2, 5 and/or 72 h cell culture medium was collected separately, 
cells were washed with PBS, trypsinised, suspended in 200 pi 20% (v/v) methanol and lysed by 
repeated freeze thawing cycles. The radioactivity in total samples was counted with a scintillation 
counter, and above values are the mean of two measurements. All cell culture incubations were 
carried out in singiicate.
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4. Discussion
4.1. Quercetin metabolism in vivo and in vitro
The metabolites produced by liver and intestinal cells suggest that both cell types 
express the relevant metabolising enzymes: P-giycosidase, to release quercetin from its 
glucose adduct and glucuronyl-transferases (UGT’s), sulfo-transferases (SULTs) and 
catechol-O-methyltransferases (COMT’s) to conjugate free quercetin with methyl, sulfate 
or glucuronide units (Stahl et al, 2002). The synthesis of quercetin conjugates by 
enterocytes was independent of intestinal micro flora, as a similar pattern of metabolite 
types and isoforms were formed by cultured cells and in rat Gl-tract.
Eleven of the 16 quercetin conjugates formed by cultured cells were identical with 
conjugates formed in rats (Table 6). Four of the five cell culture metabolites not identical 
with rat metabolites were new isoforms of metabolite types that had been found in the 
rat. Two main differences were observed between metabolite synthesis in the rat and by 
cultured cells: 1) Formation of numerous break down products of [2-*"^C]quercetin-4'- 
glucoside due to its instability in cell culture medium, 2) All cell culture metabolites 
contained a glucuronide moiety, whereas rat Gl-tract also contained quercetin and 
methyl-quercetin sulfates without a glucuronide adduct (Figure 5). However the 
presence of un-glucuronated quercetin sulfates in the Gl-tract was transient, and 
quercetin sulfates were not observed at any time point in liver, kidney or plasma (Section 
I, Figure 7). Therefore, if the formation of break down products in cell culture medium 
can be controlled, quercetin metabolism by cultured cells appears to be comparable to 
that observed in the rat, and cell culture experiments may provide a meaningful, 
expedient and economical alternative to animal experiments.
4.2. Metabolite formation by liver and intestinal cells
Cultured intestinal and liver cells produce similar types and numbers of quercetin 
metabolites. The length of exposure of the cells to intact [2-^"^C]quercetin-4’-glucoside 
may determine the quantity of formed metabolites. Liver cells converted 70%, and 
intestinal cells converted 40%, of the administered [2-^^C]quercetin-4'-glucoside into (an 
equal number of) phase II metabolites by 72 h. A higher rate of break down product
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formation in cell culture medium for intestinal cells may have contributed to the lower 
overall quantity of formed metabolites in the intestinal cell culture.
In conclusion, the results confirm that intestinal epithelial cells are capable of 
metabolising quercetin-4'-glucoside, supporting the hypothesis that intestinal tissues may 
be a major site of quercetin metabolism.
4.3. Stability and availability of quercetin-4'-glucoside in cell culture
[2-'"^C]quercetin-4'-glucoside was not stable in cell culture medium, and after 72 h 
it was completely decomposed into relatively polar compounds. Instability of quercetin 
and other Havonoids in cell culture medium and aqueous solutions has also been reported 
by Boulton et al, (1999), Kuo (1996) and Nordstroem (1968). Decomposition appeared to 
be slower in liver cell culture medium than in intestinal cell culture medium, probably 
due to a higher concentration of FCS (10% compared to 5% respectively) and 
supplementation with 1% (v/v) non-essential amino acids (NEAA). Serum proteins and 
supplemented amino acids may preserve quercetin-4'-glucoside from oxidation by 
becoming surrogate targets. Proteins, such as bovine serum albumin are commonly used 
in just this manner to stabilize small amounts of valuable enzymes or proteins (personal 
communication. Sigma, Technical Service, St. Louis, MO, USA) and amino acids, 
especially those with thiol moieties, have also been shown to function as antioxidants 
(Levine 1996).
cellular metabolism
Q4'G
in cell culture medium
break down in cell 
culture medium < C
protection by proteins 
released from cells and 
present in medium
Figure 6: Fate of [2- '^’C]quercetln-4'-glucoside in cell culture medium.
This figures summarizes the hypothesis, that the availability of quercetin-4'- 
glucoside to cultured cells depends on its degree of chemical break down in the 
culture medium, preservation against this break down and the formation of cellular 
metabolites.
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The presence of cells themselves also appeared to have a protective effect. When 
cells were present, [2-‘"^C]quercetin-4'-glucoside was stable after 5 hour incubation in 
culture medium for intestinal cells, however when quercetin-4'-glucoside was incubated 
with medium alone, all [2-''^C]quercetin-4'-glucoside was broken down. This protective 
effect may have been caused by substrates which were secreted by the cells into the 
culture medium. Liver cells appeared to protect [2-‘"^C]quercetin-4'-gliicoside better than 
cultured intestinal cells, possibly due to active secretion of protective compounds, such 
as extracellular superoxide dismutase (SOD) and other matrix proteins.
These results illustrate the complexity of the situation in cell culture medium, and 
emphasise the need to be aware that a cell culture model may include such confounding 
factors. Degradation of quercetin-4'-giucoside and other flavonoids will reduce the 
effective dose of the initial compound and observed cellular responses may be caused by 
a combination of break down products, cellular metabolites and/or the administered 
compound. It is also important to note that free quercetin aglycone was not found in cell 
culture medium at any time point. Because synthesized quercetin metabolites were 
present at 72 h, they appeared to be more stable compared with [2-‘"^C]quercetin-4’- 
glucoside.
4.4. Metabolite synthesis Inside the cells ?
At all time points >90% of the administered radioactivity was present in cell 
culture medium, and only <0.2% was associated with the cells, independently of 
confluence level or cell type (Table 7, legend of Table 1). However, at 72 h 40% and 
70% of the administered dose was found metabolised in the cell culture medium (of 
intestinal and liver cells respectively). We therefore investigated whether quercetin 
metabolites were formed in the cell culture medium rather then inside the cells. However, 
the presence of cells was essential for the formation of metabolites, suggesting that 
metabolites were either formed within the cells or on the cell surface. As metabolising 
enzymes are reportedly located in the cytosol (Donovan and Waterhouse, 2003; Duffel et 
al, 2001; Willitis et al, 2004). We hypothesize that metabolites are formed within the 
cells with quick subsequent export into cell culture medium.
Recent studies report the active export of flavonoid metabolites from cultured cells 
into culture medium and from intestinal tissue into intestinal lumen (Spencer et al, 2004; 
Crespy et al, 2003; Day et al, 2003) via multidrug-resistance-associated transporters (e.g.
p a g e  105
'g
Section II!
M RP-1, MRP-2 and MDR-1) (Spencer et al, 2004; Walgren et al, 2000b; Walle et al, 
1999).
The uptake of quercetin into cells has been reported by Kuo et al (1996) who 
observed quercetin accumulation in Caco-2 cells after exposure to 100 pM quercetin for 
40 min using fluorescence microscopy (quercetin naturally fluoresces). This observation 
was confirmed four years later by Walgren et al (2000) after incubating Caco-2 cells for 
15 min with 50 pM quercetin. Mu rota et al, (2000) detected quercetin metabolites in 
Caco-2 cells using HPLC-UV (after hydrolysis) and Salucci et al, 2002 reported the 
association of 0.5 ng quercetin with 10  ^Caco-2 cells after a 48 h incubation with 70 pM 
quercetin-3-glucoside. Our results are in the same order of magnitude with Salucci’s 
findings, as 0.2% of the administered dose (associated with the cells, Table 7), 
corresponds to 4 ng quercetin/lO'^cells. Thus evidence reported here and in the literature 
supports the conclusion that quercetin metabolites are formed inside the cells and then 
quickly excreted via active transport systems.
While metabolites may be formed within the cells, they don’t appear to accumulate 
inside the cells (Spencer et al, 2004, Mu rota et al, 2003; Shirari et al, 2002). Recently it 
has been suggested that quercetin and other flavonoids may exhibit their bioactivity via 
interactions with membrane-phospholipids or membrane-receptors. If these theories hold 
true, the retention of quercetin and/or quercetin metabolites within the cells would
therefore not be essential for their bioactivity (Shirai et al, 2002; Spencer et al, 2004).
4.5. Discussion of the applied methods
4.5.1. Recovery of radioiabeiled metabolites
To compare in vitro and in vivo metabolite formation, metabolites in cell culture
medium were extracted following the same extraction protocol as previously used for rat
tissue samples. The extraction efficiency of radioiabeiled compounds was 80% from cell
culture medium and 50% and from rat tissues (Table 1 and Section I, Table 1). The
differences in recovery may be explained by an inverse correlation of the extraction
efficiency and sample protein content, as quercetin and its metabolites have been
reported to bind to proteins (Walle et al, 2003; Zsila et al, 2002; Boulton et al, 1998).
Cell culture medium contains less protein compared with plasma and tissue samples,
therefore the recovery of quercetin metabolites would be expected to be higher.
The detection of a relatively large number of novel quercetin metabolites in this
study (Section I and Section II of this thesis), may be due to the customised extraction
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procedure, which was tailored using the radiolabel as guide for the development of an 
extraction technique for unknown (but radioiabeiled) compounds.
4.5.2. Reproducibility of the results
Due to the very limited availability of [2-^"^C]quercetin-4'-glucoside, experiments 
were designed in singiicate and were directed at qualitative outcomes. However, similar 
results at different time points confirm the consistency of the reported observations.
4.5.3. Stability of [2-i'*C]quercetin-4'-glucoside in culture medium
The addition of flavonoid aglycones or glycosides to cell culture medium is a 
commonly used procedure. Therefore, the extent of quercetin break down was not 
anticipated. Adjustment of the formulation of cell culture medium may ensure the 
stability of the compound under investigation. Also, if metabolite synthesis by different 
cell lines is to be directly compared it is advisable to use identical medium formulations, 
to exclude variations caused by different culture medium.
5. Conclusion
Cell culture experiments may provide useful model systems for the investigation of 
potential health effects of flavonoid metabolites in vivo, provided that cell-independent 
break down of the studied compound can be controlled or eliminated, and the compound 
under investigation is stable in culture medium for the duration of the experiment. 
Intestinal and liver cells formed similar types and numbers of quercetin metabolites, 
supporting the view that Gl-epithelia significantly contribute to flavonoid metabolism. 
Liver cells however formed a larger quantity of metabolites, possibly due to a better 
stability of [2-'"^C]quercetin-4'-glucoside in liver cell culture medium. From our results 
we can not conclude that metabolite formation occurred inside the cells, however, in 
accordance with recent publications our results support the hypothesis that quercetin 
metabolites are formed inside the cells with quick and efficient subsequent export into 
the cell culture medium.
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Abstract
Background:
Objective:
Design:
Quercetin iip-regulates glutathione levels in vitro and in 
vivo. This mechanism may partly explain the antioxidant 
activity of quercetin in vivo.
To investigate whether free quercetin and quercetin 
glycosides have a similar effect on intra-cellular 
glutathione concentration in vitro.
Rat liver (CC-1) and small intestinal (IEC-6) cells were 
incubated with 5-100 pM quercetin, quercetin-4'-glucoside 
and H2O2, and intra-cellular glutathione levels were 
monitored from 3-72 h.
Results:
Conclusions:
Quercetin up-regulated intra-cellular glutathione in IEC-6 
cells by 50%, but quercetin-4'-glucoside and H2O2 had no 
effect. In CC-1 cells, none of these treatments had an effect 
on glutathione concentration.
Free quercetin and glycosylated quercetin have different 
biological effects in vitro. Thus, the biological activity of 
free quercetin may not reflect that of the usual glycoslyated 
forms found in the diet.
Key words: glutathione-regulation, quercetin, quercetin-4'-glucoside,
antioxidant-activity
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1. Background and Aim
The antioxidant activity of dietary flavonoids is determined by the number and 
positioning of free hydroxyl groups on the flavonoid structure (Rice-Evans et al, 1996). 
However, quercetin appears in plasma and body tissues exclusively in the form of 
quercetin conjugates, where some of the functional hydroxyl groups are inactivated by 
the attachment of sulfate, methyl or glucuronyl moieties (Section I, Crespy et al, 2003). 
Thus, quercetin conjugates have a reduced potency to function as antioxidants (Begum 
and Terao, 2001). Nevertheless, in vivo studies reported a variety of antioxidant effects 
after ingestion of quercetin (Natarajan et al, 1999; Rathi et al, 1984), It is not clear how 
these in vivo antioxidant effects were achieved, although it has been hypothesized that 
quercetin metabolites may affect the pro- and anti-oxidant balance by interacting 
synergistically with other endogenous or exogenous antioxidants via mechanisms that do 
not involve stoichiometric antioxidant quenching (Milbury et al, 2002; Sciuto, 1997).
In recent years, it has been reported that cultured cells responded to quercetin 
exposure with up-regulation of the intra-cellular glutathione concentration (Cipak et al, 
2003; Scharf et al, 2003; Isighe et al, 2001). Animal studies also showed that glutathione 
levels in tissues were up-regulated after oral ingestion of quercetin and rutin (Cruz et al, 
1998; Martin et al, 1998, Gandhi and Khanduja, 1993). Glutathione is a small 
intracellular tri-peptide, consisting of three amino acids (y-glutamyl-cysteinyl-glycine), 
and unlike most other peptides and proteins it is synthesized enzymatically via the y- 
glutamyl cycle. Glutathione is the most abundant antioxidant in cells, and plays a major 
role in the cellular defense against oxidative stress (Deleve and Kaplowitz, 1990; Meister 
and Anderson, 1983). It can directly scavenge free radicals (Kalyanaraman et ai, 1996) or 
act as a substrate for glutathione peroxidase and glutathione-S-transferases during the 
detoxification of electrophilic compounds (Armstrong et al, 1997; Ursini et al, 1995). If 
dietary quercetin and/or its in vivo metabolites could modulate the cellular homeostasis 
of pro- and anti-oxidants via the up-regulation of glutathione synthesis, this could 
provide an explanation for the anti oxidant mechanism of glycosylated quercetin and its 
metabolites in vivo.
The aim of this study was to investigate whether dietary quercetin-4-glucoside 
triggers an increase of cellular glutathione similar to that previously reported for free 
quercetin. As the Gl-tract and the liver are the primary organs exposed to dietary
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quercetin, small intestinal epithelial cells (IEC-6) and liver epithelial cells (CC-1) were 
used to investigate the effect of quercetin-4'-giucoside on intra-cellular glutathione 
levels.
2. Materials and Methods
2.1. Cells and materials
Small intestinal epithelial cells (IEC-6) and liver epithelial cells (CC-1) were 
maintained using materials and equipment as previously described. DTNB (5,5’-Dithio- 
bis[2 nitro benzoic acid] or Ellman’s Regagent), glutathione, glutathione reductase, 
H2O2, NADPH (p-nicotinamide adenine dinucleotide phosphate in reduced form) and 
quercetin were purchased from Sigma, (Poole, Dorset, U.K.). Quercetin-4'-glucoside was 
obtained from Rotec Scientific Ltd. Milton Keynes, U.K. Working solutions for the 
glutathione assay were made up as follows: “Buffer B (1%)” and “Buffer B (0.1%)”: 67 
mM potassium di-hydrogen orthophosphate solution and 83 mM di-sodium hydrogen 
orthophosphate solution were combined at a ratio of 1.64:8.36 and 5 mM EDTA was 
added. This mixture had a pH of 7.5, if not, it was adjusted accordingly. Then either 1% 
or 0.1 % (w/v) 5-sulfosalicylic acid was added. “NADPH solution”: Buffer B (0.1%) 
containing 0.5 mM NADPH and 1.5 mM DTNB.
2.2. Cell viability and growth inhibition after exposure to flavonols and H2O2
Rat small intestinal cells (IEC-6) or rat liver cells (CC-1 ) were seeded into 6 well 
plates at 3 X 10"^  cells/ml medium. After overnight incubation, the medium was removed 
and replaced with fresh medium containing 5, 10, 20, 50 or 100 pM quercetin, quercetin- 
4'-glucoside or H2O2. Ethanol was used to dissolve quercetin and the final ethanol 
concentration in all treatments was 0.25% (v/v). After 3 days incubation, the medium 
was removed, and the cells were detached from the bottom of the 6 well plates using 0.5 
ml 1 X trypsiii/EDTA for 10 min at 37 °C. Then 0.75 ml culture medium containing FCS 
was added to stop the enzymatic reaction. The cell-media suspension was mixed, 
transferred into a microtube and the well was washed with 0.75 ml medium, which was 
collected into the same microtube. To assess the number of viable cells 50 pi trypan blue 
was added to an equal volume of cell suspension and an aliquot of the dyed
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Figure 1: IEC-6 and CC-1 cells.
Cultured rat small intestine (IEC-6) and rat liver (CC-1) cells were visualized at 20 x magnification 
using a IMT-2, Olympus phase contrast microscope (Optical Co. Ltd, Japan). The pictures were taken 
with a XC-57CE digital camera (Sony Japan) and Amigo Dazzle Multimedia software. To depict the 
size of the cells, a 1mm graticule was photographed under the same magnification as the cells 
(Graticule Ltd, Tonbridge, Kent, England, 100 x 0.01 = 1mm).
cell suspension was transferred to a Neubauer haemocytometer. According to Freshney et 
al (1986) cells with damaged membrane integrity stain blue, whilst viable cells remain 
unstained and appear white when viewed under the microscope. In this assay the number 
of unstained white cells was counted on four haemocytometer squares, and the number of 
viable cells per 1 ml cell suspension was determined. Each experiment was carried out in 
duplicate, and each sample was counted twice.
Using the trypan blue assay, both the cytotoxicity and growth inhibition were 
assessed, which are both reflected by the number of viable cells. In this study, the 
glutathione content of all cells in one well was compared with the glutathione content of 
cells from different wells. Therefore it was essential to keep the number of cells per well 
constant, as a different number of cells would have resulted in a different quantity of 
glutathione per well.
For subsequent experiments only treatments were used which had no significant 
effects on cell viability or growth (viability >80%) (Table 1). The ethanol vehicle used to 
solubilize quercetin and quercetin-4'-glucoside had no effect on growth or viability in 
both cell lines (Table 2).
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Cell Viability
% of cells found to be viable
IEC-6 cells 00-1 cells
control 100% 100%
ethanol control 105% 102%
5 gM Q4'G 104% 78 %
10 gM Q4’G 109% 101 %
20 gM Q4'G - 82%
50 gM Q4'G 97% 22%
100 gM Q4’G 83% 5%
5 gM Quercetin 105% 104%
10 gM Quercetin 105% 93%
20 gM Quercetin 108 % 72%
50 gM Quercetin 77% 38%
100 gM Quercetin 35% 10%
5 gM H2O2 95% 95 %
lOgM H2O2 100% 102%
20 gM H2O2 97% 102%
50 gM H2O2 23% 98%
100 gM H2O2 0% 43%
Table 1: Cell viability.
Freshly seeded CC-1 or IEC-6 cells were incubated with quercetin-4'- 
glucoside (Q4'G), quercetin and H2O2 for 72 h. Ethanol control and all 
flavonoi treatments contained 0.25% (v/v) ethanol. The result (% viability) is 
the mean of two experiments which were both counted in duplicate.
2.3. Experiments and sample collection
EEC-6 and CC-1 cells were seeded into 6 well plates at a concentration of 3 x 10"^  
cells/cm^. At confluence (after 3 days) the media was removed and fresh media 
containing 5-100 |iM quercetin-4'-glucoside, 5-20 piM quercetin or 10-50 ptM H2O2 was 
added. Quercetin and quercetin-4-glucoside were dissolved in ethanol and further diluted 
directly in the cell culture media. The ethanol concentration was kept constant at 0.25% 
(v/v) throughout all pilot experiments and at 0.05% (v/v) throughout all subsequent 
experiments. The relatively high ethanol concentration was unavoidable, since 0.5 g 
quercetin dissolves in 35 ml ethanol, and a final media concentration of 100 pM 
quercetin was required. However, the ethanol vehicle had no effect on inter-cellular 
glutathione levels or cell viability (p=0.64 for IEC-6 cells and p=0.52 for CC-1 cells) 
(Table 1 and Table 2),
After 3 ,6 , 12, 24, 48 and 72 h the cell culture media was removed and cell extracts 
were obtained by incubating the cell monolayer for 20 min with 900 pi 1% 5-
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sulfosalicylic acid. The cell extract was diluted in “Buffer B (1%)” by 1:3, and stored at -  
80 '"C until analysis. Initially the media was examined for its glutathione content, but 
since no glutathione was present in the cell culture media in all subsequent experiments 
only the cell extract was analysed.
intra-cellular glutathione (in nmol /  well)
untreated cells 0.25% (v/v) ethanol
IEC-6 cells 53.33 ± 6.12 51.12 ± 6.36
CC-1 cells 108.46 ±7.22 104.94 ±7.40
Table 2: Ethanol vehicle has no influence on intra cellular glutathione level.
IEC-6 and CC-1 cells were grown to confluence in 6 well plates, and incubated with no or 0.25% (v/v) ethanol for 72 
hours. Results are the mean of 4 separate experiments (±SD). One cell culture well had a surface area of 9.6 cm^, 
containing 177 ± 18 x 10  ^ IEC-6 cells or 269 ± 34x10* CC-1 cells at confluence. (p=0.64 for IEC-6 cells and p=0,52 
for CC-1 cells).
2.4. Glutathione assay
2.4.1. Assay principle
Total glutathione was measured using the enzymatic colorimetric recycling assay 
devised by Tietz 1969, with modifications described in Punchaid et al (1994). The assay 
is based on the oxidation of glutathione (GSH) by 5,5'“dithiobis-(2-nitrobenzoic acid) 
(DTNB), and resulting oxidised glutathione (GSSG) is reduced by NADPH in the 
presence of glutathione reductase. The rate of 2-nitro-5-thiobenzoic acid formation from 
DTNB is monitored at 410 nm over 10 minutes, and is proportional to the total 
glutathione concentration (GSH and GSSG) of the samples. The quantity of total 
glutathione per sample was determined by reference to a standard curve.
2.4.2. Assay protocol
An aliquot of 50 pi of the diluted samples was transferred to a flat-bottomed 96
well plate already containing standards at a concentration of 1-10 pM glutathione (1-10
nmol/ml or 0.05 -  0.5 nmol/50 pi) and two quality control samples. To the samples,
standards and quality controls, 100 pi of 0.5 mM NADPH (containing 1.5 niM DTNB in
“Buffer B (0.1%)”) was added. The enzymatic reaction was initiated by the addition of
50 pi 1 U/ml glutathione reductase to all wells excluding the blank. The reaction was
monitored at 410 nm over 10 minutes using a Dynatech Microplate Reader (MR 5000,
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Guernsey, Channel Islands). Different concentrations of 5-sulfosalicylic acid affected the 
glutathione measurements, therefore glutathione standards were made up to contain the 
same 5-sulfosalicylic acid concentration as the samples.
Quality control samples were prepared from confluent IEC-6 cells, by obtaining a 
cell extract as described above, which was then aliquoted and stored at -80 °C. The 
detection minimum was 1 pM total glutathione or 0.05 nmol/50 pi analysed sample 
aliquot.
2.5. Statistical analysis
Results were analysed using the software STATGRAPHICS Plus for Windows 4.0. 
One-way analysis of variance (ANDVA) was applied to determine whether there was a 
significant difference between treatments and control experiments. If the p value 
obtained was smaller than 0.05, the statistical difference between individual groups was 
determined using the method of Fisher’s protected least significant difference (LSD).
As common for bioassays, the results had considerable within and between “batch” 
variation (Table 3). “Batch” was defined as a cluster of cell culture experiments that 
were seeded and analysed at the same time. All results were always compared to the 
appropriate control experiment within the same “experimental batch”.
Intra and inter experiment variation 
of intra-cellular glutathione levels (in nmol/cell culture well)
mean intra assay  variation inter assay  variation
untreated IEC-6 cells 47.19 3.03 (6.4 %} 6.90 (14.6%)
untreated CC-1 cells 103.47 7.16 (6.9%) 15.37 (14.9 %)
Table 3: inter and intra a ssay  variation.
The cellular glutathione concentration in untreated CC-1 and IEC-6 cells (nmol/well) is given as the mean of 
ALL experiments. The intra and inter assay variation was calculated using ANOVA and the method of 
Fischer's protected least significant differences.
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3. Results
3.1. Effect of quercetin and quercetln-4'-glucoside on cellular glutathione 
levels
3.1.1. Pilot experiments (n=3)
IEC-6 and CC-1 cells were incubated with various concentrations of quercetin, 
quercetin-4’-glucoside and H2O2 and levels of intra-cellular glutathione were determined 
after 3, 6, 12, 24, 48 and 72 hours. In both cell lines, no change of intra-cellular 
glutathione was measured after incubation with quercetin-4-glucoside. However, 
glutathione levels were up-regulated by 30% after exposing IEC-6 cells to 20 pM 
quercetin for 24 hours (p=0.0011) (Table 4). No change of the intra-cellular glutathione 
concentrations was observed when CC-1 cells were incubated with quercetin.
Treatment with 20 pM H2O2 for 6 h increased the intracellular glutathione content 
in CC-1 cells by 10% (p=0.014). However when IEC-6 cells were exposed to the same 
dose no effect was measured.
3.1.2. Main experiments (n=9)
The result of the pilot experiments was confirmed by repeat experiments using a 
greater sample size (n=9). IEC-6 cells responded to 24 hour incubation with 10 and 20 
pM quercetin with a dose dependent increase of intra-cellular glutathione of 17% ± 9% 
and 49% ± 13% (p=0.0001) (Figure 2 and Table 5), However, when IEC-6 cells where 
treated with 20 pM quercetin-4'-glucoside or 20 pM H2O2 for the same length of time (24 
hours), no change of the glutathione level was observed.
CC-1 cells showed no significant change of intra-cellular glutathione levels after 
the 24 hour treatment period (Figure 2 and Table 5).
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Pilot experiments: Intra-celiular glutathione concentration 
(in nm ol/well) (n=3)
Section IV
%
IEC-6 cells
experiments 3 h 6 h 12 h 24 h 48 h 72 h
untreated 49.88 +  4.29 57.40 + 0.64 63.87 + 4.74 50.04 +  2.18 54.06 + 3.66 53.61+3.46
5 |x M Q - - - 55.62 +  1.971 55.01 + 4.25 52.92 +  3.43
l O p M Q - - - - - -
20 p M Q 47.58 ±  2.35 62.14+1.84 67.86 +  4.41 64.28 +  0.051 59.65 + 2.19 48.96 + 3.81
untreated 44.68 ±  2.69 47.31 ±  4.03 54.02 +  4.00 42.82 + 2.22 42.71 + 3.60 44.49 +  1.60
5 pM Q4‘G 42.87 + 4.84 46.48 + 3.74 55.04 +  4.21 40.02 + 4.16 43.82 +  2.22 42.13 +  7.05
10 pM Q4'G 41.70 + 5.81 46.92 + 0.93 53.97 + 4.23 43.23+ 1.25 44.01 ± 1.96 43.18 + 1.74
20 pM Q4'G 47.20 + 3.33 47.40 ±  8.86 54.48 + 1.14 44.67+ 1.73 42.82 + 2.53 45.34+1.94
50 pM Q4‘G 44.50 + 3.68 41.97 +  3.20 52.90 +  2.60 45.60 + 2.00 42.94 ±  1.96 38.43 +  5.28
100 pM Q4'G 41.58 + 3.18 45.15+1.52 58.94 +  2.99 47.29 + 3.47 41.91+6.42 43.92 +  2.52
untreated 39.04 +  2.05 39.35 +  2.92 40.62 + 2.45 42.59 +  1.42 45,12 + 3.06 49.99 +  2.03 A
5 pM H2O2 - - - - - -
10 pM H2O2 36.47 +  2.76 41.74 + 2.10 40.14 + 4.14 42.88 +  0.89 42.54 + 2.77 46.42 +  3.73
20 pM H2O2 39.25+ 1.99 42.71 +  1.60 42.03 +  3.22 43.94 +  1.82 44.12 +  0.36 49.29 + 1.76
50 pM H2O2 R . V . R .V . R . V . R . V . R . V . R . V . j
CC-1 cells
1
experiments 3h 6h 12 h 24 h 48 h 72 h
untreated 87.32 +  9.17 106.30 + 8.86 109.81+7.92 112.21+6.53 104.55 +  7.59 104.48 + 11.11 5
5pMQ - - - - 93.99 ±  5.33 98.77 + 7.49
lOpMQ 95.75 +  5.72 121.23 + 3.74 108.16 +  4.51 100.21+5.72 -
20 pMQ R . V . R . V . R . V . R . V . R . V . R . V .
untreated 97.49 +  2.55 114.00 + 2.10 129.11+5.62 103.55 +  3.16 108.55 + 7.73 96.67 +  14.45
5 pM Q4'G 92.88 ±  4.54 106.59 +  7.89 124.28 +  4.74 103.05 +  1.28 112.53 +  6.17 82.59 ±  8.01
10 pM Q4'G 84.51+8.81 111.02 + 8.67 129.05 +  8.76 103.89 +  7.19 109.81+5.11 98.80 + 1.42
20 pM Q4'G 100.17 +  3.86 108.94 + 5.49 125.06 +  9.18 107.40 +  5.29 114.97+1.22 84.00 ±  7.43
50 pM Q4'G R.V. R . V . R . V . R . V . R . V . R . V .
100 pM Q4'G R . V . R . V . R . V . R.V. R . V . R . V .
untreated 73.84 + 5.04 76.71 + 1.30 122.31+1.39 118.57 + 9.02 105.71 +4.20 94.85 + 4.85
5 pM H2O2 - - - - -
10 pM H2O2 64.80 +  6.58 73.26 + 2.05 120.67 +  4.64 112.15 + 4.02 98.25 +  7.45 89.38 + 3,51
20 pM H2O2 70.10 + 3.21 84.43 +  3.49 2 117.43 +  2.86 112.28 + 6.58 94.52 +  4.87 90.58 + 5.28
50 pM H2O2 76.78 + 3.39 88.03 ±  4.57 2 124.04 +  5.08 116.11+6.45 111.99 +  4.13 94.35 + 6.52
Table 4: intra-cellular glutathione in intestinal (IEC-6) and liver (CC-1) ce lls  after treatment with quercetin, 
quercetin-4'-glucoside and HaOa.
Confluent monolayers of IEC-6 and CC-1 cells were cultured in 6 well plates and incubated with quercetin (Q), 
quercetin-4'-glucoside (Q4'G) and HaOa, At 3, 6, 12, 24, 48 and 72 hours the glutathione concentration in the cell 
extract was determined in nmol/well ±SD (n=3).
Due to large inter-assay variations, all results were compared to the appropriate control (untreated cells) from the 
same “experiment batch”. Comparison is only possible within one experimental batch, e.g. dose comparison is 
possible, but comparison between different time points is not possible. Statistical differences between treatments and 
the untreated control (of the same “experimental batch”) were calculated as described in materials and methods and 
are highlighted in the table: * p= 0.0011,  ^ p= 0.014. R.V.= reduced viability: these concentrations were not used in this 
experiment as they affected the viability and growth rate of the cells (Table 1)..
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Figure 2 with Table 5: Glutathione concentration in intestinal (IEC-6) and liver (CC-1) cells after incubation with 
quercetin, quercetin-4'-glucoside and H2O2.
Confluent monolayers of IEC-6 and CC-1 cells were cultured in 6 well plates and incubated with quercetin (Q), 
quercetin-4'-glucoside (Q4'G) and H2O2 .. After 24 h intracellular glutathione concentrations were determined (in nmol 
/well). Results are the mean of 9 experiments (±SD). Statistical differences between treatments are indicated with “a", 
“b” and “c” (p= < 0.0001). R.V.= reduced viability; this concentration was not used since it affected the viability and 
growth rate of the cells (Table 1).
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4. Discussion
IEC-6 and CC-1 cell monolayers contained 53+6 and 108+7 pg total glutathione 
(GSH and GSSG) per culture well (9.6 cm^), which compai'cs to 301±34 and 403±27 pg 
total glutathione in 10"^  cells, respectively. CC-1 cells contained 33% more glutathione 
compared with the IEC-6 cells, in agreement with previous reports that liver cells contain 
higher levels of glutathione compared with other cells (Locigno and Castronovo, 2001; 
Sciuto, 1997).
4.1. Quercetin, but not quercetin-4'-glucoside, up-regulated Intra-cellular 
glutathione in IEC-6 cells
Quercetin and quercetin-4'-glucoside had different effects on the regulation of 
intra-cellular glutathione levels in IEC-6 cells. Combining the results from this Section 
with our previous results on the stability, metabolism and break down of [2- 
*''^C]qiiercetin-4'-glucoside (Section III, paragraph 4.3), none of the compounds 
(unchanged quercetin-4'-glucoside, quercetin metabolites or decomposition products of 
quercetin-4'-gIucoside) in the cell culture medium after the addition of quercetin-4'- 
glucoside affected the regulation of glutathione in IEC-6 cells. Free quercetin however 
increased cellular glutathione levels by 50%, suggesting that after application of 
quercetin to cell culture medium, either quercetin itself or derived bio active metabolites 
caused the up-regulation of glutathione (Figure 3).
De-novo glutathione synthesis is primarily determined by increased expression of 
the two subunits of the key enzyme, glutamate cysteine ligase (GCL) formerly known as 
y-glutamyl-cysteine-synthetase (y-GCS) (Dickinson and Forman, 2002, Rahman and 
MacNee, 2002). One major factor for the up-regulation of this enzyme is oxidative stress 
(Rahman and MacNee, 2002). Recently it has been shown that quercetin can be oxidised 
in cell culture environments forming quercetin-semi-quinone radicals, H2O2 and O2’* 
(Awad et al, 2002; Long et al, 2000; Awad et al, 2000, Metodiewa et al, 1999). 
Therefore, de novo synthesis of glutathione in IEC-6 cells may have been up-regulated 
by oxidative stress due to the formation of quercetin-quinones. DMNQ, a quinone which 
continuously generates H2O2 and O2"* through redox cycling, similar to quercetin, was 
shown to elevate intra-cellular glutathione levels and upregulate activity, protein and 
mRNA content of y-GCS, in rat lung epithelial cells (Shi et al, 1994).
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In conclusion, cultured intestinal cells (IEC-6 cells) up-regulated intra-cellular 
glutathione after quercetin was added to the cell culture medium. However, addition of 
quercetin-4'-glucoside had no significant effect on glutathione levels. From our results, it 
is not obvious why quercetin and glycosylated quercetin had such profoundly different 
effects. However, it has been suggested, that contact of quercetin with culture medium 
can result in the formation of free radicals, which could have an effect on glutathione 
synthesis.
Are different effects of quercetin and quercetin-4'-glucoside 
due to different intermediate products?
Quercetin metabolites
Quefcetin-4-glucoside
Quercetin
Quercetin seml-quinone radical
Break down products of 
quercetin-4'-glucoside
Quercetin glutattiioine
glutathioineQuercetin-4'-glucoside
C o m p o u n d s  
c a u s in g  th e  e ffec t
C om p ou n d  
a d d ed  to  th e  m edium
E ffect
Figure 3: Different effects of quercetin and quercetin-4'-glucoside on IEC-6 cells.
Quercetin treatment Increased intracellular glutathione levels by 50%, whereas treatment 
with quercetin-4'-glucoside had no effect. The figure summarizes the hypothesis that 
different effects may be caused by different intermediate products of quercetin and 
quercetin-4'-glucoside.
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4.2. Effect of quercetin and quercetln-4'-glucoside on Intra-cellular 
glutathione of CC-1 cells
After exposure to quercetin, cultured liver cells (CC-1) did not up-regulate intra­
cellular glutathione in a similar way as IEC-6 cells. The reasons for this are unclear and 
were not further investigated in this study. However, if the up-regulation of glutathione 
was triggered by increased oxidative stress, then higher concentration of serum (PCS) 
and amino acids (NEAA) in liver cell culture medium may have buffered pro-oxidative 
effects caused by reactive quercetin molecules. As previously discussed (Section III, 
paragraph 4.3), proteins and amino acids, particularly those with thiol groups, can 
function as antioxidants in vivo and in vitro (Acworth et al, 1997; Levine et al, 1996; 
Gutteridge et al, 1994; Ross, 1988). Therefore the different composition of the two cell 
culture mediums may explain the differential effects of quercetin on glutathione 
regulation in CC-1 and IEC-6 cells. The up-regulation of intra-cellular glutathione y- 
glutamyl-cysteine-synthetase (the key enzyme for glutathione synthesis) has been 
reported in another liver cell line, HepG2, after incubation with 10-50 pM quercetin 
(Schaif et al, 2003).
4.3. Effect of H2O2 on intra-cellular glutathione
According to stoichiometry, a maximum of 20 pM H2O2 could have been formed in 
cell culture medium during oxidation of 20 pM quercetin (Award et al, 2000). We 
therefore tested the effect of H2O2 on the regulation of intracellular glutathione in our cell 
culture model. However, the addition of 10 and 20 pM H2O2 did not trigger significant 
up-regulation of intra-cellular glutathione levels in CC-1 and IEC-6 cells (after 24 hours). 
Therefore if glutathione up-regulation in IEC-6 cells was caused by oxidative stress, the 
other two reactive molecules, quercetin-semi-quinone radicals and superoxide (O2’’), may 
be responsible. However, quercetin may also trigger the up-regulation of intra-cellular 
glutathione via other pathways, e.g. via modulation of cytokine expression (Nair et al, 
2002).
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4.5. Conclusion
The regulation of intra-cellular glutathione was “compound specific” and “tissue 
specific”: Incubation with quercetin-4'-glucoside had no effect on intra-cellular 
glutathione levels in both liver and intestinal cells (CC-1 and IEC-6 cells). Incubation 
with quercetin up-regulated intra-cellular glutathione in IEC-6 cells by 50%, but had no 
effect in CC-1 cells. These results indicate that free quercetin and glycosylated quercetin 
have different biological effects in cell culture.
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4.4. Discussion of the applied methods
4.4.1. Inter assay variation
The variation of intra-cellular glutathione levels in untreated “control” cells was 
significant and ranged from 43-63 nmol/well and 87-112 nmol/well for IEC-6 and CC-1 
cells respectively (Table 4 and Table 5). These variations occurred when different 
batches of cells were seeded on different days and may be due to slightly varying 
confluence levels e.g. different numbers of cells in one well. All experiments were 
carried out at 95-100% confluence, determined by visual observation using phase 
contrast microscopy (Figure 1). However, more consistent results may have been 
achieved, if the exact cell number per well would have been determined, e.g. by total 
protein determination per well. Due to the high inter assay variation, the obtained results
,were always compared to the appropriate control within the same “experimental batch”. I
4.4.2. Toxicity and growth inhibition of quercetin and quercetin-4'-glucoside in cell culture
Intestinal cells (IEC-6) proved to be more resistant against incubation with 
quercetin and quercetin-4'-glucoside in comparison with rat liver cells (CC-1). In both 
cell lines, free quercetin had a greater effect on cell viability compared with quercetin-4'- 
glucoside. Conjugated quercetin may be less reactive than free quercetin (Boersma et al,
2001; loku et al, 1995), and this may be the reason why plant and animal organisms 
contain the “reactivity” of quercetin by conjugating it with sugar, glucuronyl, sulfate and 
methyl moieties.
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Final comments and conclusions
1. Quercetin bioavailability
To explore potential health effects of dietary quercetin it is crucial to obtain reliable 
data on its absorption and subsequent availability at target tissues. Estimates of the 
absorption rate of quercetin from the Gl-tract, published in the last 10 years, range from 
<0.1% to 50%. Therefore, in this study the dynamics of quercetin absorption, metabolite 
formation and distribution throughout body tissues and plasma was investigated using 
radiolabelled quercetin-d'-glucoside in an animal model. Our results indicate that -10%  
of ingested dietary quercetin is absorbed in rats. It appears that quercetin absorption was 
previously both significantly over and underestimated, probably because in vivo 
metabolism of quercetin was not known or not considered. As detailed in Section 1 
(paragraph 4.1), Hollman’s and W alle’s conclusion that 50% of the ingested dietary 
quercetin was absorbed from the GTtract may have been an overestimation, because 
quercetin may have “disappeared” from the ileostomy fluid not because it was absorbed, 
but because it was methylated. Our data also provides evidence that quercetin 
bioavailability was previously underestimated. Plasma quercetin is usually quantified 
after releasing free quercetin from its conjugation with glucosyl, glucuronyl and sulfuryl 
moieties by acid or enzymatic hydrolysis. This method however does not cleave methyl 
groups from the quercetin molecule (Hollman et al, 1997). In our study 70% of plasma 
quercetin was found to be methylated (Section I, Table 9). If after the hydrolysis process, 
only free quercetin is quantified, all methylated quercetin remains un-accounted for, 
resulting in a significant underestimation of plasma quercetin, e.g. in our experiment, 
plasma quercetin would have been underestimated by 70%,
Another confounding factor in determining the true plasma concentration of 
absorbed flavonoids is the recovery rate of quercetin or its metabolites during the 
extraction process. It is evident that both the extraction solvent and technique determines 
the extraction efficiency (Section I, Figure 2), and low findings of plasma metabolites in 
previous studies may be due to inadequate extraction techniques. Internal standards, 
added to plasma samples before extraction, may not reflect the true extraction efficiency, 
as 1) virtually all plasma quercetin is metabolised (Section I) and 2) quercetin in plasma 
is bound to plasma proteins (Walie et al, 2003; Zsila et al, 2002, Boulton et al, 1998).
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Thus, reported plasma quercetin values reflect a combination of the plasma quercetin 
concentration AN D the effectiveness o f the extraction technique.
Quercetin absorption and bioavailability was frequently under or over-reported. 
From our results we conclude that 5 - 10% o f a dietary dose o f  quercetin is absorbed into 
the systemic circulation.
2. Consequences of pre-systemic metabolism of quercetin
From our results, and a number of recent reports (Crespy et al, 2003; Cermak et al, 
2003), we conclude that most o f the ingested dietary quercetin is metabolised directly in 
the Gl-tract (Section I, paragraph 4.2, Section III, paragraph 4.2). The physiological 
purpose o f pre-systemic metabolism (e.g. metabolism before entry into system ic 
circulation) is the reduction o f toxicity and quick excretion o f potentially toxic 
substances. Thus, dietary quercetin is treated in vivo like a potentially harmful substance.
Only Gl-tissues appear to be exposed to significant quantities o f dietary quercetin 
and its metabolites. Because intestinal epithelia are in direct contact with the potential 
antioxidant, it is possible that dietary quercetin has an effect on physiological or 
pathological processes in G l-tissues and on Gl-micro flora. In some animal studies, 
quercetin intake has reduced the incidence and development o f colon cancer (Deschner et 
al, 1991 ; Yang et al, 2000).
Gl-tissues appear to be the “primary target organ” for potential bioactive effects o f  
ingested dietary quercetin or its in vivo metabolites. Further research is needed to 
elucidate the potential o f dietary quercetin to contribute to intestinal health.
3. Biological relevance of quercetin metabolites
Orally ingested quercetin is extensively metabolised in the body by two distinct 
pathways: 1) phase II metabolism in body tissues and 2) ring fission and decomposition 
into phenolic acids by colonic micro flora (Figure 1). The work presented in this thesis 
(Section I and II) suggests that phase II metabolism may be predominant in the 
immediate postprandial phase, and phenolic acids appear later due to their formation by 
micro flora in the large bowel. Absorbed quercetin appears in body tissues, plasma and
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urine almost exclusively in the form of phase II and phenolic acid metabolites, 
suggesting that in vivo, health effects are caused by metabolites, not the ingested 
quercetin glycosides or free quercetin.
However, it is also possible that phase II metabolites of quercetin act as quercetin 
carriers or pro-drugs, which are transformed into active compounds when needed. Very 
recent research suggests that many body tissues are capable of effectively hydrolysing 
quercetin glucuronides (O ’Leary et al, 2003; O ’Leary et al, 2001), releasing free 
quercetin from its conjugation adducts (sulfate, methyl and glucuronyl groups). Thus, 
quercetin metabolites may be hydrolysed under certain circumstances, e.g. during 
inflammation (Shimoi et al, 2001 ).
To date, the biological relevance of quercetin metabolites is still unclear, and 
further research is needed to clarify whether and how quercetin metabolites contribute to 
human health.
Ingested
ingested forms 
of quercetin
Quercetin
Quercetin-4'-glucoside 
Quercetin-3-glucoside 
Quercetin-3,4'-di-glucoside 
Quercetin 3-rutinoslde 
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In the body
two distinct pathways of 
quercetin metabolism
Phase II metabolites:
= quercetin conjugated with 
methyl, sulfate or glucuronyl 
groups
Quercetin
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= originating from quercetin 
catabolism in the large bowel 
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Function?
potential effects of quercetin 
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Direct quenching 
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when required ?
Other effects: 
interaction with receptors 
cell membranes 
cytosolic proteins -  etc.
Direct quenching 
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Figure 1: Biological relevance of quercetin metabolites.
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4. Caution with cell culture experiments
To accept in vitro experiments as an alternative to animal testing, it is essential that 
the compound under investigation (dietary quercetin) reaches the cells in vitro in the 
same form as in vivo. The work presented in this thesis, in agreement with many other 
studies, show that human and animal plasma exclusively contains quercetin metabolites 
no matter whether the oral dose was free quercetin or dietary quercetin (e.g. quercetin 
glycosides). Therefore, if the bioactivity of orally ingested quercetin is investigated using 
a cell culture model, cultured cells must be exposed to quercetin metabolites, as present 
in human or animal plasma. As quercetin metabolites are currently not available 
commercially these would have to be synthesized in the laboratory.
Previously it was assumed that flavonoids which are resistant to high temperatures, 
acids, etc., would be stable in cell culture medium. However, results shown in Section 
III, in agreement with other recent reports, strongly suggest that neither quercetin 
aglycone nor quercetin glycosides are stable in cell culture medium. Therefore the 
response of cultured cells to quercetin or quercetin glycosides in cell culture medium 
may be due to either 1) the activity of the original compound, 2) the activity of its 
cellular metabolites 3) the activity of cell independent break down products formed in 
culture medium or 4) oxidative stress due to HiO? , O 2  and quercetin-semi-quinone 
radicals.
Biological effects ascribed to quercetin based on cell culture experiments need to 
be re-evaluated using controlled conditions to 1 ) ensure the stability ot the compound 
under investigation, 2) to eliminate confounding factors such as H2 O 2  formation and to 3) 
expose cells to quercetin metabolites as present in vivo. Cell culture experiments that 
disregard these factors are likely to report artefacts with have no relevance to the 
situation in the human body.
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Appendix Table 1: Animal and organ w eights.
At 0.5, 1, 2 and 5 hours after ingestion of [2-^ '‘C]quercetin-4'-glucoside rats were terminally anaesthetised and blood 
was removed by cardiac puncture. The livers were perfused in situ and then removed along with brain, heart, kidney, 
lung, muscle, spleen, testes and the whole Gl-tract (stomach, small and large intestine including its contents). The 
sample collection was carried out at The Rowett Research Institute, Aberdeen, by Phil Morrice and Dr. Garry G. 
Duthie. All samples were frozen in liquid nitrogen and weighed before and after lyophilization.
organs
animal 0.5 A: 415.5 g animal 0.5 B; 430.1 g animal 0.5 0: 429.7 g
fresh organ 
(in gram) or% Zl) fresh organ (in gram) freezedried organ (in gram) % dry weight Iresh organ (in gram)
brain 1.8588 0.4055 21.82 1.7648 0.3839 21.75 1.7371 0.3708 21.35
GIT 24.905 9.4349 37.88 25.2598 9.9056 39.21
heart 1.1416 0.2456 21.51 1.1685 0.2588 22.15 1.2498 0.2686 21.49
kidney 1 1.6658 0.3642 21.86 1.4668 0.3470 23.66 1.5067 0.3118 20.69
kidney II 1.9429 0.6837 35.19 1.3804 0.3575 25.90 1.5395 0.3150 20.46
liver lobe 1 7.7974 1.3918 17.85 7.5352 1.6077 21.34 7.3333 1.7555 23.94liver lobe II 12.315 2.2849 18.55 9.1715 2.0419 22Ü6 7.5103 1.7489 23.29lungs 1.7280 0.3245 18.78 1.8101 0.3546 19.59 1.6593 0.3189 19.22
muscle sample 1.6589 0.4214 25.40 1.2639 0.3256 25.76 1.8047 0,4690 25.99
spleen 0.7265 0.1555 21.40 0.7515 0.1828 24.32 0.8022 0.1767 22.03
testes 2.7732 0.4045 14.59 2.8033 0.4058 14.48 2.5345 0.3565 14.07
organs
animal 1 A: 453.3 g animal 1 B: 436.7 g animal 1 C: 403.8 g
fresh organ 
(in gram)
freezedried organ (in gram) % dry weight
fresh organ 
(in gram)
freezedried organ (in gram) % dry weight
fresh organ (in gram)
freezedried organ (in gram) % dry weight
brain 1.7078 0.3716 21.76 1.4717 0.3125 2 1 2 3 1.9296 0.4374 22.67
GIT 25.9288 9j%95 35.75 23.9615 8.8825 37.07 24.9518 9.4742 37.97heart 1.3194 0.2804 2 1 2 5 1.2886 0.2809 21.8 1 2796 0 27 59 21.56
kidney 1 1.5538 0.3576 23.01 1.5775 0.3260 20.67 1.5814 0.3348 21.17
kidney II 1.6243 0.3712 22.85 1.6680 0.3580 21.46 1.6284 0.3455 21.22
liver lobe 1 4.8042 1.0950 23.78 8.9322 1.6984 19.01 6.5897 12354 18.75
liver lobe II 10.6130 2.3378 22.03 10.3414 1.9245 18.61 12.4208 2.3409 18.85
lungs 2.0082 0.3962 19.73 1.6124 0.3023 18.75 1.7360 0.3399 19.58
muscle sample 2.2020 0.5653 25.67 1.9405 0.5036 25.95 1.7174 0.4506 26.24spleen 1.0680 0 2 7 0 9 25.37 0.8377 0.2020 24.11 0.7433 0.1737 23.37
testes 3.0226 0.4361 14.43 3.1566 0.4827 1529 2.7665 0.4195 15.16
organs
animal 2 A: 421.6 g animal 2 B: 416.3 g animal 2 0 : 430.4 g
fresh organ (in gram) freezedried organ (in gram) % dry weight
fresh organ 
(in gram)
freezedried organ (in gram) % dry weight
fresh organ (in gram) freezedried organ (in gram) % dry weight
brain 1.7376 0.3745 21.55 1.7262 0.3655 21.17 1.7706 0.3752 21.19
GIT 34.4723 13.4767 39.09 35.2468 13.6107 38.62heart 1.2357 0 28 46 23.03 1.3157 0.3049 23.17 1.3198 0 2 8 4 5 21.56
kidney 1 1.3443 0.3298 24.53 1.4822 0.3009 20.30 1.5360 0.3107 20.23
kidney II 1.4643 0.3575 24.41 1.4288 0.2800 19.60 1.5186 0.3286 21.64
liver lobe 1 6.9333 1.7694 25.52 8.5931 1.7380 20.23 7 27 86 1.8451 25.35
liver lobe II 7.7392 2.0297 26.23 8.7162 1.7051 19.56 8.8628 2.1527 24.29
lungs 1.5505 0.3842 24.78 1.6245 0.2687 16.54 1.5622 0.3152 20.18muscle sample 1.4488 0.3584 24.74 1.8866 0.4750 25.18 1.9374 0.4781 24.68spleen 0.8107 0.1929 23.79 0.7986 0.1902 23.82 0.8441 0.1906 22.58
testes 2.7710 0.4589 16.56 2.7343 0.3969 14.52 2.5099 0.3680 14.66
organs
animal 5 A: 442.4 g animal 5 B; 433.2 g animal SC: 4 1 3 .4 g
fresh organ (in gram) freezedried organ (in gram) % dry weight
fresh organ 
(in gram)
freezedried organ (in gram) % dry weight
fresh organ (In gram) freezedried organ (in gram) % dry weight
brain 1.7005 0.3677 21.62 1.7225 0.2506 14.55 1.7903 0.3938 22.00
GIT 39.8925 14.3343 35.93
heart 1.3033 0 2 9 7 0 22.79 1.2020 0.2665 22.17 1.1544 0 26 69 23.12
kidney 1 1.5108 0.3271 21.65 1.5825 0.3239 20.47 1.4105 0.2939 20.84
kidney II 1.5804 0.3317 20.99 1.6679 0.3344 20.05 1.4130 0 2958 20.93liver lobe 1 8.1624 1.7243 21.12 7.6208 1.8168 23.84 8.3850 1.9706 23.50
liver lobe II 12.3076 2.5970 21.10 10.1523 2.3416 23.06 10.1273 2.3002 22.71
lungs 1.8368 0.4049 22.04 1.8765 0.3693 19.68 1.8291 0.3357 18.35
muscle sample 2.3210 0.5893 25.39 2.1143 0.5362 25.36 1.7053 0.4333 25.41spleen 0.7914 0.1871 23.64 0.8562 0.2031 23.72 0.8380 0 20 22 24.13
testes 2.5447 0 .3K 4 15.30 2.7543 0.3838 13.93 2.6695 0.3997 14.97
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Appendix Table 2: Extraction of quercetin metabolites:
Recovery of radiolabelled com pounds in the aqueous and ethyl acetate phase of the extract.
Radiolabelled quercetin metabolites were extracted from freezedried tissue and plasma as described in materials and 
methods (Figure 2, Section I). The table shows the distribution of radiolabelled compounds (in dpm) between aqueous 
phase extract and organic phase extract, per whole organ/total plasma (15 ml).
whole organ 
(= 100%)
aqueous phase ethyl acetate phase extraction efficiency( a t |u e o i is  +  e th y l  a c e ta t e  p l i a s e )
% dpm % dpm % dpm
G [-tract 0.5 h 50,303,345 4% 2,012,134 65% 32,697,174 69% 34,709,308
Gl-tract 1 li 54,529,546 4% 2,181,181 46% 25,083,591 50% 27,264,772
Gl-tract 2 h 51,494,265 18% 9,268,968 64% 32,956,330 82% 42,225,297
Gl-tract 5 li 53,870,401 6% 3,232,224 49% 26,396,496 55% 29,628,721
plasma 0.5 h 1,695,731 30% 508,719 9% 152,616 39% 661,335
plasma 1 h 1,643,770 50% 821.885 2% 32,875 52% 854,760
plasma 2 h 1,460,021 40% 584,008 3% 43,801 43% 627,809
plasma 5 h 982,226 49% 481,291 9% 88,400 58% 569,691
liver 0.5 h 1,126,615 37% 416,848 13% 146,460 50% 563,308
liver 1 h 684,153 17% Î 16,306 29% 198.404 46% 314,710
liver 2 h 303,530 28% 84,988 6% 18,212 34% 103,200
liver 5 h 155,129 28% 43,436 26% 40,334 54% 83,770
kidney 0.5 h 594,715 22% 130,837 31% 184,362 53% 315,199
kidney 1 h 468,065 20% 93,613 19% 88,932 39% 182,545
kidney 2 h 103,846 12% 12,462 2% 2,077 14% 14,538
kidney 5 h 162,726 16% 26,036 44% 71,599 60% 97,636
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Appendix Table 3: Peak numbering in Mullen et al, 2002 and th es is  / Graf et al, 2004.
Initially only plasma and tissues samples collected at 1 h after [2-i4C]quercetin-4'-glucoside ingestion were analysed, 
and the detected radiolabelled compounds were numbered 1-19 according to their order of elution from the column. 
Later, plasma and tissue samples from the other timepoints (0.5, 2 and 5 h) were analysed and 8 additional 
compounds were identified. For the subsequent publication (Graf et al, 2004) and this thesis the 27 detected 
radiolabelled compounds were numbered continually according to their order of elution from the column, n.d. = not 
detected.
Compound Mullen et al, 2002 th esis  /  Graf e t al, 2004
Unknown n.d. 1
Unknown n.d. 2
Quercetin di-glucuronide 1 3
Unknown 2 4
Methylated quercetin di-glucuronide 3 5
Quercetin di-glucuronide 4 6
Quercetin di-glucuronide n.d. 7
Methylated quercetin di-glucuronide 5 8
Quercetin di-glucuronide 6 9
Quercetin di-glucuronide 7 10
Quercetin di-glucuronlde 8 11
Quercetin-3-glucuronide 9 12
Quercetin glucuronide suifate 10 13
Methylated quercetin di-glucuronide n.d. 14
Quercetin mono-glucuronide n.d. 15
Methylated quercetin glucuronide sulfate 11 16
Quercetin glucuronide sulfate n.d. 17
Quercetin-4'-glucoside 12 18
Methylated quercetin mono-glucuronide 13 19
Methylated quercetin mono-glucuronide 14 20
Methylated quercetin mono-glucuronide 15 21
Quercetin mono-glucuronide 16 22
Quercetin mono-glucuronide n.d. 23
Quercetin 17 24
Methylated quercetin sulfate 18 25
Quercetin sulfate 19 26
Isorhamnetin n.d. 27
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Appendix Table 4: Quantity of radiolabelled m etabolites extracted from rat t issu es  and plasma.
4 A: w hole Gl-tract 
4 B: plasma 
4 C: liver 
4 D: kidneys
Radiolabelled compounds were extracted from tissues and plasma, identified using HPLC-RC-MS/MS, and numbered 
1-27 according their order of elution from the column. Each metabolite was quantified as outlined in Materials and 
Methods (Section I). In this table the amount of each metabolite is given in dpm per extracted radioactivity from the 
whole organ, assuming the extracted aliquot of homogenized and freezedried tissue fully represented the metabolite 
spectrum of the whole organ.
On average 50% of the original radioactivity was recovered in the purified, concentrated extracts, in practice the 
extracted radioactivity varied and the exact recoveries are shown in Appendix Table 2. All quantities were calculated 
using the exact recovery and then normalized as if the extraction efficiency was always 50% to ensure comparability 
between different samples. The column labelled ‘ % ’ shows the metabolite quantity as a percentage of the extracted 
radioactivity from each organ.
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Appendix Table 4 A; Quantity of radiolabelled m etabolites extracted from rat Gl-tract.
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Appendix
No. Compound G l-trac t 0 .5  h %
G l-trac t 
1 h %
G l-trac t  
2 h %
G l-trac t 
5 h %
1 unknown - - - - - - 3 ,150,823 10.6
2 unknown - - - - - - 3 ,206,052 10.8
3 Quercetin di-qlucuronide - - 223,013 0.8 - - - -
4 unknown 612 ,517 1.8 223,013 0.8 1.256J!23 3.0 - -
5 Methylated quercetin di-qlucuronide - - 364,436 1.3 2 .309.829 5.5 - -
6 Quercetin di-qlucuronide - - 59,832 0.2 1,215,700 2.9 715 ,094 2.4
7 Quercetin di-qlucuronide - - - - - - -
8 Methvlated quercetin di-qlucuronide - - 163,180 0.6 3 ,039,249 7.2 607 ,830 2.1
9 Quercetin di-qlucuronide - - - - - - - -
10 Quercetin di-qlucuronide 748 ,632 2.2 685,358 2.5 6 ,281,114 14.9 19,774,612 66.7
11 Quercetin di-qlucuronide 1,565,322 4.5 152,301 0.6 1,539,886 3.6 - -
12 Quercetin-3-qlucuronide - - 2 ,876,558 10.6 3,647,099 8.6 - -
13 Quercetin qlucuronide sulfate - - 1,892,253 6.9 2 ,958,202 7.0 3 57 ,547 1.2
14 Methylated quercetin di-qlucuronide - - - - - - -
15 Quercetin mono-qlucuronide - - - - - - - -
16 Methylated quercetin qlucuronide sulfate - - 201,256 0,7 2 ,998,726 7.1 0 0.0
17 Quercetin qlucuronide sulfate - - - - - - - -
18 Quercetin-4'-qlucoside 17.014,367 49.0 7,133,865 26.2 - - - -
19 Methylated quercetin mono-qlucuronide - - 1,783,466 6.5 3 ,039,249 7.2 - -
20 Methylated quercetin mono-qlucuronide 884 ,747 2.5 1,323,217 4.9 2 ,958,202 7.0 - -
21 Methylated quercetin mono-qlucuronide - 3 ,890,238 9.2 - -
22 Quercetin mono-qlucuronide 1 ,156,977 3.3 3 ,336,808 12.2 - - - -
23 Quercetin mono-qlucuronide - - - - - - - -
24 Quercetin 8 ,711,356 25.1 1,956,059 7.2 2 ,836,632 6.7 1 ,816,763 6.1
25 Methylated quercetin sulfate - - - - - - - -
26 Quercetin sulfate 2 ,245,896 6.5 4 ,890,149 17.9 3 ,849,715 9.1 - -
27 Isorhamnetin 1,769,494 5.1 - - 4 05 ,233 1.0 - -
Total surri ‘ - ^
Diqiucuronides 2 ,313,954 6.7 1,648,120 6.0 14,385,778 34.1 21,097 ,535 71.2
Monoqiucuronides 2 ,041,724 5.9 9 ,320,049 34.2 13,534,788 32.1 - -
Glucuronated sulfates 0 0.0 2 ,093,509 7.7 5 ,956,928 14.1 357 .547 1.2
Sulfates 2 ,245,896 6.5 4 ,890,149 17.9 3 ,849,715 9.1 - -
is tiib  fô ô n lu d ilÉ ff'^  ...... .... r w i  .574 f p ? T
1 - I 405 .233  I 1.0 II Isorhamnetin (methvlated quercetin) 1 1 .769.494 1 5.1 I
r i W i  I III I f n i l  n r  "
1 6 12 .517  I 1.8 I 223 .013  I 0.8 I 1 ,256.223  I 3 .0  I 6 ,356.875  j 21.5 Iunknown___________ I..JI i.m m w.*.' 'u v A .m w i  X U M .
Q aglycone 1 8 ,711,356  1 25.1 | 1,956,059 | 7 .2  | 2 ,836,632  | 6 .7 | 1 ,816,763 1 6.1 J
Quercetin-4'-qlucoside 17,014,367 1 49 .0  7 ,133,865  26.2 - - i - r  1
T o t ^ iû m  ................... 1 ^ 1
methylated metabolites 884 ,747 2.5 3,835,555 14.1 18,235,493 43.2 607 ,830 2.1
not methylated metabolites 5,716,827 16.5 14,116,272 51.8 19,491,716 46.2 20,847 ,252 70.4
(Q and I not included)
methylated conjugates 2,654,241 7.6 3 ,835,555 14.1 18,640,726 44.1 607 ,830 2.1
not methylated conjugates 14,428,183 41.6 16,072,331 58.9 22,328 ,348 52.9 22,664 ,015 76.5
(including Q  and I)
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Appendix Table 4 B: Quantity of radiolabelled m etabolites extracted from rat plasma.
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Appendix
No. Compound
Plasm a  
0.5 h %
Plasma 
1 h %
Plasma  
2 h %
Plasma 
5 h %
“ Ï” 'unknown - - - -
2 unknown - - - -
3 Quercetin di-qlucuronide - - - - ■
4 unknown - - - - ~
5 Methvlated quercetin di-qlucuronide - - - - ■
6 Quercetin di-qlucuronide 4,748 1.2 54,489 6.4 60,605 9.7 44,287 7.8
7 Quercetin di-qlucuronide 17,805 4,4 - - 18,117 3.2
8 Methvlated quercetin di-qlucuronide - - - - ■
9 Quercetin di-qlucuronide 25,119 6.2 31,785 3 .7 34,188 5.4 18,117 3.2
10 Quercetin di-qlucuronide 121,982 30.0 174,820 20.5 93,239 14.9 12,078 2.1
11 Quercetin di-qlucuronide 43,184 10.6 70,382 8.2 35,742 5.7 10,065 1.8
12 Quercetin-3-qlucuronide 37,490 9.2 18,053 2.1 ■
13 Quercetin qlucuronide sulfate 6 ,592 1.6 118,060 13.8 105,671 16.8 80,522 14.1
14 Methvlated quercetin di-qlucuronide 0 0.0 - - ■
15 Quercetin mono-qlucuronide 65,317 16.0 - - "
16 Methvlated quercetin qlucuronide sulfate 38,371 9.4 372,345 43.6 298 ,365 47.5 354,295 62.2
17 Quercetin qlucuronide sulfate 13,515 3.3 0 0.0 0 0.0
18 Quercetin-4'-qlucoside 0 0.0 0 0.0 0 0.0 0 0.0
19 Methvlated quercetin mono-qlucuronide 4,638 1.1 4,457 0.5 ■
20 Methvlated quercetin mono-qlucuronide 8,503 2.1 3,677 0.4 ~ ■
21 Methylated quercetin mono-qlucuronide 10,435 2.6 6,684 0.8 ■
22 Quercetin mono-qlucuronide - - - - ~
23 Quercetin mono-qlucuronide 9 ,276 2.3 - -
24 Quercetin - - - - ■
25 Methylated quercetin sulfate - - - -
26 Quercetin sulfate - - - -
27 Isorhamnetin - - - - '
To talsurri T O W l— ^ ^ ^ m U U . U I  569.691 iiu u .m
Diqiucuronides 212,838 52.3 331 ,476 38.8 223,774 35.6 134,874 23.7
Monoqiucuronides 135,658 33.3 32,871 3.8
Glucuronated sulfates 58,478 14.4 490,405 57.4 404 ,035 64.4 434 ,817 76.3
Sulfates - - - - ■
s u m f o W h M iw t  ' r M I M I T r o q r . P T - 8 g 4 . / b 2  IIU W J r - H H  I1UU.UI M U Ü .II
Isorhamnetin (methylated quercetin) - - - — 1 — L _
S u r n '^ * IA # m # i# ! N lt e s )  ' ■ ■ 'TOW T O T fII 1 lUU.U
unknown - T ~ ~ ^ 1 - I - 1 - j _ _ .1. . .  - -
Sum — ----------------- _ 62 /,w u y  i iu u .u i ' w q
lO  aalvcone 1 T ~ ^ 1 i -LiZTTirrr.T: : mmDnmÊmoKZLm^ m^ l a t M X U M  I m  i ' l  M I l ' i ' I l M W
Quercetin-4'-glucoside
Tôfaî'sürft
1 - I
4Ub,U /4
methylated conjugates 61,947 15.2 387,163 45.3 298,365 47.5 386.504 1 67.8
not methylated conjugates 345 ,027 84.8 467,589 54.7 329 ,444 52.5 183,187 1 32.2 1
(Q and I not included)
1 methylated conjugates 61,947 15.2 387,163 45.3 298 ,365 47.5 386 ,504  j 67.8
Inot methylated conjugates 345 ,027 84.8 467,589 54.7 329 ,444 52.5 183,187 1 32.2 |
(including Q  and I)
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Appendix Table 4 C: Quantity of radiolabelled m etabolites extracted from rat liver.
For Legend please see  previous page.
Appendix
No. Compound Liver 0.5 h %
Liver 
1 h %
Liver 
2 h %
Liver 
5 h %
1 unknown - - - - - - -
2 unknown - - - - - - -
3 Quercetin di-qlucuronide 21,489 3.8 20,293 6.4 - - 29,730 35.5
4 unknown - - - - - - 3 ,950 4.7
5 Methylated quercetin di-qlucuronide 65,233 11.6 40,773 13.0 4,981 4.8 - -
6 Quercetin di-qlucuronide - - - - 3 ,188 3.1 35,608 42.5
7 Quercetin di-qlucuronide - - - - - - - -
8 Methylated quercetin di-qlucuronide 38,372 6.8 - - - - - -
9 Quercetin di-qlucuronide - - - - 6 ,973 6.8 - -
10 Quercetin di-qlucuronide 84,419 15.0 105,383 33.5 30,880 29.9 7,061 8.4
11 Quercetin di-qlucuronide 39,907 7.1 12,607 4.0 7,969 7.7 - -
12 Quercetin-3-glucuronide 0 0.0 21,565 6.9 - - - -
13 Quercetin qlucuronide sulfate 38,372 6.8 9,289 3.0 8 ,567 8.3 -
14 Methylated quercetin di-qlucuronide 0 0.0 - - - - -
15 Quercetin mono-qlucuronide - - - - - - -
16 Methylated quercetin qlucuronide sulfate 126,629 22.5 40,428 12.8 20,720 20.1 - -
17 Quercetin qlucuronide sulfate - - - - - - 1,436 1.7
18 Quercetin-4‘-qlucoside 9,977 1.8 - - - - - -
19 Methylated quercetin mono-qlucuronide 59,094 10.5 42,135 13.4 8,567 8.3 2,394 2.9
20 Methylated quercetin mono-qlucuronide 46,814 8.3 17,584 5.6 3,985 3.9 - -
21 Methylated quercetin mono-qlucuronide 33,000 5.9 - - 7,371 7.1 - -
22 Quercetin mono-qlucuronide - - - - - - -
23 Quercetin mono-qlucuronide - - - - - -
24 Quercetin - - 4,644 1.5 - - 3,591 4.3
25 Methylated quercetin sulfate - - - - - - -
26 Quercetin sulfate - - - - - - -
27 Isorhamnetin - - - - - - -
T < ^ f  èùm ' "
Diqiucuronides 249,421 44.3 179,056 56.9 53,991 52.3 72,400 86.4
Monoqiucuronides 138,908 24.7 81,284 25.8 19,923 19.3 2 ,394 2.9
Glucuronated sulfates 165,002 29.3 49,717 15.8 29,286 28.4 1,436 1.7
Sulfates - - - - * -
S u m f c o n w r n » 98.5 TOJ;8 Ü1.Ü
Isorhamnetin (methylated quercetin) - - - - - -
Sum fphâSô tl rhetabolites) 5 53 ,3^ i 3 1 0 ,0 5 / y».5 103,id00 /(j,yyi5 »T.o
I -  I 3,950 I 4.7  IIunknown 1 - I
T F i r ^ T i T i n i M 'ii'HM iM i IH iM i'i'H  iHiMiTTTnMrrniiTiMijjii
Q aqlycone _____j -  1 -  j 4,644 1 1.5 1 -  1 ■ 1 3.591 1 4 .3  1
Sum B r m % fd # e c M a # B 3 K 9 ^ M N
Quercetin-4 -glucoside J 9 ,977 1 1.8 1 -  1 1 -  1 I
Total sum
methylated conjugates 369,143 65.5 140,920 44.8 45,623 44.2 2,394 2.9
not methylated conjugates 184,188 32.7 169,137 53.7 57,577 55.8 73,836 88.1
(Q and I not included)
methylated conjugates 369,143 65.5 140,920 44.8 45,623 44.2 2,394 2.9
not methylated conjugates 184,188 32.7 173,781 55.2 57,577 55.8 77,427 92.4
(including Q  and I)
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Appendix Table 4 D: Quantity of radiolabelled m etabolites extracted from rat kidney.
For Legend please see  previous page.
No. Compound Kidney 0.5 h %
Kidney 
1 h %
Kidney 
2 h %
Kidney
5 h %
1 unknown - - - - - - - -
2 unknown - - - - - - - -
3 Quercetin di-qlucuronide 19,912 6.32 13,446 7.4 3,687 25.4 39,342 40.3
4 unknown 10,591 3 .36 8,153 4.5 - - 3.274 3.35
5 Methylated quercetin di-qlucuronide 49,568 15.73 31,012 17 2,231 15.3 - -
6 Quercetin di-qlucuronide 9,744 3.09 - - - - 16,963 17.4
7 Quercetin di-qlucuronide - - ■ - - - - -
8 Methylated quercetin di-qlucuronide 38,129 12.10 22,736 12.5 517 3.55 2 ,466 2.53
9 Quercetin di-qlucuronide 16,946 5.38 - - 2 ,419 16.6 - -
Quercetin di-qlucuronide 4 ,237 1.34 21,405 11.7 2,771 19.1 32,858 33.7
11 Quercetin di-qlucuronide 18,641 5.91 15,345 8.4 493 3.4 - -
12 Quercetin-3-qlucuronide 18.641 5.91 14,441 7.9 - - - -
13 Quercetin qlucuronide sulfate - - - - - - - -
14 Methylated quercetin di-qlucuronide - - - - - - - -
15 Quercetin mono-qlucuronide - - - - - - - -
16 Methylated quercetin qlucuronide sulfate 7,202 2.28 5,645 3.1 - - - -
17 Quercetin qlucuronide sulfate - - - - - - 986 1.0
18 Quercetin-4'-qlucoside - - - - - - - -
19 Methylated quercetin mono-qlucuronide 28,809 9.14 14,061 7 .7 1,127 7.75 - -
20 Methylated quercetin mono-glucuronide 70,750 22.45 30,594 16.8 1,292 8.89 - -
21 Methylated quercetin mono-qlucuronide 22,030 6.99 - - - - - -
22 Quercetin mono-qlucuronide - - 5 ,700 3.1 - - - -
23 Quercetin mono-qlucuronide - - - - - - -
24 Quercetin - - - - - - 1,746 1.79
Methylated quercetin sulfate - - - - - - -  I -
26 Quercetin sulfate - - - - - -  . -
27 Isorhamnetin - - - - - -
Tdfafsurh T O W TOW T O W
Diqiucuronides 157,176 49.9 103,944 56.9 12,119 83.4 91,628 93.8
Monoqiucuronides 140,230 44.5 64,796 35.5 2 419 .08562 16.6 - -
Glucuronated sulfates 7,202 2.3 5,645 3.1 - - 986 1.0
Sulfates - - - - - - - -
Sum ftiflrtÉ làaM V
Isorhamnetin (methylated quercetin)
S ü m 'm w W f# Ë a b o li t8 s ) 1 y i: ,o i4  1 y4.y
1 unknown 1 1 05 91 .3642 ) 3 .36  I 8153 I 4 .47 - 3274.34451 3.35
' 95 .889 9 8 .2 .
IQ  aglvcone 1 - I - I 1746.317071 1.791
M l  H ||| I iMiii 'iin
Q u erc e tin -4 '-^ c o s id e
To îa î sum ■ m c i w i K t ; ^ H i | i B i | H  H |i M l | i  i H i l l M I  || | M l
methylated conjugates 216,487 68.7 109,748 60.1 5,167 35.5 2,466 2.5
not methylated conjugates 88,120 28.0 70,337 38.5 9,371 64.5 90,149 92.3
(Q and I not included)
methylated conjugates 216 ,487 68.7 109,748 60.1 5,167 35.5 2,466 2.5
not methylated conjugates 88,120 28.0 70,337 38.5 9,371 64.5 91,895 94.1
(including Q  and I)
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A
MS trace 
(un-fragmented molecular Ion)
110901ral extract 6 4 c p s 0 1 p la s m a 1 2 0 # e i9  RT: 31.31 AV; 1 NL: 1G7E5 
T: - c ESI Full ms [ 150.00-1000.00]
571.0100
90
80
70
1 60s
g 50
>
13 4001CC 3 0
20
10
0
395.0
400
491.0 557.1
609.1
655.0
6 0 0
m /z
8 3 6 .4  8 9 9 .4  
80 0
MS/MS trace 
(fragmentation pattern)
110901 rat extract 6 4 cp s0 1  plasm a 120 # 6 2 0  RT: 31.37 AV: 1 NL: 7.61E4 
T: • c d Full ms2 5 7 0 .9 6 @ 4 0 .0 0  [ 145.00-585.00]
100
90
8 0  '*91-0
g  70 ■
# 60 
^  50 •s
m 40Q)
^  30  ■
9 9 3 .2
1000
20
10
0
175.1
395.0 4 9 2 .0
3 0 0 .2  316.1
3 0 0
m /z
190901 Uver extract 30  min rat 0 1 #  677 RT: 2 9 .3 2  AV: 1 NL: 1.31E5 
T: - c  ESI Full ms [ 150.00-1000.00]
557.0100
9 0
8 0
a, 70
1 6 0
50
40
CC 30
20
10
0
4 9 6 .9  664 .4
615.4 670 .5  
732 .4
9 2 2 .8
9 4 8 .7
155.9
200 4 00 6 0 0
nVz
1000
301.1
3 02 .2
477.0
190901Liver extract 3 0  m inrat 0 1 # 6 7 8  RT: 2 9 .3 7  AV: 1 NL: 6.15E4 
T: - c d  Full ms2 557 .01® 40.00  [ 140.00-570.00]
100
9 0
80
§ ™
I^  50 
I  40  
'  30 
20
10 J
0
4 0 0
190901 Uver extract 3 0  min rat 01 # 6 0 0  RT; 25 .6 4  AV: 1 NL: 3 .70E 5 
T; - c  ESI Full ms [ 150.00-1000.00]
,00
9 0  
80  
g  70
I  6 0
^  SO I 4 0  ■
-3 0 .
20
10 247
0
190901 Liver extract 3 0  min rat 01 # 6 0 1  RT: 25.70 AV: 1 NL: 2 .3 4 E 5  
T; - c d  Fullm s2 6 5 3 .0 6  @ 40.00  [ 165.00-665.00]
477.0
576.4
380 .2
4 0 0 6 0 0
m/z
691.0
733.2  811.0 921.5 ®
0 0 0  101
too
90
80
70
I 60
< 50
>
i 4001CC 30
20
10
0
301.0
2 9 9 ,9 46 0 .9
4 0 0  500
m/z
Appendix Figure 1 : MS traces of quercetin m etabolites.
Radiolabelled compounds were extracted from rat tissue and plasma after an oral dose of [2-i4C]quercetin-4'- 
glucoside. Quercetin metabolites were identified by gradient, reverse phase HPLC with online radioactivity detection 
and tandem MS/MS, operating in negative ion mode, and complete results are shown in Section I, Table 5. A: MS 
trace of methyl-quercetin-mono-glucuronide-sulfate, peak 16, detected in plasma at 2 h. The m/z of the molecular ion 
[M*H]- was 571, with fragment ions at m/z of 491 (=[M-H]- -sulfate group), 395 (=[M-H]' -glucuronyl group) and 315 
{=[M-H]- -glucuronide group, and -sulfate group). The fragment ion at m/z 315 corresponds with methyl quercetin. B: 
MS trace of quercetin-mono-glucuronide-sulfate, peak 13, in liver extract at 0.5 h. The m/z for the molecular ion [M-H]- 
was 557, the fragment ions had a m/z of 477 (=[M-H]- - sulfate group), 381 (=[M-H]- - glucuronyl group) and 301 (=[M- 
H]- - glucuronide group and - sulfate group). The fragment ion at m/z 301 corresponds with quercetin. C: MS trace of 
quercetin-di-giucuronide, peak 10, in liver extract at 0.5 h. The m/z for the molecular ion [M-H]- was 653, the fragment 
ions had a m/z of 477 (=[M-H]- - glucuronyl group) and 301 (=[M-Hj- - two glucuronyl groups). The fragment ion at m/z 
301 corresponds with quercetin.
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D
MS trace 
(un-fragmented molecular Ion)
J 0 0 9 0 1 3 0  kidney 01 # 3 6 4  HT: 2 9 ,0 8  AV; 1 NL; 1.01E5 
T: - c ESI Full ms ] 150 .00-2000 .00]
9 0  ■
80
0 '1 60:
5  50
■I 40.œ
: 491.0 771.5
20  '
10 3 9 2 .4
0 .
MS/MS trace 
(fragmentation pattern)
10 0 9 0 1 3 0  kidney 0 1#  3 6 5  RT: 29.16 AV; 1 NL: 6.12E4 
T: - c d Full ms2 6 6 7 .0 3 @ 4 0 .0 0  [ 170 .00-680 .00]
491.0
^ 1215.5
1258.4 1612,7
1940.4
100
90
80
s 70
1 60
§ 50
>3 40
0CC 30
20
10
0
1000
m /z
1500 2000
315.0
4 0 0
519.6 536.4 
500 6 0 0 !
1 0 0 9 0 1 3 0  k id n ay O lf tS e ï RT: 4 3 .9 8  AV: 1 NL: 1.46E5 
T: - c ESI Full ms [ 150.00-20 00 .0 0 ]
491.0
8 2 4 .8  1005.4 1114.6 ■'291-6
1516.0
1 0 0 9 0 1 3 0  kidney 01 # 5 6 2  RT: 4 4 .0 6  AV: 1 NL: 9 .64E 4  
T: - c d  Fullm s2 4 9 1 .0 3 @ 4 0 .0 0 ] 125.00-505.00]
100
90
80
I  60
§  50g
'IS 40  
=  30  
2 0
10 ■'
0
500 1000
m/z
3 0 0
m/z
3 9 6 .9  410.6 
4 0 0  450
501.3
500
190901 Intest ex tract 30  min rat 01 # 1141 RT: 4 6 .9 2  AV: 1 NL: 6.45E5 
T; - c ESI Full ms [ 150.00-1000.00]
9 0  
8 0  
8  70 ■
I§  50ÎH 40
887.
30
20 514.5
301.3 3 8 3 .0  ^76.3
10 495.1 599.3  650 .3  837 .0
190901 intest extract 3 0  min rat 0 1 #  1142 RT: 4 6 .9 7  AV: 1 NL 5.70E5 
T: - c d  Full ms2 3 8 1 .0 0 0 4 0 ,0 0  [ 9 0 .0 0 -3 9 5 ,0 0 ]
,00
90  
80  
a, 70 •
I  6 0
<  50 >% 40 
30  
20 
10 
0
6 0 0
m /z
8 0 0
168.7 
150 2 0 0 250
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Continuation of Appendix Figure 1: MS traces of quercetin metabolites.
D: MS trace of methyl-quercetin-di-glucuronide, peak 8, in kidney extract at 0.5 h. The m/z for the molecular ion [M-H]- 
was 667, the fragment ion had a m/z of 477 (=[M-H|- - giucuronyl group) and 315 (=[M-Hj- - two glucuronyl groups). 
The fragment Ion at m/z 315 corresponds with methylated quercetin.
E: MS trace of methyl quercetin mono-glucuronide, peak 20, kidney extract at 0.5 h. The m/z for the molecular ion [M- 
H]- was 491, the fragment ion had a m/z of 315 (=[M-H]- - glucuronyl group). The fragment ion at m/z 315 corresponds 
with methylated quercetin.
F: MS trace of quercetin sulfate, peak 26, intestine extract at 0.5 h. The m/z for the molecular ion [M-Hj- was 381, the 
fragment ion had a m/z of 301 (=[M-H|- - glucuronyl group). The fragment ion at m/z 301 corresponds with quercetin.
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